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Regulator of calcineurin 1 (RCAN1) has been shown to act as a negative regulator of 
vascular endothelial growth factor (VEGF)-signalling in endothelial cells. Two 
isoforms are detectable in cells, RCAN1.1 and RCAN1.4, produced by alternative 
splicing of the RCAN1 mRNA. In this study it was demonstrated that only RCAN1.4 
is induced in human dermal microvascular endothelial cells (HDMECs) in response 
to VEGF. Using siRNA-mediated gene silencing this work shows that RCAN1 
depletion leads to a reduction in VEGFR-2 internalisation following VEGF-A 
stimulation. RCAN1 depletion also leads to a reduction in cell polarity and 
cytoskeletal reorganisation in response to VEGF. siRNA-mediated silencing of 
RCAN1 led to an inhibition of VEGF-A mediated migration of HDMECs. These 
effects of RCAN1 knockdown appear to be specific to VEGFR-2, as no apparent 
effect on hepatocyte growth factor receptor (HGFR) internalisation and cytoskeletal 
reorganisation and migration in response to HGF was observed in HDMECs. Over-
expression of RCAN1.4 isoform using adenoviral mediated gene delivery resulted in 
increased migration of HDMECs in the absence of ligand. This effect was insensitive 
to the calcineurin inhibitor cyclosporine, indicating that RCAN1.4 was not operating 
through the classical calcineurin/NFAT pathway to regulate cell migration. Instead, 
the RCAN1.4 effect was sensitive to a small molecule VEGFR-2 kinase inhibitor, 
which blocked cell migration.  
This study also examined the role of phospholipase D (PLD) in endothelial cell 
function. By utilising siRNA for PLD1 and PLD2 it was shown that both PLD1 and 
PLD2 are required for VEGF-A mediated proliferation, migration and tubular 
morphogenesis in HDMECs. 
Overall, the data presented in this thesis defines a novel role for both RCAN1 and 
PLD in regulating in endothelial cell function.  Both proteins could be potential 
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1.1 The vascular system and endothelial cells 
 
The structure of the large macrovascular vessels, such as arteries and veins, consists 
of an inner layer (tunica intima) comprising a monolayer of endothelial cells 
surrounded by a sheet-like basement membrane home to the extracellular matrix 
proteins (ECM). This basement membrane is surrounded by the tunica media layer, 
which consists of vascular smooth muscle cells, whose function is to allow vessel 
contraction. The outermost tunica adventia layer provides the supporting connective 
tissue. By contrast, the structure of the microvascular vessels, for example capillaries 
and arterioles, comprises a monolayer of endothelial cells surrounded by a basement 
membrane and stabilised by a layer of specialised smooth muscle cells, known as 
pericytes (Aird, 2007). 
The continuous endothelial monolayer lining the blood vessels forms a size-selective 
and semipermeable barrier between the blood plasma and interstitium. The passage 
of proteins, solutes and gases is controlled by transcellular and paracellular 
processes. Transcellular transport involves transcytosis, an energy-dependent 
trafficking of vesicles across the endothelium, which results in the transport of 
macromolecules such as albumin (Komarova and Malik, 2010). Paracellular 
transport is regulated by interendothelial junctions. Two types of interendothelial 
junctions are present in the endothelium, tight junctions and adherens junctions, 
which regulate the movement of solutes larger than 3nm in size (Komarova and 
Malik, 2010).  
 
The endothelium regulates haemostasis by promoting anti-coagulant properties and 
counteracting platelet activation and aggregation.  Binding of antithrombin III and 
thrombomodulin (TM) expression inhibit blood coagulation  (van Hinsbergh, 2012). 
Platelet adhesion and activation are regulated by von Willebrand factor (vWF) 
released from endothelial cells. vWF is stored in Weibel-Palade bodies within the 
endothelial cells and released by vasoactive agents such as histamine, bradkinin and 
thrombin (van Hinsbergh, 2012). Nitric oxide released to the vascular lumen is an 
inhibitor of adhesion and platelet aggregation. Furthermore, endothelial expressed 
cyclooxygenease-2 (COX-2) generates the eicosanoid prostacyclin (PGI2), which 
inhibits platelet activation (Weksler et al., 1977). 
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Inflammatory cytokines such as tumour necrosis factor α (TNFα) and interleukin-1β 
(IL-1β) cause endothelial dysfunction and induce expression of adhesion molecules 
such as vascular cell adhesion molecule-1 (VCAM-1) and E-Selectin leading to 
leukocyte adhesion and infiltration into surrounding tissues (Hayden and Ghosh, 
2004)	  One of the central mediators of most inflammatory stimuli is the transcription 
factor nuclear factor κB (NF-κΒ) (Hayden and Ghosh, 2004). The net effect of NF-
κB activation is the disruption of the non-inflammatory, non-thrombogenic 
endothelial surface. Conversely, laminar shear stress (LSS) induces the expression of 
various factors including endothelial NOS (eNOS) and thrombomodulin (TM) 
(Topper et al., 1996) that are essential for regulation of vascular tone and 
maintenance of a quiescent endothelium.  
Endothelial surface enzymes modify vasoactive peptides in the bloodstream.  
Angiotensin-converting enzyme is expressed on the luminal surface of endothelial 
cells which converts angiotensin I to angiotensin II resulting in vasoconstriction..  
Endothelial nitric oxide synthase (eNOS) generates the vasoprotective molecule 
nitric oxide  (NO) (Förstermann et al., 1994). Furthermore, vascular nitric oxide 
dilates blood vessels by stimulating soluble guanylyl cyclase (sGC) and increasing 
cGMP in smooth muscle cells (Förstermann et al., 1994).  
1.2 Angiogenesis 	  
Angiogenesis is the process involved in the growth of new blood vessels from pre-
existing vessels (Dulak, 2005). It is one of the fundamental biological processes in 
higher vertebrates and involves a number of steps. First of all, the basement 
membrane of the existing blood vessels is degraded, and then endothelial cells 
migrate into the interstitial space in the direction of the angiogenic stimulus. The 
endothelial cells then proliferate while other endothelial cells generate the stalk of 
the sprout. Then the sprout develops a lumen and becomes a mature capillary. The 
maturation process is completed when pericytes and smooth muscle cells develop to 
stabilise the new blood vessels. Subsequently, these vessels differentiate into venules 
and arterioles. The degradation step is mediated by proteolytic enzymes and cell 
adhesion molecules. Angiogenic factors support proliferation and differentiation of 
the new vessels (Douglas et al., 2005).  
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Angiogenesis is a process that occurs both in the physiological and pathological 
state. The physiological states dependent on angiogenesis include: wound healing, 
repair, ovulation, placenta formation and chronic inflammation (Hoeben et al., 2004). 
Pathological angiogenesis is induced in diseases such as cancer, atherosclerosis, 
stroke, and diabetic retinopathies. Experiments have shown that angiogenesis-
dependent diseases are caused by unchecked production of normal and abnormal 
forms of pro-angiogenic mediators and insufficient inhibitory molecules (Felmeden 
et al., 2003).  In chronic cardiac conditions such as myocardial infraction and stroke, 
dysfunction of angiogenesis leads to loss of tissue and eventually increased 
morbidity and mortality (Nishida et al., 2004, Leon et al., 2005). Angiogenesis is 
driven by a number of growth factors (Senger et al., 1997) and pro-angiogenic 
cytokines acting on their cognate receptor (Fiedler and Augustin, 2006) and 
moderated by a number of endogenous inhibitors resulting in tightly regulated 
process; imbalance results in malignant, immune disorders, ischaemic, inflammatory 
and infectious disorders (Douglas et al., 2005, Lamalice et al., 2007). 
1.3 Molecular regulation of angiogenesis  
Regulators of angiogenesis can be broadly categorised into stimulators and 
inhibitors. Most regulators are proteins, primarily growth factors that stimulate 
endothelial cells to divide and migrate towards the stimuli. There exist numerous 
factors that can trigger angiogenesis and the most prominent of these is hypoxia 
(Minchenko et al., 1993). Hypoxia-inducible factor-1 (HIF)-1 is composed of two 
subunits, an oxygen-sensitive HIF-1α subunit and a constitutively expressed HIF-1β 
subunit (Wang and Semenza, 1995). Both HIF-1α and HIF-1β are members of the 
basic helix-loop-helix Per/Sim/Arnt (HLH-PAS) family of transcription factors 
(Salceda and Caro, 1997). In contrast to the constitutively expressed HIF-1β subunit, 
HIF-1α is an oxygen labile protein that becomes stabilized in response to hypoxia, 
iron chelators, and divalent cations (Lok and Ponka, 1999). Under normal oxygen 
levels (normoxia) in the body, HIF-1α is hydroxylated on proline residues by a 
family of prolyl hydroxylase (PHD) enzymes which ultimately leads to degradation 
by promoting interaction with the von Hippel-Lindau tumor-suppressor protein 
(pVHL) and subsequent proteosomal degradation (Masson et al., 2001). In low 
oxygen environments (hypoxia) HIF-1α hydroxylation is prevented, leading to a 
substantial increase in the half-life of the protein which facilitates dimerisation with 
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HIF-1β and translocation to the nucleus where the HIF-1 complex binds to the 
hypoxia responsive elements in the promoter region of a number of genes which 
regulate glucose homeostasis, vascular physiology and adaption to a low oxygen 
environment.  The VEGF-A gene contains a hypoxia response element (HRE) 
element in its promoter and hypoxia leads to an upregulation in VEGF-A mRNA and 
subsequent translation of the VEGF-A protein (Pugh and Ratcliffe, 2003, Laughner 
et al., 2001). 
 
The vascular endothelial growth factor (VEGF) family comprises five members 
VEGF-A, -B, -C, -D and placental growth factor (PIGF). These ligands bind to three 
different receptor tyrosine kinases (RTK) known as VEGF-receptor 1, 2 and 3 
(VEGFR) (Figure 1). VEGFR-1 is involved in haematopoietic cell development; 
VEGFR-2 is involved in vascular endothelial development and VEGFR-3 is involved 
in lymphatic endothelial cell development (Holmes et al., 2007).  
 
VEGF-A binds and activates VEGFR2 expressed on endothelial cells. This binding 
leads to receptor dimerization and phosphorylation of specific tyrosine residues in 
the intracellular domain of the receptor (Clauss and Breier, 2005). As a result, 
docking sites for several adaptor molecules are created. A number of key signalling 
molecules such as mitogen activated protein kinases are activated in order to regulate 
endothelial proliferation, vascular permeability and migration. In addition, VEGF-A 
binds to VEGFR1, expressed on haematopoietic progenitor cells, macrophages and 
monocytes. VEGFR1 activation results in chemotactic signals in hematopoietic 
progenitor cells. In mammals, VEGF-A exists in a number of different isoforms 
following alternative splicing of a single precursor mRNA (Robinson and Stringer, 
2001). In humans, six VEGF-A splice variants have been detected: VEGF-A121, 
VEGF-A145, VEGF-A165, VEGF-A183, VEGF-A189 and VEGF-A206. Although VEGF-
A121, VEGF-A183 andVEGF-A189 are expressed in various tissues, VEGF-A165 is the 
most abundantly expressed form, whereas VEGF-A145 and VEGF-A206 are relatively 
rare (Robinson and Stringer, 2001, Zacharoulis et al., 2005). All isoforms except 
VEGF-A121 bind to heparan sulphate proteoglycans found on the plasma membrane 
of most cells and in the extracellular matrix. They create a concentration gradient 
that guides the endothelial cells to efficiently migrate to the region of hypoxia. 
VEGF-B also binds to VEGFR1. Recently, it has been shown that VEGF-B acting on 
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VEGFR-1 is required for the uptake of fatty acids from the heart and skeletal muscle 
endothelium (Hagberg et al., 2010). PIGF also binds to VEGFR1 where it works in 
synergy with other VEGF in the regulatory process. VEGF-C and VEGF-D bind to 
VEGFR3, however, their role in the development of blood vessels is not so 
prominent (Felmeden et al., 2003).  
VEGF-E which is expressed in the parapox Orf virus-encoded VEGF (Takahashi and 
Shibuya, 2005) and VEGF-F which is expressed in snake venom (Suto et al., 2005, 
Holmes et al., 2007) bind to VEGFR-2.  
 
Another factor that regulates angiogenesis is the angiopoietin system (Felmeden et 
al., 2003). In humans, the system consist of three ligands: angiopoietin (ANGPT)1, 2 
and 4 and their cognate receptor, TIE-2 (Augustin et al., 2009), The function of a 
closely related orphan receptor, TIE-1, is less well understood, but it has been shown 
to dynamically interact with TIE-2 and to modulate its function upon binding of 
different angiopoietins (Seegar et al., 2010). The role of ANGPTs in angiogenesis 
are complex and context dependent. Depending on the level of expression and the 
presence of other factors such as VEGF, ANGPT1 and ANGPT2 have either pro- or 
anti-angiogenic effects and are believed to oppose each others function by competing 
for binding to TIE-2 (Maisonpierre et al., 1997). The general model is that ANGPT1, 
which is expressed by mural cells, pericytes and fibroblasts, activates TIE-2 on 
endothelial cells which results in stabilization of endothelial junctions and 
recruitment of pericytes, ultimately leading to vascular quiescence (Saharinen et al., 
2008). ANGPT2 is predominantly expressed by endothelial cells and stored in 
specialized granules (Weibel-Palade bodies), from where it is released upon 
angiogenic or inflammatory activation. ANGPT2 normally does not induce TIE-2 
phosphorylation. Instead, it inhibits activation of TIE-2 by ANGPT1, leading to 
vessel destabilization and pericyte detachment and thereby sensitizes endothelial 
cells to angiogenic and pro-inflammatory signals (Fiedler et al., 2006). 
 
Inflammatory cells associated with the inflammatory stage of wound healing 
promote angiogenesis. Chronic inflammation is characterised by an increase in 
oxygen utilisation by the neutrophil cells leading to localised hypoxia. This condition 
induces stabilisation of HIF-1α that stimulates pro-angiogenic growth factors 
(Bonnet and Walsh, 2005). Pro-inflammatory cytokines activate endothelial cells 
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thereby inducing development of several angiogenesis stimulating factors such as 
matrix-degrading proteases. Inflammatory cells produce chemokines that are 
involved in control of angiogenesis. Leukocytes that are recruited from the blood 
stream to the inflammation site secrete a number of pro-angiogenic factors such as 
VEGF (Boghozian et al., 2013).  
Angiogenesis is down-regulated by anti-angiogenic factors such as as angiostatin, 
endostatin and thrombospondin (TSP-1) (Lawler and Lawler, 2012). These factors 
inhibit angiogenesis through antagonising the effects of VEGF. Angiostatin is a 38 
kDa proteolytic fragment of a larger protein, plasminogen (O'Reilly et al., 1994). 
Endostatin is a naturally-occurring, 20-kDa C-terminal fragment derived from type 
XVIII collagen, a component of the extracellular matrix (ECM) (O'Reilly et al., 
1997). Both angiostatin and endostatin have been shown to inhibit endothelial cell 
migration in response to FGF and VEGF stimulation (Eriksson et al., 2003).  
However, the agents have been shown to have many pleiotropic effects in endothelial 
cells. Thrombospondin-1 (TSP-1), a multifunctional extracellular protein, was the 
first naturally occurring angiostatic agent to be discovered (Good et al., 1990). 
Unlike many angiostatic agents such as endostatin and angiostatin, TSP-1 is not a 
cleavage product and is effective as native, full-length protein (Tabruyn and 
Griffioen, 2007). The antiangiogenic effects of thrombospondin (TSP-1) have been 
most extensively characterized in the tumour microenvironment. TSP-1 antagonizes 
VEGF in several important ways, via inhibition of VEGF release from the 
extracellular matrix, direct interaction, and inhibition of VEGF signal transduction 
(Good et al., 1990). Thrombospondin binds to CD3, CD47 and integrin receptors. 
CD36 and beta-1 integrins work together in transmitting signals initiated by the anti-




VEGF-A is the most potent stimulator of angiogenesis. It is produced by a wide 
variety of cells, organs and tissues including tumour cells, the corpus luteum, the 
heart, liver, stomach mucosa, adrenal cortex cardiac myocytes, renal glomeruli, 
epithelial cells of lung and macrophages (Berse et al., 1992).  
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 The importance of VEGF-A in vascular function was highlighted by the fact that 
VEGF-A knock out in mice results in such severe defects that mice die due to a lack 
of vascular development at E9.5-10.5 (Carmeliet et al., 1996). Another study 
demonstrated that the lack of just one VEGF-A allele results in death and vascular 
abnormalities at E11-12 (Ferrara et al., 1996).  
 
In humans the VEGF-A gene is located on chromosome 6p21.3 (Vincenti et al., 
1996). Six VEGF-A splice variants are expressed in humans, differing in the number 
of amino acids they contain and are named accordingly; VEGF-A121, VEGF-A145, 
VEGF-A165, VEGF-A183, VEGF-A189 and VEGF-A206. (Figure 1.1) (Robinson and 
Stringer, 2001). The most commonly expressed isoform is VEGF-A165, which like all 




Figure 1.1:Exon structure of human VEGF-A mRNA splice variants 
This diagram illustrates the gene encoding VEGF-A comparing the 8 exons which code for 
the different motifs. In humans the most predominant form is VEGF-A165. Different mRNA 
splicing can generate the formation of many isoforms that vary in amino acid number. 
Adapted from Holmes et al., 2007. 
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VEGF-A121 lacks any heparin binding domains from exons 6 and 7 whereas the other 
variants have varying numbers of these domains. These heparin binding domains 
allow VEGF isoforms to bind to heparan sulfate proteoglycan (HSPG) and the co-
receptor neuropilins in the extracellular matrix (ECM), which help enhance 
activation and migration in endothelial cells. VEGF isoforms also contain a plasmin 
cleavage domain which has been shown to play a key role in cleaving ECM-bound 
VEGF thereby releasing soluble and bioactive proteolytic fragments (Park et al., 
1993). In 2005 it was demonstrated that extracellular VEGF can be regulated by 
matrix metalloproteinases (MMPs) and that they may cleave matrix bound VEGF-
A165 to generate non-heparin binding fragments indicating that the regulation of 
extracellular VEGF may also play a critical role in vascular development (Lee et al., 
2005).  
As discussed previously, one of the key regulators of VEGF-A expression is oxygen 
tension. Alterations in the amount of oxygen tension during hypoxia results in a 
significant increase in the expression of VEGF-A mRNA through the hypoxia 
responsive element in the 5ʹ′ and 3ʹ′ flanking regions of human VEGF-A gene 
(Minchenko et al., 1993, Shweiki et al., 1992). In addition to the classical VEGF-A 
isoforms, a novel VEGF-A165b isoform was discovered and reported as a key 
regulator of angiogenesis in health and disease (Bates et al., 2002, Perrin et al., 
2005). VEGFA-A165b is generated by exon 8 distal splice site (DSS) selection. It has 
been reported that alternative VEGF-A mRNA splicing potentially generates two 
families of proteins that differ by their c-terminal six amino acids. The difference 
between VEGF-A165 and VEGF-A165b is a change of the 6 c-terminal the amino 
acids from CDKPRR to SLTRKD (Harper and Bates, 2008). It has been shown that 
VEGF-165b behaves as a partial VEGFR-2 agonist (Kawamura et al., 2008) as it is no 
longer able to bind to neuropilin.  More recent data has shown that in vivo, 
overexpression of VEGF165b, leads to insufficient angiogenesis in patients with 
systemic sclerosis (Manetti et al., 2011). 
1.3.2 The VEGF Receptors 	  
 
It has been shown that VEGF receptors function similarly to other receptor tyrosine 
kinases such as epidermal growth factor receptor (EGFR), hepatocyte growth factor 
receptor (HGFR) and platelet derived growth factor receptor (PDGFR). Ligand 
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interaction with the cognate receptor induces receptor dimerization, which creates a 
docking site for signalling and the activation of the tyrosine kinase. In addition, 
VEGFRs induce cellular functions that are common to wide variety of growth factor 
receptors which include cell survival, proliferation and cell migration (Olsson et al., 
2006). VEGF-A can also bind to neuropilin, which acts as a co-receptor for VEGF-
A, augmenting its signalling (Soker et al., 1998).  
 
	  
Figure 1.2: VEGF receptor binding properties 
This diagram shows the different VEGF ligands and which VEGF receptors they are able to 
bind to. Adapted from Holmes et al., 2007. 
 	  
The VEGFR receptors are key regulators of angiogenesis; vasculogenesis and 
lymphangiogenesis (Lohela et al., 2009). VEGF receptors are expressed on a range 
of different cell types. VEGFR1 (Flt1) plays a role in hematopoietic stem cell 
migration of macrophages and monocytes (Olsson et al., 2006). VEGFR1 and 
VEGFR2 (Flk1/KDR) are both expressed on the vascular endothelial cells (Olsson et 
al., 2006). VEGFR2 activates a range of responses such as cells migration and 
proliferation ultimately leading to angiogenesis (Zeng et al., 2002, Holmes et al., 
2007). VEGFR3 (Flt4) is expressed predominantly on lymphatic endothelial cells 
(see Figure 1.1 and Figure 1.2) (Olsson et al., 2006). VEGF-A has been shown to 
bind and activate VEGFR1 and 2 on endothelial cells (Figure 1.2). The co-receptor 
neuropilins (NRP-1&2) are transmembrane non-protein tyrosine kinases which have 
been shown to interact with VEGFR2 in the presence of VEGF-A165 at endogenous 
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and exogenous levels in endothelial cells (Whitaker et al., 2001). When VEGF-A 
binds to neuropilin it promotes complex formation with VEGFR2 and enhances 
VEGFR-2 function (Whitaker et al., 2001, Soker et al., 2002, Terman et al., 1991, 
Simons, 2012). 
 
VEGF-B binds only to VEGFR1; this interaction however can be blocked by excess 
VEGFR1 suggesting that binding sites on the receptor are somewhat overlapping 
(Olofsson et al., 1998). Although VEGF-C and D have been shown to play a role in 
the development of primary capillary vasculatures of mid-gestation embryos, they 
later promote the growth and maintenance of the lymphatic vasculature (Mäkinen et 
al., 2001). Both VEGF- C and D are initially secreted as pro-peptides, which then 
undergo proteolytic processing. Partially processed VEGF-C and VEGF-D can bind 
to and activate VEGFR-3, whereas the fully processed forms of VEGF-C and VEGF-
D can bind to and activate both VEGFR-2 and VEGFR-3 (Joukov et al., 1996).  
 
Studies have identified a novel member of the VEGF family termed VEGF-E, which 
is encoded in the sequence of parapox Orf virus. VEGF-E binds with high affinity 
only to VEGFR2, which leads to receptor autophosphorylation and increases calcium 
(Ca2+) concentration. This suggests the activation of VEGFR2 can stimulate 
angiogenesis (Meyer et al., 1999, Simons, 2012).  
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Figure 1.3: Receptor tyrosine kinase expression patterns and downstream functioning 
VEGFR1 is expressed on haematopoietic stem cells, monocytes, vascular endothelium and 
macrophages. VEGFR2 is expressed on lymphatic and vascular endothelium. VEGFR3 is 
predominantly expressed on the lymphatic endothelium. The cellular effect on these 
receptors in the vascular endothelium includes cell migration, proliferation, survival and 




In early mouse development, VEGFR2 was initially identified at E7.0 in mesodermal 
blood island progenitors. Later in development, expression is located in the blood 
vessels and developing endothelial cells suggesting that it could be an early marker 
of endothelial cell precursors (Yamaguchi et al., 1993). The most significant function 
of VEGFR2 has been revealed through a study of knockout mice which 
demonstrated that VEGFR-2 -/- mutant embryos die in utero between E8.5 and 9.5 
because of damage in development in endothelial cells, haematopoietic and blood 
islands, which suggests that VEGFR2 is critical for vasculogenesis in the developing 
mouse embryo (Shalaby et al., 1995). 
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1.3.4 VEGFR2 Intracellular Signalling 
 
VEGFR2 (also known as kinase-insert domain receptor (KDR) and foetal liver 
kinase (Flk)-1) plays a critical role in cellular physiology, pathological and vascular 
development upon stimulation by VEGF-A in endothelial cells.  In 1991 Terman and 
colleagues identified VEGFR2 from a human endothelial cell cDNA library. The 
human VEGFR2 gene is 7.0 kb and is located on chromosome 4 (Terman et al., 
1991). In-depth analysis using in situ hybridization has localized the human 
VEGFR2 gene to chromosome 4q11q12 which is in close proximity to the locus of 
two other RTKs namely PDGFR-α and c-KIT (Shibuya, 2002). Full-length VEGFR2 
is 1365 amino acids (Sait et al., 1995) and structurally comprises an extracellular 
region containing 7 immunoglobulin-like (Ig-like) domains and an intracellular 
(cytoplasmic) region which contains the tyrosine kinase domain (Shibuya, 2002). 
The immature form of VEGFR2 is translated as a 150-kDa protein without 
glycosylation. It then undergoes post-translational modification in the form of 
glycosylation after which it is expressed on the cell surface as a mature 230 kDa 
protein (Takahashi and Shibuya, 1997).  
 
The first mapping of VEGFR2 to determine the location of residues implicated in 
autophosphorylation in a bacterial model identified tyrosines Y951, Y996, Y1054, 
Y1059 as potential phosphorylation sites. These were later determined to be the 
identical phosphorylated sites of VEGF2 in human cells (Doughervermazen et al., 
1994). VEGFR2 binds to phospholipase Cγ through the autophosphorylation sites 
Y801 and Y1175 (Cunningham et al., 1997). The main phosphorylation sites of 
VEGFR2 are Y951 in the kinase insert domain and Y1175 and Y1214 located in the 
C-terminal tail of the receptor (Matsumoto et al., 2005).  
 
After phosphorylation of tyrosine Y951, VEGFR-associated protein (VRAP also 
known as T-cell adaptor TSAd) is able to bind VEGFR2. VRAP is a highly 
expressed adaptor protein that has been identified in human umbilical vein 
endothelial cells (HUVECs), spleen, peripheral leukocytes, thymus, heart and lung. 
In endothelial cells VRAP acts to recruit downstream effector protein such as PLCγ 
and PI3 kinase to induce physiological responses (Wu et al., 2000). 
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Figure 1.4: VEGFR-2 intracellular signalling 
VEGF-A binding to VEGFR2 leads to dimerisation and autophosphorylation at specific 
tyrosine residues. The resulting downstream signalling cascade stimulates cell survival, 
permeability, migration and proliferation. Adapted from Holmes et al., 2007. 
 
1.3.5 VEGFR2 and Cell Survival 	  
In a study of HUVECs, VEGF activation of VEGFR2 was able to prevent apoptosis 
occurring through the activation of the PI3K/AKT signal transduction pathway 
(Gerber et al., 1998a).  
 
Phosphoinositide 3-kinase (PI3K) is activated in response to VEGFR2 stimulation to 
catalyse the production of membrane bound phosphatidylinositol (3,4,5)-
trisphosphate (PIP3) from phosphatidylinositol (4,5)-bisphosphate (PIP2). PIP3 then 
engages the AKT PH domain, resulting in the translocation of AKT from the 
cytoplasm to the plasma membrane and enhances conformational changes that reveal 
the catalytic kinase core. This prepares AKT for phosphorylation at two regulatory 
sites.  Firstly, phosphorylation of Thr308 within the catalytic domain, which is 
mediated by phosphoinositide-dependent kinases 1 (PDK 1) (Lawlor and Alessi, 
2001). Secondly, the Ser473 in the hydrophobic motif, which has been proposed to 
Chapter 1                                                                                                     Introduction 
	  15	  
occur through phosphoinositide-dependent kinases 2 (PDK 2) (Toker and Marmiroli, 
2014, Cantley, 2002). This activated AKT then inhibits two pro-apoptotic proteins, 
Bcl-2 associated death promoter (BAD) and caspase 9 by phosphorylating them and 
suppressing apoptosis therefore supporting cell survival (Cardone et al., 1998) (Song 
et al., 2005). VEGF-A also induces the expression of anti-apoptotic proteins Bcl-2 
and A1, which have been shown to play a critical role in mediating the survival of 
endothelial cells (Gerber et al., 1998a).  More recent data has shown that VEGF-
mediated activation of the ERK5 kinase is able to regulate AKT phosphorylation and 
tubular morphogenesis  in human endothelial cells (Roberts et al., 2010).  
 
Survival of endothelial cells can also be affected by the surrounding 
microenvironment of the extracellular matrix. VEGFR2 can interact with integrin 
αvβ3 which results in enhanced VEGFR2 activation and AKT activity (Soldi et al., 
1999). Furthermore, VEGF mediated angiogenesis has been shown to induce 
expression of α1β1 and α2β2 integrins in endothelial cells, which appears to increase 
angiogenic potential and vessel formation on collagen (Senger et al., 1997). 
 
1.3.6 Cell motility  	  
Cell motility is defined as the ability to move actively while consuming energy 
resources at the same time. Cell migration is a complex, dynamic process that 
involves continuous remodeling of the cellular architecture, which is needed in order 
for the cell to move and adapt to changes in the surrounding environment. Cell 
migration in a 3D extracellular matrix (ECM) is a multistep process involving 
changes in the cytoskeleton, cell-substrate adhesions and the extracellular matrix 
components. Cell migration is generally initiated in response to extracellular stimuli, 
which can be diffusible factors, signals on neighboring cells, and/or signals from the 
extracellular matrix. Cell migration is regulated by the coordinated activation of Rho 
family GTPases (Hall, 1998), which regulate various aspects of cytoskeletal 
reorganisation. In 1992,  Hall and co-workers identified Rho-A as a regulator of 
lyso-phosphatidic acid (LPA)-mediated actin-stress fibre formation (Ridley and Hall, 
1992) and Rac as a regulator of growth factor stimulated lamellipodia (membrane 
ruffle) formation (Ridley et al., 1992). Later work revealed that, upon activation, 
Cdc42 induced peripheral actin-rich microspikes (filopodia) and also activated Rac 
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(producing lamellipodia), demonstrating cross-talk within the Rho family (Nobes and 
Hall, 1995, Kozma et al., 1995).  Over the last two decades research has revealed the 
molecular regulation of Rho family GTPases and cytoskeletal reorganisation leading 
to cell migration, which can be divided into five separate steps (Lauffenburger and 
Horwitz, 1996):  
 
1) Lamellipodia extension at the leading edge: Lamellipodia consist of 
branched or unbranched filament networks formed through the actin nucleating 
activity of the actin-related proteins 2/3 (Arp2/3) protein complex (Pollard et al., 
2000). Rac-1 regulates lamellipodia formation in response to growth factors 
(Hall, 1998). Rac-1 activation is dependent on phosphoinositide 3-kinase (PI3K) 
activity generating phosphatidylinositol (3,4,5)P3 (PIP3) which activates Vav, the 
Rac guanidine exchange factor (GEF) (Buchsbaum, 2007). 
2) Formation of new focal adhesions complexes: Extending lammelipodia and 
filpodia make contact with the ECM via integrin attachment leading to activation 
of focal adhesion kinase (FAK). FAK is known to regulate Rho-mediated actin 
stress fibre formation FAK by phosphorylation and activation of p190RhoGEF 
(Zhai et al., 2003). 
3) Secretion of surface protease to ECM contacts and focalized proteolysis: 
In order for cells to migrate it is important to degrade the ECM (Murphy and 
Gavrilovic, 1999). Activated Rac-1 can induce expression of matrix 
metalloproteinase (MMP1) in fibroblasts (Kheradmand et al., 1998) and MMP2 
in tumour cells (Zhuge and Xu, 2001) facilitating cell migration. 
4) Cell body contraction by actomyosin complexes: Stress-fibre assembly and 
contraction are controlled by myosin II and induced by Rho and its important 
downstream effector, the Rho-associated serine/threonine kinase (ROCK).  Rho 
acts via ROCKs to affect myosin light chain phosphorylation. This generates 
tension forces which enable retraction of the rear of cell body during migration 
(Vicente-Manzanares et al., 2008).  
5) Tail detachment: Cell-substrate linkages are preferentially disrupted at the 
trailing edge of the cell whereas the leading edge remains attached to the ECM 
and further elongates (Palecek et al., 1998).	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1.3.7 VEGFR2 and Cell Migration 	  
Migration of endothelial cells is one of the key factors in angiogenesis. (Holmes et 
al., 2007). Angiogenesis only occurs when endothelial cells migrate towards their 
target. This is controlled by haptotactic, chemotactic and mechanotactic stimuli, 
which in turn promote cell migration (Lamalice et al., 2007). Chemotaxis is the 
process by which cells migrate in a directional manner along a gradient of 
chemoattractant, usually in a fluid phase. One mechanism of chemotaxis is called 
haptotaxis, which occurs when attractant molecules are attached to a support such as 
the extracellular matrix (Seppä et al., 1982). In addition, necrotaxis is a special type 
of chemotaxis, which takes place when chemoattractant molecules are released from 
apoptotic or necrotic cells. These attractant molecules can influence both cell 
migration, direction, and speed (Lauber et al., 2003, Zachary, 2003). 
 
Cell migration is a critical component of the angiogenic response as endothelial cells 
migrate towards growth factors such as VEGF and FGF. The extracellular matrix is 
critical for stabilising blood vessels through interaction with smooth muscle cells 
(SMCs), endothelial cells and the basement membrane. These must all be remodelled 
so that cells can migrate and form new blood vessels during disease and development 
(Zachary, 2003). This blood vessel interaction can occur by triggered induction of 
matrix metalloproteinases (MMPs). There are two MMPs, MMP2 and MMP9, that 
have been shown to play a critical role in enhancing tumour angiogenesis and have 
been seen to be upregulated along with VEGFR2 in angiogenic lesions (Lee et al., 
2005). VEGF receptor-associated protein (VRAP) binds to phosphorylated Y951 of 
VEGFR2. Its importance has been highlighted as gene ablation of VRAP in mice has 
been shown to block VEGF-A mediated reorganization of the cytoskeleton and cell 
migration (Matsumoto et al., 2005). VEGFR-2 also utilises the adaptor protein Shb 
to regulate cell migration. The Shb protein has been shown to bind to phosphorylated 
Y1175 in the VEGFR-2  and to regulate activation of PI 3-Kinase and FAK-
mediated focal adhesion formation (Holmqvist et al., 2004).   
 
Rho GTPases play a critical role in cell migration and endothelial cell permeability 
(Wojciak-Stothard and Ridley, 2002). Proteins like Rac1 and RhoA are activated by 
VEGFR2 phosphorylation at Tyr 951 in response to VEGF-A, which is required for 
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VEGFR2 mediated endothelial cell migration (Zeng et al., 2002). In addition, a 
recent study analysing RhoJ, which is  known to be expressed in endothelial cells 
and to regulate endothelial cell chemotaxis (Kaur et al., 2011), reported that RhoJ -/- 
mice show a reduction in human xenograft tumour growth and diminished tumour 
vessel density (Wilson et al., 2014). 
 
 
Phosphorylation of Y1214 on VEGFR2 activation recruits Nck, which leads to the 
sequential activation of Fyn, and then Cdc42, which in turn activates enhanced stress 
activated protein kinase, which is also known as p38 mitogen-activated protein 
kinase (SAPK2/p38 MAPK) leading to actin polymerization and cytoskeleton 
reorganization in endothelial cells (Lamalice et al., 2004). This leads to 
phosphorylation of Heat Shock Protein 27 (HSP27) which is an actin capping 
protein, that once removed allows for actin polymerisation (Lamalice et al., 2007).  
 
Studies in fibroblasts have shown that phosphoinositide 3-kinase (PI3-kinase) plays a 
critical role in cell migration; through the generation of phosphatidylinositol (3,4,5)-
trisphosphate (PIP3)it is able to activate guanosine triphosphate (GTP) binding 
protein Rac, which results in membrane ruffles and cell motility (Ridley et al., 1992). 
The Grb2 bound adaptor protein Gab1 has been shown to couple VEGFR2 activation 
with PI3K/AKT and enhance cellular migration. Gab1 has been demonstrated to bind 
to the p85 subunit of PI3 Kinase and activate it, although the precise site of 
interaction with VEGFR2 is unclear (Dance et al., 2006). 
 
Angiogenesis is a complex process that involves the co-ordinated response of 
endothelial cells to form branched structures. There are two cell types that have been 
identified to be involved in this process. Firstly, specialised tip cells at the leading 
front of an angiogenic sprout, form long filopodia in response to VEGF-A. These 
filopodia are guided by VEGF-A gradients leading to directed migration. Secondly, 
stalk cells, which sit behind this leading cell, respond to VEGF-A by proliferating 
rather than migrating. This response is regulated by VEGF-A concentration to 
enhance stalk cell elongation (Gerhardt et al., 2003). Recent studies in endothelial 
cells have linked tip cells to increased expression of Delta-like 4 (DLL4). DLL4 is 
known to be upregulated in response to VEGF signalling in endothelial cells and is 
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induced preferentially in tip cells as they are in contact with the highest levels of 
VEGF. This membrane bound DLL4 in the tip cell then activates the Notch 
Receptor, which is expressed by adjacent stalk cells. This Notch signalling then 
down-regulates the expression of VEGFR2 whilst increasing the expression of 
VEGFR1, further increasing the VEGF response gap between the stalk and tip cells 
(Affolter et al., 2009, Tung et al., 2012).  
 
The complex formation of a vessel network is therefore carefully regulated by the 
specific expression and distribution of VEGF, which is secreted by a wide variety of 
cells in response to hypoxia and the signalling interactions between DLL4 and Notch 
that result in endothelial cell migration and tube formation towards hypoxic areas 
(Fraisl et al., 2009, Affolter et al., 2009). 
 
1.3.8 VEGFR2 Cell Proliferation 
 
VEGFR2 activates cell proliferation via the typical extracellular signal-regulated 
kinase (Erk) pathway. VEGFR2 signalling occurs through activation of the Raf-1-
MEK-MAP kinase cascade, however this seems to be independent of Ras. Studies 
have shown that dominant negative Ras in primary sinusoidal endothelial cells, did 
not block VEGF activation of MAP kinase phosphorylation to the same extent as 
blockade of PKC (Xia et al., 1996). This suggests that VEGF induced activation of 
Erk is through a PKC-dependent pathway which also includes the activation of PLCγ 
(Takahashi et al., 1999, Takahashi et al., 2001). Further studies have determined that 
Ras is linked to proliferation in HUVEC cells via a PKC-dependent pathway. 
(Meadows et al., 2001, Shu et al., 2002).  
 
Autophosphorylation of Y1175 in the C-terminal tail of VEGF2 results in the 
binding of PLCγ. Once PLCγ is bound, it is phosphorylated resulting in enhanced 
catalytic activity. Mutations of Y1175 which block PLCγ binding, significantly 
reduced MAP kinase phosphorylation and DNA synthesis, suggesting that this 
interaction is crucial for endothelial cell proliferation (Takahashi et al., 2001).  
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PLCγ hydrolyses membrane bound PIP2 to generate diacylglycerol (DAG) and 
inositol 1,4,5-trisphosphate (IP3). DAG is a physiological activator of PKC whilst IP3 
production enhances the intracellular calcium concentration by binding to the IP3 
receptor on the endoplasmic reticulum (ER) stimulating release of Ca2+ stores. 
Proliferation in endothelial cells has been linked to several PKC isoforms including 
α, β and ζ (Xia et al., 1996, Wellner et al., 1999).  
 
1.3.9 VEGFR2 Trafficking and Internalization   	  
 
Membrane trafficking is important for receptors to detect and respond to external 
signals (Murphy et al., 2009). Ligand induced activation of receptor tyrosine kinases 
enhances internalization and trafficking that promotes signalling from plasma 
membrane and endosomal compartments and ends through lysosomal degradation of 
the receptor (Horowitz and Seerapu, 2012). Trafficking of VEGFR2 is regulated by 
different mechanisms to other well-characterised growth factor receptors, e.g. EGFR. 
VEGFR2 activation occurs by binding VEGF to VEGFR2 which then induces 
internalization of VEGFR2 by endocytosis. The VEGFR-2 can then be either 
recycled back to the cell surface, or is delivered to the lysosome for subsequent 
degradation. Unlike other growth factor receptors, VEGFR2 is constantly cycling 
between a membrane pool and a cytosolic pool. Receptor tyrosine kinase 
internalization occurs through the canonical clathrin-dependent endocytic pathway 
that implicates the small GTP binding protein Rab5 (Goh and Sorkin 2013). 
VEGFR2 internalisation requires ancilliary proteins such as neuropilin 1 (Soker et 
al., 1998), synectin (Lanahan et al., 2010), and ephrin-B2 (Sawamiphak et al., 2010). 
Dephosphorylation of VEGFR2 is regulated by a variety of recently identified 
phosphatases such as DEP1 (Lampugnani et al., 2003) and VE-PTP, which cause 
delayed VEGFR2 internalisation (Mellberg et al., 2009).  
 
In vitro studies have revealed that in the absence of VE-cadherin, VEGFR2 
undergoes rapid internalisation and is retained in endosomes for longer periods of 
time (Lampugnani et al., 2006). Further studies suggest that VEGFR2 internalisation 
may be controlled by another receptor tyrosine kinase, ephrin-B2. Ephrin-B2 located 
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at the tip cell filopodia may regulate activation of VEGFR2 signalling endocytosis to 
filopodial extension (Sawamiphak et al., 2010).  
Stimulation of cells with the NRP-1–binding VEGF-A165 led to sequential NRP-1–
mediated VEGFR-2 recycling through Rab5, Rab4, and Rab11 vesicles. Recycling 
was accompanied by dephosphorylation of VEGFR-2 between Rab4 and Rab11 
vesicles. Interestingly, in cells stimulated with VEGF-A165b, an isoform unable to 
bind NRP-1, VEGFR-2 bypassed Rab11 vesicles and was routed to the degradative 
pathway specified by Rab7 vesicles (Ballmer-Hofer et al., 2011). Co-localisation of 
internalised VEGFR-2 with GTPase and Rab7 required for late endosome fusion 
with lysosomes, indicating that VEGFR-2 was targeted to that compartment rather 
than to the proteasome (Stenmark, 2009).  
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Figure 1.5: VEGFR-2 internalisation 
This figure illustrates VEGFR-2 internalisation after VEGF-A by endocytosis. 
VEGFR2 is mobilised by myosin and cross-linked to neuropilin (Nrp) via synectin 
and internalises together with Nrp to Early Endosomes (EE) through Rab5. Then 
early endosomes bring Nrp and VEGF complex to recycling endosomes (RE) 
through Rab4. Recycling to the cell surface occurs via Rab11 or to lysosomes for 
degradation through Rab7. This mechanism shows how VGFR signalling from the 
cell surface via early endosomes results in down-stream activation in Akt and Erk 
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1.4 Phospholipases  
Phospholipids consist of a fatty acid backbone, phosphate groups, glycerol unit and 
polar head group molecules. Phospholipase enzymes hydrolyse the membrane 
phospholipids phosphatidylcholine, phosphatidylserine, phosphatidylglycerol and 
phosphatidylethanolamine. Phospholipids are hydrolysed by lipolytic enzyme that 
include: phospholipase A, phospholipase C and phospholipase D, resulting in the 
conversion of phospholipids into lipid mediators or second messengers that regulate 
many physiological and pathological cell functions. Dysfunction of phospholipase 
activity is implicated in diseases such as inflammation and cancer progression 
(Brown et al., 1993, Flower and Blackwell, 1979).  
	  
Figure 1.6: Phospholipases 
This diagram illustrates the site of action of different phospholipase enzymes in hydrolysing 
phospholipids. Adapted from Vasudevan et al., 2010. 	  	  
1.4.1 Phospholipase D  	  
Phospholipase D (PLD) is an enzyme whose key function is to hydrolyse 
phosphatidyl choline (PtdCho) to produce the signalling molecule phosphatidic acid 
(PtdOH) and choline (Cho) (Figure 1.7). The PLD reaction activity relies on PIP2 as 
a co-factor through conversion of phosphatidylcholine to phosphatidic acid. In the 
plasma membrane, PIP2 co-localises with Arf- and Rho-regulated PLD as a result of 
possible docking of PLD (Hammond et al., 1997).  Two mammalian isoforms of 
PLD have been cloned; PLD1 localized on the long arm (q) of chromosome 3 (3q26) 
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(Park et al., 1998a) and PLD2 localized on the short arm (p) of chromosome 17 
(17p13) (Park et al., 1998b). 
 
Figure 1.7: Phospholipase D hydrolysis 
Phospholipase D hydrolysis of phosphatidylcholine generates phosphatidic acid and choline. 
Adapted from Formhman and Morris, 1999.  	  
1.4.2 Structure of Mammalian Phospholipase D Isoforms 	  
The first structure for PLD was determined from Streptomyces and bacterial 
endonucleases. The overall structure of PLD is four highly conserved functional and 
structural domains as illustrated in Figure 1.8 and discussed below.  
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Figure 1.8: Structure and domains of PLD family members 
A schematic of mammalian phospholipase D. Top line illustrates amino acid (aa) position. 
PX, Phox homology domain and PH, Pleackstrin homology domain mediate protein and 
lipid binding; HKD domain consists of HxKxxxxD/E mediating the catalytic reactions; PIP2, 
a second phosphatidylinositol 4,5-bisphosphate; Loop domain located in PLD1. Adapted 
from Peng and Forhman, 2012. 	  
1.4.3 HKD Domain 	  
The PLD superfamily structure possesses two HKD catalytic domains, which are 
defined by the peptide sequence HxK(x)4D(x)6GSxN. The HKD domains confer 
strong PLD enzymatic activity and are located in the N-terminal and C-terminal 
regions (Xie et al., 1998). PLD plays a role in membrane vesicular trafficking and 
cell signalling. By using site-directed mutagenesis, point mutations in PLD1 suggest 
the HKD domain and specific serines/threonines in all members of the PLD 
superfamily are critical for PLD activity and catalytic mechanisms (Sung et al., 
1997). 	  
1.4.4 Pleckstrin Homology (PH) Domain  
 
The PH domain is highly conserved between PLD1 and PLD2 and has been shown to 
be involved in the binding of PIP as well as a number of other proteins. The PH 
domains of PLD1 and PLD2 have been shown to modulate membrane-recycling 
machinery. There are two PLD isoforms, PLD1 and PLD2, which share similar 
domain structures. Both PLD isoform activities rely on PtdIns(4,5)P2. In addition, 
high affinity to lipid surfaces containing PtdIns(4,5)P2 bound to PLD1 indicates a 
critical role for the PH domain in PLD function.. In summary, the PH domain 
regulates PLD enzyme activity by mediating interaction with polyphosphoinositide, 
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inducing conformational change, thus regulating catalytic activity (Hodgkin et al., 
2000).  
 
PLD generates a lipid-signalling pathway that coordinates membrane trafficking with 
cellular signalling. Both human and yeast PLD contain N-terminal PH domains that 
specify both regulation of PLD activity and subcellular localisation through 
interaction with PtdIns(4,5)P2. Mutation of PLD PH domains in human and yeast 
generates active PtdIns(4,5)P2-regulated enzymes with impaired biological function. 
Rearrangement of the PH domain of PLD2 causes re-localisation of the protein from 
PtdIns(4,5)P2 containing plasma membrane to the endosome (Sciorra et al., 2002). 
Disruption of the PH domain can be caused by mutations within the PH in vivo. As a 
result, phosphoinositides have a dual role in PLD regulation: stimulation of catalysis 
mediated by a polybasic motif and membrane targeting mediated by the PH domain 
(Sciorra et al., 2002). 
1.4.5 Phox Homology (PX) Domain 
 
Phosphoinositides are regulators of diverse cellular processes. PX domains are 
located in a wide range of signalling molecules and bind simultaneously to 
PtdIns(3)P, PtdIns(3,)P2, PtdIns(4,5)P2, PtdIns(3,5)P2 (XU et al., 2001). PLD 
facilitates membrane trafficking, and PLD subcellular localisation is regulated by 
PX, PH domains and PtdIns(4,5)P2-binding sites critical for PLD activation. In COS-
7 cells, PLD co-localises to perinuclear endosomes and the Golgi apparatus. Under 
stimulation, PLD1 translocates to the plasma membrane and then returns to the 
endosomes. The PtdIns(4,5)P2  is known to mediate outward translocation and 
interaction with the plasma membrane. In the absence of a PX domain, PLD was 
unable to translocate to the endosomes. The PX and PH domains play a role in 
internalization; however, the PH domain drives PLD1 to enter into the lipid raft. In 
comparison, the PX domain mediated binding to PI5P, which is a known lipid 
recognized to accumulate in endocytosing vesicular trafficking. This study concluded 
that the PX domain is required for PLD1-regulated exocytosis in PC12 cells (Du et 
al., 2003).   
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1.4.6 PLD Expression 	  
Phospholipase D activity was first identified in 1947 in carrots (Hanahan and 
Chaikoff, 1947) and cabbage leaves (Hanahan and Chaikoff, 1948). The 
investigation of PLD over the past 60 years has demonstrated many physiological 
functions such as cardiac and neuronal roles as well as implications in the 
development of disease. PLD has been shown to be expressed and extracted from rat 
liver, heart, lung, testis and brain (Bocckino et al., 1991). Currently, specific 
monoclonal antibodies are commercially available for PLD1, though, due to the lack 
of a good commercial antibody for PLD2, studies rely on mRNA analysis (Scott et 
al., 2009). 
 
1.4.7 Animal Knockouts of PLD1 and PLD2  	  
PLD1 knockout mouse models have increased platelet aggregation leading to stroke 
or myocardial infarction, indicating that PLD1 is an essential regulator of platelet 
activity in cardiovascular or cerebrovascular diseases (Elvers et al., 2010). In 
addition, recent studies using PLD1 knockout mice have shown a decrease in 
starvation-induced autophagosome expansion, which indicates that the PLD1 
pathway modulates macroautophagy (Dall'Armi et al., 2010). PLD2 knockout mice 
identified a critical role for PLD2 in Alzheimer’s disease, suggesting that drugs 
targeting PLD2 could be a viable therapy target for neurodegenerative disease 
(Oliveira et al., 2010). Other reports on PLD2 knockout mice have reported normal 
development with the use of specific PLD inhibitors allowing the identification of 
PLD1 as a regulator of phorbol-ester-, chemoattractant, adhesion-dependent and Fcγ-
receptor-stimulated production of reactive oxygen species (ROS) in neutrophils 
(Norton et al., 2011). 
1.4.8 Physiological Role of PLD1 and PLD2 	  
The physiological role of PLD1 and PLD2 in cell function is based on siRNA 
knockdown, which established different functions for PLD1 and PLD2. The 
mammalian target of rapamycin (mTOR) regulates cell proliferation via ribosomal 
S6 kinase 1 (S6K1) (Fang et al., 2003). This study identified phosphatidic acid (PA) 
as a mediator of the mTOR pathway and proposed PLD1 as an upstream regulator of 
mTOR. Overexpression of PLD1 increased S6K1 activity in serum-stimulated cells 
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and, in contrast, knockdown of PLD1 in both HEK293 and COS-7 cells showed 
reduced cell size suggesting a critical role in cell growth. This study revealed that 
PLD1 was involved in the mTOR pathway and cell size control, suggesting a 
molecular mechanism for Cdc42 activation of S6K1, thus proposing a new signalling 
cascade to connect mitogenic signalling to the mTOR pathway through PLD1and 
Cdc42 (Fang et al., 2003).  
Generally, PLD is involved in multiple types of membrane vesicle trafficking 
signalling. Studies utilising overexpression of human PLD1 have reported 
localisation in the Golgi apparatus and perinuclear vesicles (Colley et al., 1997, Toda 
et al., 1999, Lucocq et al., 2001). In overexpression mouse studies, PLD2 was 
localized to the plasma membrane. Under serum stimulation conditions, 
internalisation of membrane vesicles occurs. In addition, overexpression and siRNA 
of PLD2 revealed that PLD2 blocks angiotensin II receptor internalization at the 
plasma membrane (Du et al., 2004). 
 
PLD activity generates phosphatidic acid and choline, which is implicated in the 
regulation of cytoskeleton reorganization. Mast cells stimulated with antigen also 
illustrate cytoskeleton rearrangement. By using butan-1-ol, which diverts the 
production of PA generated by PLD to the corresponding phosphatidylalcohol, 
butan-1-ol inhibited antigen-stimulated membrane ruffling (O'Luanaigh et al., 2002). 
Blocking by butan-1-ol was reversible, and the activation of PLD by antigen was 
required for PA production through membrane ruffling. Activation of PLD2 is 
essential for PIP2 generation, which regulates actin cytoskeleton rearrangement 
(O'Luanaigh et al., 2002). This is further supported by the work of Cross et al., who 
have shown a role for PLD in actin stress fibre formation and cytoskeletal 
rearrangement in endothelial cells (Cross et al., 1996). Both PLD1 and PLD2 are 
implicated in the control of the small GTPases, ARF and Rho. A recent review 
proposed that PLD2 plays a critical role in Rho function, where PLD1 activity is 
downstream of this activation (Rudge and Wakelam, 2009). A recent report by 
Powner et al., has concluded that PLD-derived PA regulates integrin activation and 
the propensity of the cell to adhere to the substratum (Powner et al., 2007).  
 
 
Chapter 1                                                                                                     Introduction 
	  29	  
1.4.9 Mammalian PLD Activities 	  
PLD catalyses the transphosphatidylation reaction, utilizing primary alcohols as a 
nucleophilic acceptor with a greater affinity than water in the production of 
phosphatidylalcohols, indicating that PLD plays multiple roles in controlling 
secretion and membrane trafficking (Frohman and Morris, 1999). To understand 
PLD activity, many studies have identified phosphatidylalcohol formation as a 
biological marker for the function of PLD and phosphatidic acid (PA).   
 
Additional studies have investigated stimuli such as phorbol esters, growth factors, 
GPTγS, FMLP, serum and ATP epinephrine to show activation of PLD activity, 
whereas PLD facilitates the degradation of phosphatidic acid and PtdCho in 
diacylglycerol pathways. In addition, a clear link demonstrated PLD hydrolysis of 
phosphatidylcholine and an increase in phosphatidic acid, which clarified that PLD 
was not involved in the phospholipase C pathway (Frohman and Morris, 1999). 
1.4.9.1 Receptor Tyrosine Kinases and PLD 	  
In many cell types, PLD has been activated by a wide variety of cytokines and 
growth factors, hormones and neurotransmitters. These growth factors act through 
cognate membrane receptors coupled to G-proteins whose final concentration 
stimulates downstream signalling cascades. Specifically, the receptor tyrosine kinase 
has been implicated to regulate PLD phosphorylation. In HUVEC, VEGFR2 co-
localized in the endothelial caveolae with PLD2 and Ras, which, in turn, suggests 
that PKC and PLD responded to VEGF stimulation and activate MEK and ERK 
pathways involved in the regulation of cellular function (Cho et al., 2004). 
1.4.9.2 Signalling Proteins such as PKC 
 
Phorbol esters stimulate activation of PKC in a range of cell types (Castagna et al., 
1982). Down-regulation of PKC isoforms by chronic exposure to phorbol esters 
leads to reduced PLD activity in most mammalian cells (Exton, 1997). In addition, 
there are three isoforms of PKCα: β or γ stimulated by DAG, Ca+2 and PtdSer. 
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1.4.9.3 Phosphorylation of PLD 
 
Selective inhibitors for tyrosine kinase have also implicated these kinases in the 
activation of PLD by agonists acting via these receptors that couple to G-protein. 
Vanadate, an inhibitor of tyrosine phosphatases (Weiser and Shenolikar, 2003), 
inhibited the activation of PLD by ATP in the human promonocytic leucocyte line 
(U937) (Dubyak et al., 1993). In addition, in Swiss 3T3 fibroblast cells, the effect of 
PKC down-regulation indicated that protein-tyrosine kinase and PKC participate to 
induce PLD activation in these cells (Kim and Exton, 1998).  
 
PLD phosphorylation has been identified to work indirectly and directly in regulating 
PLD (McDermott et al., 2004). Many studies have reported that PLD activation used 
a wide variety of growth factors, such as FGF, IGF-I and FGF-2, in vitro and in vivo. 
Using a selective inhibitor for protein kinase C, this study reports that the activation 
of EGF, IGF-I and bFGF stimulates PLD activity (Rydzewska and Morisset, 1995). 
Interestingly, EGF stimulates both PLD isoforms 1 and 2, whereas EGFR has been 
reported to induce phosphorylation only with PLD2 at the Tyr11 residue of PLD2 
following EGF stimulation (Slaaby et al., 1998).  
1.4.10 Intracellular localisation of PLD 	  	  
Phospholipase D1 and 2 have been expressed in many cells and tissues (Meier et al., 
1999). In MDCK-D1 cells, PLD activity has been characterised in the nuclei (Balboa 
and Insel, 1995), and has also been shown to be located in the Golgi complex, 
indicating a possible link between transport events and the lipid bilayer (Ktistakis et 
al., 1995). Furthermore, analysis of rat tissue samples has revealed that PLD is 
present in all tissue fractions with the highest activity in the spleen, lung and kidney. 
In subcellular fractions of rat liver, PLD activity was increased in all tissue 
compartments using GTP except microsomes and mitochondria, which showed low 
activity (Provost et al., 1996).  
Additional studies have shown the regulation of PLD by small GTP-binding proteins 
in a HL60 membrane study, which was activated by GPTγS and confirmed the 
critical role of phosphatidylinositol(4,5)P2.  This molecule is stimulated by small 
GTP-binding protein, which indicates that PLD activity plays a critical role in the 
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action of the ADP-ribosylation factor (Arf) (Brown et al., 1993). In another study, 
PLD expression was purified from pig brain, where it was localised in membranes, 
and showed an increase in activity by Rho, ARF, and PtdIns(4,5)P2, indicating 
localisation in the cell membrane and suggesting a link for the physiological 
regulation of PLD (Brown et al., 1995). Phosphorylation of cofilin by LIM-Kinase1 
caused relocalisation of PLD1 from the intracellular compartment to the plasma 
membrane (Han et al., 2007). Furthermore, in a study on human parotid duct cells, 
PLD was determined to be involved in the formation of Golgi-associated clathrin-
coated vesicles and in the structure of the Golgi apparatus (de Souza et al., 2014). A 
recent review showed that PLD1 is mostly localised in the endosome, Golgi 
apparatus, secretory granules and lysosome compared to PLD2, which is localised at 
the plasma membrane, indicating different physiological roles for phospholipase D 
isoforms (Peng and Frohman, 2012). 
1.4.11 Phospholipase D Inhibitors 	  
Due to the lack of commercial inhibitors, most studies of PLD inhibition depend on 
primary alcohols, for instance butan-1-ol, which prevents phosphatidic acid 
generation. The chemical reaction of PLD with primary alcohols causes 
transphosphatidylation, generating a phosphatidylalcohol alternative instead of 
phospatidic acid owing to the fact that primary alcohols are stronger nucleophilic 
acceptors in the transphosphatidylation reaction than water. The discovery of specific 
small molecule PLD inhibitors is essential for the PLD research field. A selective 
inhibitor called 5-fluoro-2-Indolyl des-chlorohalopemide (FIPI) has demonstrated the 
effective inhibition of PLD and prevents cell spreading, chemotaxis and cytoskeletal 
reorganization (Su et al., 2009, Monovich et al., 2007). Another PLD1 and PLD2 is  
halopemide, which is used therapeutically in psychiatric disorders and can inhibit 
dopamine receptors. Both inhibitors have been proposed as part of a novel approach 
for the treatment of cancer (Scott et al., 2009).  	  




Figure 1.9: Phospholipase D inhibitors structure 
This figure illustrates PLD structure. Halopemide is a potent inhibitor of PLD1and PLD2 
inhibiting both human PLD1 and PLD2 in vitro. CAY10594 is a potent inhibitor of PLD2, 
inhibiting human PLD2 in vitro. Adapted from Scott et al., 2009.  
 
 
1.4.12 Phospholipase D in Cancer and Tumour Angiogenesis 
 	  
Recently, research on phospholipase D and cancer has increased significantly. Breast 
cancer research has shown that PLD2 activity is involved in cell migration and in the 
growth and development of breast lung metastases in vivo. In the breast cancer model 
(MDA-MB-231), lentiviral-mediated PLD2 knockdown of cell followed by 
xenografts in mice indicates a reduction by about 65% of tumour compared to 
controls (Henkels et al., 2013). In support of a role for PLD2 in cancer, 
overexpression of PLD2 in breast cancer cells (MCF-7) using a retroviral vector 
followed by tumour xenografts in mice resulted in overgrowth and development of 
lung tumours (Hsu et al., 2010). Taken together this data implicates PLD2 in the 
development of metastasis and development of breast cancer, thus highlighting its 
potential as a selective therapeutic target (Hsu et al., 2010). 
1.4.13 Phospholipase D and Endothelial Function 
 
PLD has been demonstrated in many studies to play a critical role in endothelial cell 
function. A study carried out on bovine pulmonary artery endothelial cells (BPAEC) 
showed a breakdown of phosphatidylcholine (PC) following stimulation with 
purinergic agonist (Martin and Michaelis, 1989). A study using HUVECs showed for 
the first time that PLD could be involved in mediating endothelial cell responses to 
tumour-secreted VEGF, especially cytoskeletal reorganisation and endothelial cell 
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migration (Seymour et al., 1996).  Analysis of FGFR-1 signalling in PAE cells 
revealed that FGFR-1 mutation of Y766F, which prevents PLC-gamma binding and 
subsequent activation of PLC, resulted in a loss of both PLD and PLA2 activity 
(Cross et al., 2000). A study of bovine pulmonary artery endothelial cells (BPAECs) 
suggests that PLD could play a critical role in vascular endothelial cell lipid 
signalling function and cardiovascular diseases (Sherwani et al., 2013). In human 
pulmonary artery endothelial cells (HPAECs), it has been shown that a signal 
cascade initiated by sphingosine 1-phospahate (S1P) leads to the activation of the 
PLD2 pathway, suggesting PLD2 plays a critical role in stimulating the migration of 
lung endothelial cells (Gorshkova et al., 2008). Another study showed that PLD 
signalling in mercury-induced endothelial dysfunction was an indicator for many 
heart diseases (Hagele et al., 2007). Endothelial cells function as a regulator of 
thrombosis, inflammatory disease and haemostasis by secreting various factors such 
as von Willebrand Factor (vWF). A study has shown that PLD1 regulates vWF 
secretion by translocating PLD1 to the plasma membrane upon stimulation of the 
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1.5 The Regulator of Calcineurin (RCAN1)  
1.5.1 The Discovery of RCAN1 
 
The three members of the regulator of calcineurin (RCAN) family were first 
identified by the group of Estivil in 2007 (DSCR1/RCAN1) RCAN1, RCAN 2 and 
RCAN3. RCAN1 was originally named Down Syndrome Critical Region 1 (DSCR1) 
due to its location on chromosome 21 from region 21q22.1-q22.2; trisomy of 
chromosome 21 results in Down Syndrome (Fuentes et al., 1997, Davies et al., 
2007). RCAN1 is a protein containing an acidic domain with serine-proline motif, a 
putative DNA binding domain and a proline-rich region that may bind to SH3 
domains. This could suggest that RCAN1 is involved in signal transduction and 
activation of transcription factors. RCAN1 is extensively expressed in the heart and 
brain. Furthermore, overexpression of RCAN1 suggests a role in mental retardation 
and cardiac defects in patients with Down syndrome (Fuentes et al., 1995). 
 
	  
Figure 1.10: The exon structure of the human RCAN1 isoform 
Exon structure of RCAN1, illustrating the alternative first exons used by RCAN1.1 and 
RCAN1.4 isoform. Adapted from Holmes et al., 2010.  
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Figure 1.11: Structure of RCAN1 
This figure illustrates the major RCAN1 family protein isoforms and protein motifs.. 
RPM=(RNA recognition motif); SP=(serine/proline) motif incorporating the LxxP. Family 
signature and ExxP domains = PxIxIT-like domain and TxxP motif. Adapted from Pritch 
and Martin, 2013.  
 
 RCAN1 has also been termed Adapt 78 (Crawford et al., 1997) myocyte-enriched 
calcinurin interacting protein 1 (MCIP1) (see Table 1.1). Muscle differentiation 
results in expression of RCAN1 and inhibition of the calcineurin pathway, which can 
regulate hypertrophic growth in striated muscles (Rothermel et al., 2000).  
 
Down syndrome results from trisomy of chromosome 21 resulting in an extra copy 
of this chromosome. Patients with Down syndrome display congenital heart 
malformation and mental retardation (Baird and Sadovnick, 1987).  Down syndrome 
also involves other clinical features such as immune system defects, gastrointestinal 
anomalies and Alzheimers disease. Overexpression of RCAN1 in the brain in Down 
syndrome leads to interaction with calcineurin A, a protein phosphatase. This study 
revealed that overexpression of RCAN1 inhibited calcineurin activity and subsequent 
nuclear translocation of NFAT affecting numerous cell functions (Fuentes et al., 
2000). The physiological role of RCAN1 is to protect cells against numerous cell 
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Table 1.1 Overview of historical RCAN1 Gene Names 
Name Source 



























Saccharomyces cerevisia  
Caenorhabitis elegans  
Mus musculus  
Criceltulus griseus  
Homo sapiens  
Mus musculus  





Drosophila melanogaster  
Drosophila melanogaster  
Homo sapiens  
 








This table is adapted from Davies et al., 2007.   
 
1.5.2 Regulation of RCAN1 expression  
 
Alternative first exons, allowing the generation of different isoforms, which show 
different patterns of expression and regulation (Fuentes et al., 1997). Exon one gives 
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rise to the isoform RCAN1.1 (Genescà et al., 2003). Exon two lacks a methionine 
start site required for translation, and exon three encodes only three amino acids. 
Exon four gives rise to the isoform RCAN1.4 and is under the control of calcineurin 
responsive promoter, comprising multiple consensus binding sites for the 
transcription factor of activated T-cells (NFAT) (Yang et al., 2000) GATA-2/3 sites 
(Minami et al., 2004). Five consensus binding sites for activator protein 1 (AP-1) 
transcription factors have been identified in the region flanking exon four (Zhao et 
al., 2008). Recent data has shown that the CCAAT/enhancer binding protein beta 
(C/EBPbeta) cooperates with NFAT to control expression of the calcineurin 
regulatory protein RCAN1-4 (Oh et al., 2010).  
 
1.5.3 Role of RCAN1 in Regulating Intracellular Signalling  
 
Endothelial cells are involved in vascular disorders involving inflammation, 
atherosclerosis and tumour growth (Hesser et al., 2004). Microarray analysis 
revealed that upregulation of RCAN1.4 was stimulated by VEGF and thrombin 
providing a negative feedback regulator of the Ca+2 /calcineurin/ NFAT signalling 
pathway. In vivo experiments have shown overexpression of RCAN1.4 reduced 
vascular density and melanoma growth in an animal human tumour xenograft model, 
suggesting a negative feed-back loop of RCAN1.4 induction and inhibition of NFAT 
pathway signalling (Minami et al., 2004).  
 
A recent study has investigated the role of c-Jun in the regulation of ER stress using 
Thapsigargin (an inhibitor of sarco/endoplasmic reticulum Ca+2 ATPase). This study 
revealed that c-Jun, a down stream target of the JNK signalling pathway upregulates 
RCAN1 expression in response to thapsigargin-induced endoplasmic reticulum (ER) 
stress and contributes to protection against thapsigargin-induced cell death (Zhao et 
al., 2008).  
Furthermore, the role of RCAN1 in vivo has been identified in RCAN-/- mice where 
gene knockout of RCAN1.4 and RCAN1.1 resulted in no anatomical abnormalities 
(Hoeffer et al., 2007). In addition, a recent study with RCAN-/- mice focussing on 
tumour angiogenesis identified hyperactivation of the calcineurin/NFAT pathway in 
endothelial cells from these mice resulting in endothelial cell apoptosis. This finding 
lead to decreased tumour angiogenesis in a murine tumour xenograft (Ryeom et al., 
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2008).  Recently, a study reported overexpression of RCAN1 in mice protects against 
post-ischaemic neuronal injury (Brait et al., 2012). Several studies have been 
reported that RCAN1 is also regulated via phosphorylation at multiple sites, which 
modulate its calcineurin binding activity leading to subcellular localisation and a 
decrease in RCAN1 half-life (Genescà et al., 2003). 
1.5.4 Calcineurin  	  
 
Calcineurin  (CN), also called protein phosphatase 2B, is a heterodimeric 
Ca2+/calmodulin-dependent serine/threonine protein phosphatase composed of CNB 
regulatory and CNA catalytic subunits (Rusnak and Mertz, 2000). Originally 
identified in the brain, CN was later found to play a critical role in T cell function, 
through activation of nuclear factor of activated T cell-mediated transcription of 
cytokine genes, including the IL-2 gene (Snyder et al., 1998). Calcineurin is a target 
for the immunosuppressants, cyclosporin A and FK506, which associate with 
immunophilins and bind to and inactivate calcineurin. More recently, calcineurin has 
been shown to play an important role in CNS functions, including neurite extension, 
synaptic plasticity and learning and memory (Winder and Sweatt, 2001, Zeng et al., 
2001). 
 
Calcineurin has been implicated in the development of cardiac hypertrophy (Wilkins 
et al., 2004). RCAN1.4 binds the catalytic domain of calcineurin and inhibits its 
activity.  RCAN1.4 is phosphorylated by MAPK and glycogen synthase kinase 3 
(GSK-3) and allows phosphorylated RCAN1.4 to act as a substrate for calcineurin 
(Vega et al., 2002). Overexpression of RCAN1 protein inhibits calcineurin in the 
nanomolar range, acting similar to the pharmacological agents FK506 and 
Cyclosporin A (Chan et al., 2005). 
 
1.6 VEGFR2 and RCAN1 Signalling 	  
The first study showing VEGF-stimulated regulation of RCAN1 looked at genome 
analysis and identified RCAN1.4 to be significantly induced by VEGF (Hesser et al., 
2004). RCAN1 acts on calcineurin signalling by blocking dephosphorylation of 
nuclear factor of activated T-cell (NAFT) preventing nuclear translocation (Hesser et 
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al., 2004). Studies in HDMECs have shown that cyclosporin prevented VEGF-
mediated induction of RCAN1.4 and that siRNA mediated silencing of RCAN1.4 
increased the expression of NFAT-regulated genes such as COX-2 and IL-8 (Holmes 
et al., 2010).  However, this study also reported that PMA-stimulated RCAN1.4 
expression was not blocked by pre-incubation with cyclosporine but was blocked by 
pre-incubation with the PKC inhibitor GF 109203X (Holmes et al., 2010).  To 
confirm this finding, siRNA-mediated silencing of multiple PKC isoforms revealed 
that silencing of PKC-delta expression blocked VEGF-stimulated RCAN1.4 
expression. This data suggests that in addition to the classical PLC-gamma mediated 
hydrolysis of PIP2, generating an intracellular increase in Ca2+ and subsequent 
activation of calcineurin/NFAT resulting in RCAN1.4 expression, an additional 
pathway from DAG-mediated PKC-delta activation also regulated RCAN1.4 
expression suggesting the existence of an NFAT-independent pathway leading to 
RCAN1.4 expression.  Interestingly, it has been shown that the CCAAT/enhancer 
binding protein beta (C/EBPbeta) cooperates with NFAT to control expression of 
RCAN1.4 (Oh et al., 2010).  
Analysis of endothelial cell function has revealed that siRNA mediated silencing of 
RCAN1 results in disrupted VEGF-mediated tubular morphogenesis and cell 
migration (Holmes et al., 2010). Endothelial cells isolated from RCAN1 -/- mice 
show increased apoptosis (Ryeom et al., 2008), suggesting that RCAN1.1 and 
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Figure 1.12: Overview of RCAN1.4 regulation pathway 
VEGFR2 activation leads to PLC-γ activation and an increase in intracellular Ca2+ that 
causes activation of calcineurin and NFAT that enhance RCAN1.4 expression to increase. 
VEGFR2 activation results in phosphorylation of PKCδ, which contributes to the up-
regulation of RCAN1.4 through an unknown pathway. RCAN1.4 acts to regulate VEGFR2 
mediated tubular morphogenesis and migration. Adapted from Holmes et. al 2010. 
 
1.7 Human Dermal Microvascular Endothelial cells (HDMECs) as a Model 
Cell Line 
 
In vitro culture of endothelial cells from human dermal microvascular endothelial 
cells (HDMECs) has provided a suitable model for investigation of microvascular 
behaviour and functions having a broad range of applications such as tumour 
metastasis, cell differentiation, cytokine expression, haemorrhagic disorder, 
thrombosis, and hypersensitivity (Florey, 1966, Simionescu and Simionescu, 1992, 
Miyasaka and Tanaka, 2004, Förstermann and Münzel, 2006).  In this current study 
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HDMECs were utilised as a model for in vivo vascular physiology. HDMECs keep 
their cobblestone morphology and endothelial characteristics from passage one until 
passage twelve. Studies in microvascular endothelial cells and pulmonary artery 
endothelial cells show cellular junction formation and permeability is preserved in 
multiple passaged cells (Kelly et al., 1998). The characteristic morphology of 
HDMECs is normally assessed by immunofluorescence using specific markers for 
endothelial cells such as CD-31, VEGFR2 and von-Willebrand factor. Furthermore, 
HDMECs form capillary–like tubes within 4-6 hours when overlaid with a collagen 
matrix and stimulated with VEGF-A (Roberts et al., 2010).  Overall, these cells 
provide a suitable model in which to study vascular physiology and angiogenesis. 
 
1.8 Aims of the thesis 
Previous work within the group has identified a role for RCAN1 in regulating 
VEGF-mediated gene expression and ultimately cell migration (Holmes et al., 2010). 
Cell migration is a critical component of the angiogenic response and deregulation of 
RCAN1 signalling could have profound implications for both physiological and 
pathological angiogenesis. The initial aim of this thesis was to identify the 
mechanism by which RCAN1 regulated VEGF-mediated migration by studying 
effects on VEGFR-2 activation and downstream signalling. This would utilise both 
siRNA to target RCAN1.1 and RCAN1.4 and adenoviral mediated overexpression of 
the RCAN1.4 isoform. By analysing effects of other growth factors, the specificity of 
RCAN1 for regulating VEGF signalling will also be analysed. The second aim was 
to determine the role of RCAN1 in affecting the ability of endothelial cells to 
undergo tubular morphogenesis and vascular sprout formation using 3D spheroid 
assays. The final aim of the thesis was based around analysing the role of PLD 
activity in endothelial cells as this phospholipase has not been studied in any detail 
with respect to endothelial cell function. 
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2.1 Materials 
All materials listed in every experimental protocol 	  
2.2 Reagents 
All reagents were obtained from Invitrogen (Paisley, U.K), Peprotech EC (Rocky 
Hill, NJ, U.S.A), R&D System Inc. (Minneapolis, MN, U.S.A), Sigma Aldrich 
(Dorset, UK), GE Healthcare (Amersham, U.K), Greiner Bio one (Stonehouse, U.K) 
Fisher Scientific (Loughborough, U.K) unless stated otherwise.   
2.3 Equipment  
Table 2.2: Equipment 
Equipment  Manufacture and Model  
Cell culture hoods (1) 
Cell culture hoods (2) 








PCR machine  
Gel system  
Gel power pack  
-80˚ Freezer  
Balance 
Vortex  
Centrifuge rotors  
Waterbath 






TriMAT2 Class I, BS5726, CAS, Manchester,UK 
ESCO Class II, BSC 
SANYO MCO-18 AIC, Loughborough, U.K 
Sigma, 3k30C, Philip Harris 
Spectrafuge 24D, JENCONS-PLS 
MSE Soniprep 150 
Thermomixer comfort, Eppendorf 
PCH-1, Grant, Bio, Scientific Laboratory Supplier  
NanoDrop®, Spectrophotometer ND-1000 
ABI Prism®, 700 Sequence Detection System 
GeneAmp® PCR system 9700, Applied Biosystems 
Invitrogen  
Invitrogen 
SANYO, VIP Series  
Acculab, Sartorius group  
Stuart, BioCote 
MSE, Mistral 2000 
Clifton, Nickel-Electro, LTD 
Nikon, Eclipse-TS100 
Nikon, Digital Sight  
Axio Observer Zesis microscope   
VASCUSAFE Comfort, IBS Integra, Biosciences  
Priorclave EV150 
State Bourne, Biorack 3000 
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2.4 Solutions  
The solutions used are described in Table 2.3. Water was ultra deionized 18.2 
megohm H2O as the standard solution applied unless otherwise stated.  
 
Table 2.3: Solutions 
Buffer  Composition  
LB  
 
MOPS buffer Running buffer (WB) 
 
 
SDS-Page Tank Running Buffer 
for(WB) 
 
Transfer buffer for (WB) 
 
X10 Tris Buffer Saline (TBS) 
 
TBST 
5% BSA Blocking buffer for (WB) 
2% BSA Blocking buffer for (WB) 
20g LB Broth, 1 litre ddH2O 
 
(209.2g MOPS, 121.2g Tris, 800ml 
ddH2O), 6g EDTA, 20ml (20%SDS) ≈ 
100 dH2O 
30g/l Tris, 144 g/l Glycine, 50 ml SDS 
(20%) 
18.2 g Tris, 90 g Glycine, 100ml 
Methanol and dH2O 380ml 
24.2g/l Tris, 80g/l NaCl, 950ml dH2O, 
pH7.6 
1L 1X TBS+ 10ml (10%Tween) 
25g BSA+ 500ml 1X TBST 
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2.5 Cell Culture 
2.5.1 Cell Lines and Primary Cells 
 
 
Table 2.4: Cell Lines used in this Study 
Name Cell type  Source 
HDMEC Human Dermal Microvascular Endothelial 
Cells 
Juvenile cells established from a 3 year old 
male Caucasian (Lot Number 6060707.1). 
PromoCell (C-­‐12210) 
(Heidelberg, Germany) 
NHDF Normal Human Dermal Fibroblast Cells  
Juvenile cells established from a 5 year old 
male Caucasian  
(Lot Number 0083002.2) 
PromoCell (C-12300) 
(Heidelberg, Germany) 
A375 Malignant Melanoma Cells ATCC (CRL-1619) 
MAE wt Mouse Aortic Endothelial Cells Angio-proteomie (cAP-
m0001) 
HEK293a  Human Embryonic Kidney Cells  Life Technology 
HeLa  Cervical Cancer Cells Sigma -12B006 
 
2.5.2 Cell Culture Technique 	  
All work was carried out in a sterile cell culture hood. Media was warmed in the 
water bath at 37˚C before use.  All cells were cultured in a 37˚C incubator, with an 
atmosphere of 5% CO2 and a humidified environment. 
 
2.5.3 Culture of HDMECs 	  
Human Dermal Microvascular Endothelial Cells (HDMECs) were cultured on 
gelatin coated 10cm dishes (Greiner, #664160). Gelatin (Sigma #G1890) was made 
up as a 1% (w/v) solution, in dH2O and autoclaved prior to use. Dishes were coated 
for approximately 15 minutes in a 37˚C incubator and gelatin aspirated off 
immediately prior to addition of cells. Endothelial cells were grown in EBM MV2 kit 
(PromoCell #C-22121), consisting of Endothelial Basal Media (EMB) MV2 
Chapter 2                                                                                    Materials and Methods 
	  46	  
containing 5% (v/v) FCS, VEGF (0.5ng/ml), EGF (5ng/ml), R3IGF-1 (20ng/ml), 
FGF-2 (10ng/ml), ascorbic acid (1µg/ml) and hydrocortisone (0.2µg/ml).  
 
2.5.4 Culture of NHDFs 
 
Normal Human Dermal Fibroblasts (NHDF) were cultured on gelatin coated 10cm 
dishes (as above) in Fibroblast Growth Medium Kit (PromoCell #C-23110) which 
consists of Fibroblast Basal Media containing basic human Fibroblast Growth Factor 
(1ng/ml) and insulin (5µg/ml). 
 
 
2.5.5 Culture of HEK293T, Hela, A375 and MAE cells 
 
These cells were cultured in vented T75 flasks (Fisher Scientific, #1036-4131) in 
Dulbecco’s Modified Eagle’s Medium (DMEM, Sigma #D6429) supplemented with 
10% Foetal Calf Serum (FCS, Invitrogen #10270-098). 
 
2.5.6 Defrosting Frozen Cell Vials  	  
Cells were stored in liquid nitrogen and thawed in a 37˚C water bath for 3 minutes. 
The vial was disinfected with 100% isopropanol before pipetting the contents of the 
tube into 9ml of growth media in a 15ml tube. This was then centrifuged at 92 x g for 
5 minutes before aspirating off the supernatant containing any remaining freeze 
media. The cells were then re-suspended in 8ml fresh media and seeded in a gelatin 
coated 10 cm dish. Plates were incubated for 24 hours before changing the media.  
 
2.5.7 Routine Cell Culture and Passaging 	  
All cells were split at approximately 80-90% confluence, and seeded at an 
appropriate ratio (see Table	   2.5). Cells were washed twice with 4ml of Versene  
(Dulbeccos Ca+2/Mg+2-free PBS, Lonza #BE17-512F supplemented with 0.5mM 
EDTA, Sigma #E7889). Plates were then incubated with 1ml of 0.05% Trypsin 
EDTA (Invitrogen, #25300-054) for 3 minutes at 37˚C to detach the cells from the 
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flask. Cells were collected and re-suspended in the appropriate media and split onto 
new dishes, see Table 2.5.  
 
Table 2.5: Routine Cell Culture and Passaging 
Cell 
Type 
Media  Ratio Passage (from-to) 
HDMEC EBM MV2 plus growth factors  1:4 every 2 days p4-p12 
NHDF Fibroblast growth medium  1:5 every 2 days p4-p25 
HEK293 DMEM containing 10% FCS 1:8 every 2 days p1-p25 
A375 DMEM containing 10% FCS 1:10 every 2 days p1-p25 
MAE DMEM containing 10% FCS 1:6 every 2 days p1-p25 
 
2.5.8 Serum Starvation 
 
To create a low serum environment prior to agonist stimulation, cells were first 
washed twice in PBS with calcium and magnesium (Lonza # 3MB057) and then 
placed in the media described in Table	  2.6 overnight in a 37˚C incubator, with an 
atmosphere of 5% CO2 and a humidified environment.  
 
Table 2.6: Serum Starvation Medias 
Cell Type Media  
HDMEC EBM MV2 plus 1% FCS (Promocell, #proC-22221)  
NHDF Fibroblast growth medium plus 1% FCS (Promocell, #C-
23320) 
HEK293 DMEM plus 1% FCS (Invitrogen, #10270-098) 
A375 DMEM 1% FCS (Invitrogen, #10270-098) 
MAE DMEM 1% FCS (Invitrogen, #10270-098) 
 
2.5.9 Cell Counting 	  
Before any experiment, cells were counted. This involved washing with PBS  and 
trypsinising in 1ml of trypsin for 3 minutes followed by re-suspending in media. 
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Cells were then counted on a Neubauer Improved haemocytometer (Heacht 
Assistant, Sondheim Germany) and resuspended in growth media at relevant density. 
2.5.10 Cell Transfection 
 
2.5.11  Transient Transfection of Mammalian Cells with Plasmid DNA 
 
Cells were transiently transfected with plasmid DNA constructs (see Table	   2.10) 
using the transfection reagent Lipofectamine™ 2000 (Invitrogen #11668-027). Cells 
were seeded at 1 × 105 per well of a 6-well plate 24 hours before the transfection. 
Two tubes were filled with 250µl of OPTIMEM (+GlutaMAX I) media (Invitrogen 
#51985-026). To one tube 5µl of Lipofecatmine™ 2000 was added and to the second 
tube, 1µg of plasmid was added. Both tubes were left for five minutes at room 
temperature. The lipofectamine mixture was added slowly to the plasmid mix and 
incubated for a further 20-30 minutes at room temperature. Prior to the end of the 
incubation, media was aspirated from the cells and replaced with 2 ml of OPTIMEM. 
After gentle mixing the mixture was added drop-wise to the cells. The plate was 
returned to the incubator for 6 hours and then the transfection mixture was removed 
and the cells washed twice with PBS containing Mg+2/Ca+2. Fresh growth media was 
added to the cells and returned to the incubator for 24 hours, after which the cells 
were used experimentally such as growth factor stimulation (section 2.6.1) or a 
wound healing assay (section 2.17.1). 
 
2.5.12  RNA Interference of Mammalian Cells (siRNA) 	  
To selectively knockdown the expression of a particular protein, small interfering 
RNAs (siRNA) were transfected into cells. Pre-designed siRNAs (see Table	   2.7) 
were used. On day zero cells were seeded at 1 ×	  105 cells per well of a 6-well plate 
in growth media for approximately 24 hours before transfection. On the day of 
transfection, two tubes were prepared containing 250µl of OPTIMEM (+GlutaMAX 
I) media (Invitrogen #51985-026). To one tube 2.5µl of Lipofectamine™ RNAi 
MAX (Invitrogen #51985-026) was added, to the second tube the	  required	  amount	  of	  siRNA	  duplex	  was	  added	  to	  give	  a	  final	  concentration	  of	  20nM	  in	  a	  2.5	  ml	  final	  volume	  and left for 5 minutes at room temperature. The lipofectamine mixture was 
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added slowly to the siRNA mix and incubated for a further 20-30 minutes at room 
temperature. Once again, media was aspirated from cells and replaced with 2ml 
OPTIMEM. The transfection mix was added dropwise to each well giving a final 
volume of 2.5ml. The plates were returned to the incubator for 6 hours. After 6 hours 
the transfection mix was removed, and cells were washed with PBS containing 
Mg+2/Ca+2. After washing, 2ml of growth media was added, and the cells returned to 
the incubator for 24 hours. On the third day, the cells were serum starved overnight 
prior to stimulation. 
2.5.13 siRNA Oligonucleotides 
 
A list of all small interfering ribonucleic acids used in this work. 
 
Table 2.7: siRNA Oligonucleotides 
Target Gene  Target sequence Company 
AllStar Neg. control 





























Hs_DSCR1_5 HP, SI03224900* 


















* Sequence not provided by the supplier and product code provided instead.  
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2.5.14 Amaxa Nucleofector Transfection  
 
Amaxa Nucleofector and HMVEC-L Nucleofector® Kit (Lonza; Cat#VPB-1003) 
was used according to the manufacturer’s instructions. Briefly, 5 ×	   105 cells per 
sample were first counted and then re-suspended in 100µl Nucleofector Solution at 
room temperature. This was then combined with 2µg DNA (pmaxGFP) and the 
suspension transferred into a certified cuvette. The amount of DNA used was 
optimised according the to manufacture’s protocol. The bottom of the cuvette was 
covered by sample without any air bubbles and the cap closed. The Nucleofector 
Programe S-005 was selected and the cuvette inserted into the Nucleofector cuvette 
holder and the selected program run. The cuvette was taken out of the holder when 
the program was finished and 500µl of growth media added to the cuvette. The 
resulting suspension was then carefully transferred into a well of a 12 well plate. 
Finally cells were incubated over night before being analysed.  
 
2.5.15 Transfection with NEB Transpass 
 
Cells were plated at 4 ×	  104 cells per well in a 12-well plate in 1ml of growth media 
overnight for 24 hours at 37˚C. On the day of transfection, the media on the cells was 
changed to fresh growth media whilst the transfection mix was prepared according to 
the manufacturer’s instructions in the Transpass HUVEC Transfection Reagent kit 
(NEB# M2558S). Firstly, 100µl of OPTIMEM (+GlutaMAX I) (Invitrogen/Gibco 
#51985-026) media was placed in a tube along with 1 µg of plasmid DNA, 2µl of 
HUVEC Reagent Component and 2µl of the Transpass V Component. This was 
mixed gently and incubated for 30 minutes. This transfection mixture was then added 
drop-wise to the cells and the plate gently swirled five times to ensure the reagent 
reached all the cells before incubating for six hours at 37˚C. After 6 hours the 
transfection mix was removed from the plates and the cells washed with PBS 
containing Mg+2/Ca+2 before adding 1ml of normal growth media and returning to the 
incubator for 24 hours.  
2.5.16 Infection of HDMEC with Adenovirus 
HDMECs were plated at 7 × 1044 cells/well in 12 well plates. Cells were grown for 
24 hours in the plates and cells were infected with an empty control virus and 
adenovirus expressing RCAN1.4 from see Table 2.10 at a multiplicity of infection 
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(MOI) of 50. Previous work in the group had shown that a MOI of 50 gave optimal 
over-expression of RCAN1.4 (K.Holmes, unpublisded data). After 24 hours of 
transfection the virus was removed and media changed on the cells.  
2.6 Cell Stimulation and Signalling Inhibition 
  
2.6.1 Cell Stimulation 
 
Before stimulating the cells with growth factors, they were serum starved for at least 
16 hours at 37˚C (see Section 2.5.8). Growth factors (see Table	   2.8) were then 
diluted in the relevant low serum media (see Table 2.6). The final concentration and 
the respective incubation times for each condition used in this study are given in the 
text.  
 
Table 2.8: Growth Factors 

















2.6.2 Signal Transduction Inhibition 
 
All inhibitors in this study were dissolved in sterile (1-30µM) DMSO and aliquoted 
and stored at -80˚C. Before use, they were warmed to room temperature and then 
diluted to the relevant concentration. Where a vehicle control is included, an 
equivalent volume of DMSO was used instead of the inhibitor. Exact concentrations 
used and incubation times are listed where relevant in the results section.    
 
Table 2.9: Inhibitors Used in the Study 
Name  Target  Company 
ZM323881 VEGFR2 Tocris (#2475) 














2.7 Plasmid Constructs and Preparation 	  	  
Table 2.10: Plasmids and viruses Used in this Study 
Plasmid or 
viruses  
Description  Source 
pcDNA3.1-
PLD1 
pcDNA mammalian expression vector  




Babraham Institute  
pcDNA3.1-
PD2 
pcDNA mammalin expression vector 




Babraham Institute  
pcDNA3.1-
RCAN1.4 
pcDNA mammalian expression vector 










2.7.1 Chemical Transformation of Bacterial Cells (Heat Shock Method) 	  
Prior to commencing, sterile LB media was prepared by adding 20g LB Broth 
(Sigma, #L3022) to 1L of distilled water and autoclaving. Also, LB plates were 
poured containing 1L LB media with 15g agar (Sigma, 9012-36-6), 5 g yeast extract, 
5 g NaCl, 10 g of tryptan, 1ml of 1M NaOH to 1L distilled water and 50µg/ml 
ampicillin (Sigma). 
 
One Shot Top10 Chemically Competent E. coli cells (Life Technologies, #C4040) 
were thawed on ice and 50ng of plasmid to be transformed added into the vial and 
placed on ice for 30 minutes. The tube was then placed in the water bath at 42˚C for 
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90 seconds and chilled on ice for three minutes. 900µl of warm LB media was added 
to the cells and incubated at 37˚C for one hour while shaking at 250 rpm. 200µl of 




2.7.2 Maxi Preparation of Plasmid DNA  	  
Plasmid DNA was prepared using the EndoFree plasmid kit (Qiagen, #12362) 
according to the manufacture’s instructions. Briefly, a single bacterial colony was 
picked using an autoclaved 200µl tip from LB agar plate containing ampicillin 
(50µg/ml) and grown for 8 hours at 37°C with shaking at 250 rpm. Then the starter 
culture was diluted 1:500 in 250ml of LB media and grown at 37°C for 17 hours 
with shaking at 250rpm. The following day bacterial cells were harvested by 
centrifuging at 6000 x g for 15 minutes at 4°C. The pellet was re-suspended in 10 ml 
of buffer P1 until the pellet dissolved and 10 ml of buffer P2 added. The samples 
were mixed well until a homogenous blue coloured mixture was achieved and 
incubated for 5 minutes at room temperature. 10 ml of chilled buffer P3 was then 
added and mixed vigorously. The whole lysate mixture was transferred to QIAfilter 
cartridges and incubated at room temperature for 10 minutes to allow precipitation to 
occur. The plunger was inserted into the QIAfilter maxi cartridge and the lysate 
filtered into a new 50ml tube. 2.5 ml of buffer ER was then added and incubated on 
ice for 30 minutes. A Qiagen-tip 500 was equilibrated by first adding 10 ml of buffer 
QBT. The lysate was then added to Qiagen-tip 500 and allowed to enter the resin 
using gravity flow. The Qiagen-tip was washed twice with 30 ml of buffer QC and 
plasmid DNA was eluted by the addition of 15 ml of buffer QN. Genomic DNA was 
precipitated by adding 10.5ml of isopropanol, mixing and then centrifuging at 15,000 
xg for 30 minutes at 4°C. The supernatant was removed and the pellet washed with 5 
ml of 70% ethanol and centrifuged again. The pellet was then air dried for 10 
minutes before being re-suspended with double distilled water. The NanoDrop 
spectrophotometer was then used to determine the quantity of plasmid DNA by 
taking measurements of absorbance at 260 nm and 280 nm. 
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2.8 Preparation of Cell Lysates 	  
Cell lysates were prepared following cell stimulation. Media was first aspirated and 
cells were then washed twice on ice with ice-cold PBS (without Ca2+/Mg2+). The 
cells were then lysed in the required volume of lysis buffer (20mM Tris pH7.5, 
150mM NaCl, 2.5mm EDTA, 10% (w/v) glycerol and 1% (w/v) Triton X-100, 1mM 
Na3VO4 (Sigma S-6508), 10µg/ml Aprotinin (Sigma A-4529), 10µg/ml Leupeptin 
(Sigma L-8511), 1mM PMSF) and kept on ice with gentle agitation for 15 minutes to 
allow complete lysis. The cells were scraped into 1.5 ml tubes and cleared of cell 
debris by centrifugation at 17968 x g for 20 minutes at 4˚C and the supernatant 
transferred to fresh tubes. For SDS-PAGE an appropriate volume of 1x LDS (Life 
Technology #NP0008) sample loading buffer was added to the sample which was 
then heated at 90˚C for 5 minutes before loading.  
 
2.9 Western Blotting  
2.9.1 Gel Types 	  
Two types of SDS-PAGE gels have been used throughout this study: 
2.9.2 Precast Gels 	  
Pre-cast gels purchased from Invitrogen - NuPAGE® 4-12% Bis Tris Gel 1.5mm, 15 
well (Invitrogen, SKU#NP0336BOX) or NuPAGE® 4-12% Bis Tris Gel 1.0mm, 12 
well (Invitrogen, SKU#NP0322BOX). Gels were run in 1X MOPS SDS (Invitrogen) 
for 2 hours, at 200V and 50mA. 
2.9.3  Self-Cast Gels 
 
Self-cast gels were made in XCell SurLockTM Mini-Cell, XCell II TM Blot Module, 
Cassette 1.5mm (Invitrogen, SKU#NC2015). The desired percentage of acrylamide 
gel was poured according to the recipe described in the below table. APS and 
TEMED were added last to catalyze the polymerization. 1ml of water saturated 
butanol was added to level the running gel and prevent any bubbles and then the gel 
allowed to set for 30-60 minutes at room temperature. The butanol was then washed 
and the stacker gel added, (made according to the table below) and a comb placed 
into the top cassette.  
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Gels were run in 1X SDS-PAGAE Tris Glycine at 125V and 35mA for the 
appropriate period of time depending on the percentage of the gel.  
Table 2.11: Composition of SDS-PAGE gels 
 
2.9.4 Gel Transfer 	  
Gels were transferred onto Hybond-ECL Nitrocellulose membrane (Amersham 
Bioscience, RPN3032D) in transfer buffer (Table	  2.3:	  Solutions) for 2 hours at 50 
V, 125 mA).  The membrane was first blocked in 5% (w/v) BSA in TBST + 0.02% 
(w/v) azide (Sigma # S-6508) for 1 hour at room temperature and then incubated in 
primary antibody diluted in 2% BSA in TBST + 0.02% (w/v) azide overnight at 4°C 
under continuous shaking. The blots were then washed six times in TBST for 10 
mins each time with gentle rocking. Blots were then incubated with the appropriate 
HRP conjugated secondary antibody made up in 2% (w/v) BSA/TBST for two hours 
at 4°C under gentle agitation. Membranes were again washed six times in TBST for 
10 mins each time and the final wash was carried out in TBS only.  
 
2.9.5 Western Blot Development 	  
Membranes were incubated for 5 minutes in ECL reagent (Amersham, RPN2106) to 
detect signals from HRP conjugated secondary antibodies. The blot was then 
arranged in a plastic wallet and placed in a cassette for exposure for the desired 
amount of time on Fuji Medical X-Ray Film, Super RX, 100NF (Jet X-Ray, 
Mini Gel Units Stacker Running Gel 
   5% 6% 7% 8% 10% 12% 15% 
30%Acrylamide/0.8%Bis  ml 0.7 1.7 2.0 2.3 2.7 3.3 4.0 5.0 
2.0M Tris/HCl pH8.8  ml - 2.0 2.0 2.0 2.0 2.0 2.0 2.0 
0.5M Tris/HCl pH6.8  ml 0.7        
87% Glycerol  ml - 0.7 0.7 0.7 0.7 0.7 0.7 0.7 
dH2O ml 3.6 5.6 5.3 5.0 4.6 4.0 3.3 2.3 
          
Total Volume  µl 5 10 10 10 10 10 10 10 
10%APS  µl 2.5 22.9 22.9 22.9 22.9 22.9 22.9 22.9 
TEMED  µl 5 5 5 5 5 5 5 5 
Chapter 2                                                                                    Materials and Methods 
	  56	  
London). The film was then developed by hand in developer (Sigma #1900984) and 
fixer (Sigma#1902485) solutions and was then rinsed in water and left to dry.  
 
2.9.6 Antibodies 	  
All antibodies used in this study are listed in tables 2.12 and 2.13 with dilutions used 
for western blotting (W.B). All species are indicated by the following abbreviations: 
R=Rabbit, G=Goat, M=Mouse, Rt=Rat. 
 
Table 2.12: Primary antibodies used for W.B 
Antibody name  Antigen W.B Company  Catalogue 
number 
R α Actin 
R αVECadherin 
R α RCAN1 
M αDSCR1 
R α PLD1 
R α PLD2 
R α PLD2 
R α MAC444 
 
R α VEGFR2 
R α pVEGFR2 
      
R α pPLCγ 
G α KDR  
R α VEGFR1  
R α Akt  
R α pAkt  
R α Erk1/2 
R α pErk1/2  
R α GFP 
R α Caspase3  
R α GAPDH 
G α c-Met 
R α c-Met 





















Human Caspase3  
Human GAPDH 



































Babraham Institute, Cambridge 
Wakelam Lab 
Cell Signaling Technology 
Cell Signaling Technology 
 
Cell Signaling Technology 
R&D System 
Cell Signaling Technology 
Cell Signaling Technology 
Cell Signaling Technology 
Cell Signaling Technology 
Cell Signaling Technology 
Cell Signaling Technology 
Cell Signaling Technology 
Cell Signaling Technology 
R&D System 
Cell Signaling Technology 
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Table 2.13: Secondary antibodies used for W.B 














































2.9.7 Stripping and Re-probing Blots 	  
To re-probe membranes with an alternative antibody, the first set of antibodies were 
removed using stripping buffer (62.5m Tris-HC1, pH 6.8, 20 (9w/v)% SDS, 100mM 
of β-Mercaptoethanol) and incubated at 50˚C for 20 minutes with occasional 
agitation. The membrane was then washed three times in TBST at room temperature 
using a large volume of TBST buffer and blocked again in 5% BSA in TBST. The 
membrane was then treated with primary and secondary antibodies as described 
above.  
 
2.9.8 Densitometric Quantification of Protein Expression  	  
The immune reactive bands detected on X-ray film were quantified to identify the 
relative amount of specific proteins. The X-ray film was first scanned (Bio Rad #GS-
800, Photoshope CS6) and the densitometric analysis was achieved using ImageJ 
(National Institute of Health (NIH), Version 1.47n). Actin or GAPDH were 
quantified to correct for protein loading. 
 
2.10 Immunoprecipitation Protocol 	  
Cells were first lysed in lysis buffer ((20mM Tris pH7.5, 150mM NaCl, 2.5mM 
EDTA, 10% (w/v) glycerol and 1% (w/v) Triton X-100, 1mM Na3VO4 (Sigma S-
6508), 10µg/ml Aprotinin (Sigma A-4529), 10µg/ml Leupeptin (Sigma L-8511), 
1mM PMSF) and 200µl of cell lysate was then taken and mixed with 1µl of primary 
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antibody and incubated with gentle rocking overnight at 4˚C.  Twenty-five microliter 
of protein G of agarose beads (Sigma#027K2030) slurry was then added, mixed and 
incubated with gentle rocking for 3 hours at 4˚C. Tubes were spun in a benchtop 
centrifuge to pellet beads and the supernatant taken for an immunodepleted sample. 
The pellet was then washed three times in 500µl of lysis buffer and finally 
resuspended in 20µl 3X LDS. The samples were then heated at 90˚C for ten minutes 
and centrifuged for 1 minute at 17968 x g. The supernatant was then analyzed by 
western blotting.  
 
2.11 RNA extraction 
 
RNA was extracted using the RNeasy mini kit (Qiagen Cat#74106) according to 
manufacturer’s instructions. Briefly, following treatment, cells were washed with 
PBS and 600 µl of RLT buffer was added to each well. The cells were scraped with a 
cell scraper and transferred into a Qiashredder  (Qiagen Cat #79656) and centrifuged 
for two minutes at 8000g. After centrifugation, 420µl of 100% ethanol was added, 
and 700µl of the sample added onto an RNeasy mini column, spun at 8000 xg for 30 
seconds. After centrifugation, 350µl of RW1 buffer was pipetted onto the silica-gel 
membrane and the flow through discarded. To digest DNA, 80µl of DNase 1 solution 
was added directly onto the RNeasy silica-gel membrane and incubated for 15 
minute at room temperature. The membrane was then washed with 350µl RW1 
buffer at 8000g, with the flow disregarded, and 500 µl RPE buffer added. After 
centrifugation, a final wash 500µl of RPE buffer was added to the RNeasy column 
and centrifuged for two minutes at 8000g. The RNeasy column was transferred to a 
new tube and 30µl of RNase free water pipetted onto the membrane to elute the 
RNA. The quality of RNA was assessed using a Nano Drop ND-1000 
spectrophotometer (Labtech International, Lewes, U.K).   
 
2.12 Reverse Transcription of mRNA (cDNA Synthesis) 
 
Prior to cDNA synthesis, each RNA sample was checked using a Nano drop to 
ensure an accurate concentration measurement. A PCH-1 heating unit was used for 
all incubation steps. In a sterile 0.5ml eppendorf, 1µl oligo dT (500µg/ml, Oligo 
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d(T)18) was mixed with 1µg RNA, and 1µl dNTP mix (10mM, Invitrogen Cat # 
18427-013) and dH2O to give a final volume of 12µl. This was then heated to 65°C 
for five minutes, and then briefly chilled on ice. A master mix was then prepared to 
add to each tube containing 4µl 5x first strand buffer, 2µl 0.1 MDTT, 1µl 
RNaseOUT and 1µl of M-MLV Reverse Transcriptase (Invitrogen Cat#28025-013, 
supplied with 0.1M DTT and 5x First Strand Buffer).  8µl of the master mix was 
added to each tube and incubated at 25°C for five minutes, and a further 60 minutes 
at 37°C. The reaction was then inactivated by heating at 70°C for 15 minutes and the 
sample was diluted with 130µl sterile dH2O to gain a final concentration of 6.7ng/µl.   
 
2.13 Primer Design and PCR Based Primer Testing 
 
Primers were purchased from Invitrogen. Upon arrival primers were spun briefly to 
collect material in the tube. The primers were reconstituted to 100µM using Tris-
EDTA (TE) buffer, pH 8.0, incubated at room temperature for two minutes to 
rehydrate and vortexed for 20 seconds. A working concentration of 2.5µM prepared 
in dH2O, was then used in qRT-PCR reactions. 
 
Table 2.14: Primer sequence table 





















To test these primers, a master mix was prepared (1.1x number of samples) with 4µl 
5x Buffer, 2.4µl MgCl2, 2µl dNTP mix (2mM of each dNTP, Promega #U1330), 
5.8µl dH2O Sigma #W4502), and 0.2µl GoTaq Flexi DNA polymerase (Promega 
Ca#M8031, supplied with MgCl2 and 5x Buffer). Secondly, the PCR reactions were 
set up as following, 2µl Forward primer, 2µl Reverse primer, 1.6µl cDNA and 14.4µl 
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Master mix with the PCR cycles run at 10 minutes at 95°C, and then 15 seconds at 
95°C followed by 1 minute at 60°C for 30 cycles.  
 
All PCR products were run on a 4.5% agarose gel, made by adding 4.5g agarose 
(Melford cat#MB1200) to 150ml TBE buffer (89mM Tris base, 89mM Boric Acid, 
2mM EDTA), dissolved by heating and then mixed with Ethidium Bromide (VWR 
#443922U) to a final concentration of 0.5µg/ml (1:10,000) with gentle swirling. PCR 
products were loaded in the gel along with 10µl of 100bp DNA Ladder (BioLab 
Cat#N0467S) and the gel was run at 100V for 1 hour. The DNA bands were 
visualized using a UV transilluminator and imaged with a camera system (Bio-Rad 
#170-8265).  
 
2.14 Real-Time PCR 	  
All pipette tips used were RNase, DNase free, sterile filter tips and work was carried 
out on a clean bench. PCR reactions were set up by mixing 1.5µl (10ng) cDNA 
template and 2.5µl of nuclease- free ddH2O (Sigma Cat #W4502), 10µl 2x Power 
SYBR Green Mastermix Applied Biosystems Cat #4368702), 2µl forward primer 
final concentration 0.25µM and 2µl reverse primers in a final volume of 20µl for 
each reaction. qRT-PCR reactions were mixed by vortexing before loading in a 96-
well PCR plate (Greiner Cat #652290) and sealed with Optically clear sealing film 
(Bioline Cat#UC-500). The plate was then run on an ABI 7000 PCR System 
(Applied Biosystems, Foster City, CA, U.S.A). The following cycling parameters in 
ABI 7000 software were applied: 50˚C for two minutes and 95˚C for 10 minutes, 
followed by 40 cycles of 95˚C for 15 second and 60˚C for one minute. 
2.15 Interpreting RT-PCR Results 	  
The gene expression of the gene of interest was demonstrated by using the 
comparative Ct method for relative quantification of gene expression. For the first 
stage, the mean and standard deviation of the replicate sample results was calculated 
and for the second stage, the ∆Ct value for the basal was calculated by subtracting 
the Ct value of the target gene from the Ct value for the reference gene as exhibited 
in this equation below: 
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∆Ct= Ct target gene – Ct reference gene 
For the third stage, the standard deviation of ∆Ct value was calculated from the 
standard deviation for the target and reference gene Ct values, as shown below: 
(s=standard deviation) 
s1= standard deviation of reference gene Ct values 
s2= standard deviation of target gene Ct values  
s(∆Ct)=(s12+s22)1/2 
For the fourth stage, the ∆∆Ct value was calculated by subtracting ∆Ct of the 
stimulated samples from the ∆Ct of the basal samples as shown below:  
∆∆Ct=∆Ct stimulated samples - ∆Ct basal samples  
Finally the range in fold increase was calculated as follows this equation:  
2-(∆∆Ct+2) to 2-(∆∆Ct-s) 
 
House keeping genes used in this study were either GAPDH or β-Actin. 
2.16 Immunofluorescent Staining of Cells 
 
Cells were first washed twice in PBS to remove any media and then fixed with 2% 
(w/v) paraformaldehyde (PFA, Sigma, #P6148) for 15 minutes at room temperature. 
This was then aspirated and the cells washed in quench solution (PBS with 50mM 
ammonium chloride, Sigma #A0171), this was then aspirated and replaced with fresh 
quench solution for 10 minutes, prior to being washed three times with PBS. To stain 
intracellular components, cells were permeabilized with PBS containing 0.2% (w/v) 
Triton X-100 (Sigma, #T9284) for 10 minutes at room temperature and washed twice 
with TBS. Cells were then blocked for one hour at room temperature with TBS 
containing 0.1% Tween-20 and 1% BSA (Sigma #A3059) and 5% serum (from the 
same animal species in which the secondary antibody was raised). The primary 
antibody was diluted accordingly (Table	  2.15) in TBST and incubated for one hour 
at room temperature, then washed three times for 10 mins in TBST. The alexa 
fluorophore coupled secondary antibody (Table	   2.16) was diluted in TBST and 
incubated for one hour at room temperature. From this step forward, the dish was 
covered with foil to protect the plate from light, as the fluorescent dyes are light 
sensitive. At this step, phalloidin was also included in the incubation if required. The 
cells were then washed twice in TBST and the nuclei were stained with Hoechst stain 
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(2µg/ml, Invitrogen, H-21492) for 10 minutes then finally washed three times in 
TBST. Coverslips were then mounted by adding 10µl of Prolong Gold onto a glass 
slide and placing the coverslip face down on this, then sealing with clear nail varnish. 
This was then left to set overnight before imaging and stored at 4°C.  All images 
were visualised and acquired using an inverted Zeiss Axio Observer microscope and 
analysed with Zen Pro software.  
 
Table 2.15: Primary Antibodies Used for IF 
All antibodies used in this study are listed in tables 17 and 18 with dilutions used for 
Immunofluoresence (IF). All species are indicated by the following abbreviations: 
R=Rabbit, G=Goat, M=Mouse, Rt=Rat. 	  
Antibody name  Antigen Dilution Company  Catalogue 
number  
Mα EEA1 
R α EEA1 
M α GM130 
R α Pericentrin 
R α RCAN1 
M αDSCR1 
R α PLD1 
R α PLD2 
R α PLD2 
R α VEGFR2 
R α pVEGFR2 
     (Y1175) 
R α pPLCγ 
G α KDR  
G α c-Met 
R α c-Met 



































BD Bioscience  








Cell Signaling Technology 
Cell Signaling Technology 
 
Cell Signaling Technology 
R&D System 
R&D System 
Cell Signaling Technology 
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Table 2.16: Secondary antibodies used for IF 











































































2.17 Cell Physiology Assays  
 
2.17.1 Wound Healing Migration Assay 
 
HUVECs or HDMECs were seeded in a 12 well plate in 1ml of growth media for 24 
hours before being serum starved overnight with 1%FCS media by which time they 
have formed a confluent monolayer. Using a sterile 200µl pipette tip a scratch wound 
was introduced in the cells across the centre of the well, using the straight edge of a 
sterile ruler as a guide. Floating cell debris was removed by washing with PBS and 
fresh 1% FCS media added with any required growth factors. Cells were left to 
migrate overnight at 37°C in an incubator or monitored by live cell imaging. After 
approximately 16 hours cells were washed with PBS and fixed with 2% PFA for 15 
minutes at room temperature. Cells were stained by adding 100µl of crystal violet 
(Sigma #HT90132) to each well and then left at room temperature with gentle 
swirling for 15 minutes. The cells were then washed in PBS and kept in PBS at 4°C 
ready for imaging. The scratch was visualized using a Nikon Eclipse TS100 inverted 
light microscope (10x objective) fitted with LCD colour imaging system. 
 
To calculate wound healing migration, a time zero image was taken immediately 
after wounding the cells (Figure 2.1). After 16 hours, a further three images were 
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taken of each scratch and migration measured in each image to give an average value 
for each condition compared to the time zero point (Figure 2.1).  
 
	  
Figure 2.1: Wound healing analysis 
This figure shows how wound healing was measured. At time zero an image was taken and 
then after the cells were fixed, three more images were taken. A line was drawn between 
zero time and 16 hours stimulation to calculate cell migration and an average of that 
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2.17.2 Polarisation Study and Quantification 
 
Cells were set up for a migration assay, as described above, but seeded onto glass 
coverslips and the scratch wound assay carried out before being fixed with 2%PFA. 
The cells were then stained (see section 2.16) with the Golgi specific marker GM130 
and the centriolar specific marker pericentrin (Table	  2.15). To quantify polarisation 
10 separate images were taken along the wound edge and then the number of 
polarised cells counted. Polarisation was determined by drawing a circle in the centre 
of the nucleus with a 120° segment facing the scratch wound. If the GM130 and 
pericentrin markers were located within this segment, the cell was counted as 
polarised (Figure 2.2). This analysis was based on a similar analysis used by Linford 
et al., (Linford et al., 2012). 
 
	  
Figure 2.2: Polarisation study 
The figure shows how polarity was assessed. Firstly images were taken along the wound 
edge (top of the image) and polarity was determined by drawing a circle centred on the 
nucleus of each cell (on Hoechst) with a 120° segment facing the leading edge.   If the 
GM130 (green) and pericentrin (red) staining was within this 120° segment, the cell was 
determined to be polarised (left panel), whereas if it was outside of this angle, the cell was 
determined to be non-polarised (right panel). The scale bar is 20 µm.  
  
 
2.17.3 In Vitro 3D-collagen Matrix Tube Formation Assay  	  
This technique consists of sandwiching endothelial cells between two layers of 
collagen gel, which induces a process of tubular morphogenesis over a period of 16 
hours if the cells are exposed to the relevant growth factors (Roberts et al., 2010). 
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Firstly, the lower layer collagen gel was prepared, making up the necessary volume 
of collagen mix to plate 300µl of collagen into each well of a 24 well plate. The 
collagen was made such that it contains ((8 parts Bovine Collagen type-1 solution 
(PureCol™, #5005), 1 part 0.1 M NaOH (sterile filtered), 1 part x10 Ham’s F-12 
(PromoCell #C-72190)). To reach the final volume the following was added,  diluted 
as shown  (1:50 1M HEPS (Gibco #15630-056). final concentration =20mM), (1:64 
7.5% Bicarbonate Solution (Gibco #25080-060). final concentration =0.117%),1:100 
Glutamax-1 (Gibco #35050-038) final concentration =1% (2mM)). 
 
The collagen was prepared on ice and then the plate incubated overnight at 37°C to 
allow the collagen to set. Prior to adding cells, 1ml per well of serum free EBM MV2 
endothelial media was added to facilitate cellular adherence and wash the collagen 
gel.  
 
HDMEC cells, which had been previously been serum starved overnight in EBM 
MV2 media containing 1% FCS, were washed twice in 4ml of Versene and 1ml of 
Accutase (PromoCell, #C-41310) added per 10cm dish. Cells were returned to the 
incubator for approximately 3 minutes and the dissociated cells re-suspended in 3ml 
of EBM MV2 media with 1% FCS. The cells were then counted using a 
haemocytometer before being spun at 92 x g for 5min and re-suspended to the 
required cells density in fresh EBM MV2 media with 1% FCS. Before adding the re-
suspended cells to the collagen, the serum free media was aspirated. The required 
numbers of cells, 90,000 cells per well, were then added gently, swirled and 
incubated at 37°C for 2 hours to allow cellular attachment. After cell seeding the 
cellular attachment was judged by examination with an inverted light microscope. 
Once the cells were fully adhered, the upper layer was made as described previously, 
making up enough collagen to add 200µl to each well. Before adding the second 
layer the media was carefully aspirated. The second collagen layer was then allowed 
to set for between 1.5 to 2 hours. Cells were normally plated out in the absence of 
growth factors, which were then added following gelification of the upper layer of 
collagen. A total of 0.5ml of EBM MV2 media with 1% FCS was added to each 
well, containing X2 concentration of the required growth factor, to correct for the 
volume of collagen. This was added very gently over the top layer of collagen and 
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cells returned to the incubator at 37°C for 16-24 hours. Cells were normally fixed 
following tube formation assay by adding 0.5ml of 4% paraformaldehyde and stored 
at 4°C.  
 
2.17.4  Image Analysis and Quantification of 3D Collagen Tube Formation  	  	  
The tube formation assay was quantified by imaging three randomly chosen fields of 
view. In every condition triplicate wells and areas were selected at high 
magnification (×	   10 objective) using an inverted light microscope connected to a 
Nikon DS-Fi1-L2 digital camera (Nikon, Ltd, U.K). Images were saved as TIF files 
and the total number of cell junctions, branches, total length of branches and meshes 
area calculated. Meshes are area enclosed by segments or master segments. Images 
were quantified using ImageJ and the plugin “Carpentier G., Angiogenesis Analyser 
for ImageJ (2012)” (Figure 2.3). 
 (imagej.nih.gov/ij/macros/toolsets/Angiogenesis%20Analyzer.txt)  
 
	  
Figure 2.3: Angiogenesis analysis 
This figure illustrates how the angiogenesis analyzer allows analysis of cellular networks. 
Yellow line shows entire junction formed after stimulation, Green line shows branch and 
Red line shows master junctions. 
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2.17.5  Proliferation Assays 
 
2.17.6 Crystal Violet 
 
Cells were plated at 15,000 cells per well in a 24 well plate in 0.5ml growth media. 
Prior to undertaking the proliferation assay, cells were first siRNA transfected (see 
2.5.12), after which they were starved in 1% media and the following day stimulated 
with agonists (see Table	  2.8) at 50ng/ml and then incubated for 72 hours. The cells 
were then washed twice in PBS and 100µl of crystal violet (Sigma #HT90132) stain 
was added to each well and then incubated for 10 minutes at room temperature. 
Plates were carefully immersed in a container containing dH2O to rinse out the 
crystal violet.  The plates were drained on the bench and then 600µl 1% SDS (Sigma, 
#S1020) added to solubilize the stain. 100µl of this solution was then transferred to a 
clear flat-bottomed 96-well plate and absorbance read at 570 nm determined on the 
Varioskan plate reader. On the last day of the experiment, a standard curve was set 
up by plating cells at the 0, 10,000, 20,000, 40,000, 60,000, 80,000, and 100,000 
cells per well in a 24 well plate for 4 hours. These cells were then stained and lysed 
at the same time as the experimental conditions, allowing cell numbers to be 
estimated. 
 
2.17.7 CellTiter-Glo Assay 
 
Cell proliferation was also assessed using the CellTiter-Glo® luminescent cell 
viability kit (Promega, #product code), which quantifies the number of viable cells in 
every condition based on the quantification of ATP. According to the manufacturer’s 
instructions, both the CellTiter-Glo Buffer and Substrate was thawed and 
equilibrated to room temperature before being mixed together and vortexed. 
HDMEC cells were plated out in 24 well plates at a cell density of 15,000 cells per 
well. The following day, the cells were serum starved with 1% FCS media for 24 
hours before being stimulated with agonists (see Table	  2.8) for a further 72 hours. 
Every condition was tested in triplicate. After stimulation media was aspirated from 
each well and washed in PBS containing Ca+2/Mg+2 and a final 200µl of PBS added 
to each well before lysing in 200µl of the CellTiter-Glow mix. Plates were shaken for 
two minutes to ensure complete lysis. 100 µl of this lysate was then transferred to a 
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new opaque walled 96 well plate and luminescence was recorded at 570 nm using a 
Varioskan plate reader (Thermo, Varioskan Flash). On the day of lysis, a standard 
curve was prepared by plating HDMECs in triplicate at densities of 0, 10,000, 
20,000, 40,000, 60,000, 80,000 and 100,000 cells per well. These cells were then 
incubated for four hours before being also lysed in the same way. Readings collected 
from these samples were then used to generate a standard curve of cell numbers 
which would be compared to the final assay results.  
 
2.17.8 Cell Tracker Staining 
 
Pre-warmed EBM MV2 serum free media containing 5µM of Cell Tracker™ Green, 
Orange, Red or Blue (Invitrogen, C7025, C2927) was incubated with the cells for 30-
45 minutes at 37˚C. The Cell Tracker dye is able to cross the membrane and enter 
live cells where it is then processed into membrane impermeant products by 
intracellular esterase and fluorescently labels the cells. The dye working solution was 
then replaced with fresh serum free media for 30 minutes before being washed in 
PBS and incubated with 1%FCS media.  
2.17.9 Statistical analysis  
For statistical analysis an unpaired Student’s t-test was chosen. This test allows 
comparison between two different population means which are normally distributed. 
Data were analysed using an un-paired Student’s t-test in Excel. Statistical 
significance was set at a P-value less than 0.05 (*), or 0.01 (**) or 0.001(***).  
Pearson’s correlation was performed to analyse co-localisation using ImageJ 
software. Three regions of interest were analysed for each experimental condition. 
Background signal was determined from region with no obvious cells structure. 
Expression of VEGFR-2 was compared with EEA1 and HGFR with EEA1.   
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The role of RCAN1 in regulating VEGF-2 signalling and 
function in endothelial cells 
  




VEGF signalling in endothelial cells is primarily mediated by VEGF receptor 2. The 
binding of VEGF to VEGFR2 results in receptor activation characterised by receptor 
autophosphorylation and initiation of series of signalling cascades within the cell 
(Holmes et al., 2007). RCAN1 is expressed in brain, heart, muscle, adrenal gland and 
pancreas (Fuentes et al., 1995, Ermak et al., 2001, Peiris et al., 2012). RCAN1 
protein commonly exists as two isoforms: RCAN1.4 and RCAN1.1. Targeted gene 
ablation of RCAN1.1 and RCAN1.4 in mice resulted in mice with no anatomical 
differences (Hoeffer et al., 2007). Studies aimed at investigating the role of RCAN1 
in endothelial cells have utilised endothelial cells of non-human origin including 
mice (Ryeom et al., 2008, Brait et al., 2012). Data documenting the role of RCAN1 
in human endothelial cells has been confined to the use of HDMECs (Holmes et al., 
2010). A previous study from the group reported that RCAN1 is highly up-regulated 
in endothelial cells in response to VEGF, but not to any other growth factors 
(Holmes et al., 2010).  
This chapter describes experiments performed to characterise RCAN1 signalling in 
HDMECs, with the aim of understanding the signalling pathways potentially 
perturbed by RCAN1 in response to different growth factors in HDMECs. This 
project will use a range of specific studies for cell migration such as cell polarity, 
cytoskeleton reorganisation, and a scratch wound assay to determine which 
parameters are regulated by RCAN1.  
 
3.2 VEGF-A stimulate an increase in RCAN1.4 expression in HDMECs 
The RCAN1 gene consists of seven exons, of which exons one to four can be 
alternatively transcribed or spliced to produce different mRNA isoforms. This results 
in a protein of 252 amino acids (RCAN1.1) and 197 amino acids (RCAN1.4) (Figure 
1.11). At the start of the project a specific antibody for RCAN1 needed to be 
validated to determine the specificity and optimum concentration. Different 
commercial antibodies were used to study the expression of RCAN1 in various cells 
and tissue profiles. The antibody in this study was validated through three methods: 
western blot, mRNA level and immunofluorescence.  
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In order to check the specificity of antibodies short-interfering ribonucleic acid 
(siRNA) gene silencing was used. This study shows that RCAN1.4 and 1.1 are 
highly expressed in HEK293, A375 melanoma, human liver, human cardiac myocyte 
and fibroblast cells (Figure 3.1A). Two individual siRNA duplexes targeting both 
RCAN1.1 & 1.4 mRNA were utilised to analyse the expression of both RCAN1.1 
and RCAN1.4. HDMECs stimulated with VEGF-A for 1 hour showed up-regulation 
of only the RCAN1.4 isoform, with no up-regulation in RCAN1.1 observed. 
RCAN1.4 migrated at a molecular weight of 29 kDa whereas RCAN1.1 migrated at 
around 39 kDa. RCAN1 was assessed using the western blot protocol in combination 
with siRNA. Lysates from rat cardiac endothelial cells were also included to see if 
the antibody recognised the rat protein (Figure 3.1A).  
To optimize knock down, a pool of two individual siRNA duplexes targeting 
RCAN1 was used to transfect HDMECs (Figure 3.1B). Non-silence was used in 
parallel as control for siRNA. Post transfection, cells were serum starved for 24 
hours and stimulated for 60 minutes with VEGF-A and harvested for analysis by 
western blotting. The difference between the specific siRNA and non-silence can be 
seen in figure 3.1B. The RCAN1 siRNA transfected cells illustrated a complete 
knock down of both isoform RCAN1.1 and RCAN1.4 in the basal condition 
compared to untreated or non-silence samples. In addition, one-hour stimulation with 
VEGF-A showed an increase of RCAN1.4 expression in untransfected and non-
silence siRNA conditions compared to the RCAN1 siRNA sample.  
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Figure 3.1: Antibody validation for RCAN1 
A. HDMECs plated at 7 × 104 and transfected with siRNA. 48 hours post transfection cells 
were stimulation with VEGF-A for 1 hour then lysed proteins to separate by SDS-PAGE. 
Levels of RCAN1 (Sigma). Rat (RCEC rat cardiac endothelial cells from VecTechnologies), 
HCM (Human Cardio Myocytes), Hela cell H=High rainbow marker and L= low rainbow 
marker. B. Western blotted analysis with antibody against RCAN1 protein. All bands 
showed an expected molecular weight. HDMECs= Human Dermal Microvascular 
Endothelial Cells, HEK293= Human Endothelial Kidney Cells, A375= Melanoma cells line, 
Hu Liver= Human Liver, HCM= Human Cardiac Myocytes, HCMEC= Human Cardio 
Microvascular Endothelial Cells, NHDF= Normal Human Dermal Fibroblast. These 
experiments have been performed once.  
 
RT-PCR was used to analyse the expression of RCAN1.1 and RCAN1.4 mRNA. In a 
time course experiment RCAN1.1 mRNA only increased 2-fold above basal 
following VEGF-A stimulation for 180 minutes.  This is in contrast to expression of 
RCAN 1.4 mRNA, which showed an increase after 30 minutes VEGF-A stimulation 
and increased to nearly 20-fold above basal at 60 minutes, remaining at 10-fold 
above basal after 3 hours (Figure 3.2). This data confirmed that VEGF-A was a 
potent inducer of RCAN1.4 mRNA expression. 
Analysis of VEGFR-2 signalling in HDMECs revealed that VEGFR2 is down-
regulated in response to stimulation with VEGF-A with this being evident at 5 
minutes and continuing up to 180 minutes (Figure 3.2). Furthermore, 
phosphorylation of the VEGFR-2 following agonist stimulation was evident at 5 
minutes, with this transient response significantly reduced after 20 minutes. Analysis 
of downstream signalling pathways revealed that phosphorylation of Akt, required 
for cell survival (Gerber et al., 1998b), was increased after 10 minutes in response to 
VEGF-A stimulation. In addition, phosphorylation of Erk1/2, required for cell 
A	  
B	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proliferation (Brunet et al., 1999), increased in response to VEGF-A and was evident 
at 5 minutes and maximal at 10 minutes.  Analysis of RCAN1.1 and 1.4 levels 
revealed that VEGF-A only induced expression of RCAN1.4, with increased levels 
evident after 60 minutes stimulation.  




	  	   	  
Figure 3.2: Time course of VEGFR-2 stimulation and RCAN1 induction in HDMECs 
 A. The bar chart shows qRT-PCR analysis for RCAN1.1 and 1.4 mRNA level. HDMECs 
RNA were extracted and cDNA prepared. Data were analyzed by the ΔΔCt value method 
and expression was normalized to β-actin expression and illustrated as fold change. 
HDMECs cells were stimulated with VEGF-A 50ng/ml for 5, 10, 20, 30, 60 and 180 
minutes. B. Cells were harvested by Triton X-100 lysis. 10µg of loading total protein 
isolated from HDMECs and subjected to 4-12% NuPAGE gel then analyzed by western blot 
with anti-Total VEGFR2, pVEGFR2, pAKT, pErk1/2, and RCAN1 antibodies. Actin was 
used as a loading control. C. Graphs illustrate the expression of each protein in response to 
VEGF-A as determined from relative intensity of the band compared to the basal condition. 
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3.2.1 RCAN1 regulates VEGFR2 level in endothelial cells 	  
The human RCAN1 gene consists of seven exons that are spliced into two major 
isoforms giving rise to RCAN1.4 (197 amino acids) and RCAN1.1 (252 amino 
acids).  The regulation of RCAN1 is activated by the calcineurin NFAT pathway in 
response to different growth factors such as VEGF (Hesser et al., 2004, Minami et 
al., 2004). In endothelial cells, VEGF-A165 stimulates expression of RCAN1.4 
(Holmes et al., 2010), an effect not observed with other growth factors such as HGF 
and FGF-2. This previous study also reported that RCAN1 was required for 
VEGFR2-mediated migration of HDMECs. The current study focussed on exploring 
the mechanism utilised by RCAN1.4 to regulate VEGFR2 physiological functions 
and endothelial cell migration. Two independent duplexes of siRNA were used to 
target RCAN1.1 and RCAN1.4 as it has not been possible to design isoform-specific 
siRNAs.   
In endothelial cells, VEGF-A induced increased phosphorylation of the VEGFR-2 
and an apparent decrease in total receptor level (see Figure 3.3). In contrast, levels of 
VEGFR-1 did not appear to change following siRNA mediated gene silencing of 
RCAN1.  Analysis of downstream pathways in the RCAN1 siRNA transfected cells 
revealed that VEGF-A mediated AKT phosphorylation appeared to be increased at 5 
and 10 minutes with a slight increase in ERK1/2 phosphorylation compared with the 
non-silencing control and untransfected conditions. Downstream targets of VEGFR-
2 were analysed: Erk1/2 phosphorylation, which is required for cell proliferation 
(Brunet et al., 1999) and AKT phosphorylation which is required for cell survival 
(Gerber et al., 1998b). To analyse the role of RCAN1 in VEGFR2 signalling siRNA 
mediated gene silencing is used here. Two independent duplexes of siRNA were 
used to target RCAN1.1 and RCAN1.4 as it has not been possible to design isoform-
specific siRNAs.  siRNA mediated silencing of RCAN1 caused a decrease in VEGF-
A mediated VEGFR2 down-regulation (evident at 10 mins) compared with 
untransfected and non-silencing conditions (Figure 3.3).   
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Figure 3.3: RCAN1 regulates VEGFR-2 level in HDMECs 
A. HDMEC were transfected with siRNA. 48 hours post transfection cells were stimulated 
with VEGF-A then lysed proteins to separate by SDS-PAGE. Levels of VEGFR2 
phosphorylation (tyrosine 1175), total VEGFR-2, VEGFR-1, phospho-Akt Ser 473, 
phospho-Erk1/2 and RCAN1.4 expression were determined by western blotting.  GAPDH 
was used as a loading control. B. Graphs illustrate the expression of each protein in response 
to VEGF-A as determined from relative intensity of the band compared to the basal 
condition. Data shows mean ± SD. The data is representative of three experiments. 
 
In addition, to determine if this effect of RCAN1 on receptor internalisation and 
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HDMECs, we examined the hepatocyte growth factor receptor (HGFR/c-Met). 
Analysis of HGF stimulation of HDMECs showed that the mature 155 kDa HGFR 
level decreased, with reduction apparent after 60 minutes of stimulation. siRNA 
mediated silencing of RCAN1 caused no change in the down-regulation of the 
HGFR or the downstream intracellular signalling cascade from HGFR, as indicated 
by Akt and ERK1/2 phosphorylation (Figure 3.4). This result was in contrast to the 





Figure 3.4: HGFR regulation 
A. HDMEC were transfected with siRNA as indicated. 48 hours post transfection cells were 
stimulated with HGF then lysed proteins to separate by SDS-PAGE. Levels of total HGFR, 
phospho-HGFR, phospho-Akt Ser 473, phospho-Erk1/2 and RCAN1.4 expression were 
determined by western blotting. GAPDH was used as a loading control. B. Graphs illustrate 
the expression of each protein in response to VEGF-A as determined from relative intensity 
of the band compared to the basal condition. Data shows mean ± SD. The data is 
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3.3 RCAN1 regulates VEGFR-2 internalisation  
Previous data had shown that RCAN1 plays an apparent role in regulating the level 
of VEGFR-2 following VEGF-A stimulation. However, the western blotting does not 
reveal the intracellular localisation of the VEGFR-2.  VEGF-mediated activation of 
VEGFR-2 is known to cause receptor internalisation and degradation with 
intracellular trafficking (Horowitz and Seerapu, 2012). In order to analyse the cell 
surface expressed VEGFR-2, an antibody to the N-terminal extracellular domain of 
the VEGFR-2 was used and immunofluorescence analysis performed in the absence 
of cell permeabilisation, meaning that only receptors present on the cell surface, 
available for ligand interaction, would be visualised.  
To examine whether RCAN1 is directly required for cell surface internalisation of 
VEGFR2, siRNA was employed to knockdown RCAN1. VEGF stimulation led to a 
time-dependent decrease in surface VEGFR-2 levels with internalisation evident 
after 10 min agonist stimulation (Figure 3.5). siRNA-mediated silencing of RCAN1 
expression caused a reduction in the degree of VEGFR-2 internalisation as evidenced 
by increased fluorescence following VEGF stimulation relative to the untreated and 
non-silencing siRNA samples. Previous data has identified a role for RCAN1 in 
HDMEC migration using a scratch wound assay (Holmes et al., 2010).  Therefore in 
order to see if VEGFR-2 internalisation was affected in migrating cells, a scratch 
wound was introduced prior to addition of VEGF-A (Figure 3.5). However, RCAN1 
silencing appeared to delay VEGFR-2 internalisation at the leading edge of the 
scratch wound.  
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Figure 3.5: RCAN1 and VEGFR2 internalisation 
HDMECs were seeded at 7 × 104 cells/wells onto pre-coated gelatin for 24 hour using FGM. 
Cells were transfected with siRNA of RCAN1 and non-silencing (N.S). Cells were serum 
starved in 1%FCS media overnight. A scratch was introduced to each well using a sterile 
200µl Gilson pipette and stimulated with VEGF-A 50ng/ml for 10, 30 and 60 minutes. The 
cells were fixed with 2% PFA for 10 minutes. Cells were blocked for 1 hour in 5%BSA then 
incubated for one hour with anti-Goat KDR (R&D system) (1:200) following that secondary 
for 1 hour. Final staining with Hoechst for nuclei using Hoechst for 10 minutes. Images were 
taken pairwise with same exposure time for VEGF-A samples for each assay analyzed at 40x 
object using Zen software. Scale bar: 20µm. The data is representative of three experiments. 
 
To analyse the specificity of the effect of RCAN1 siRNA silencing on VEGFR-2 
internalisation a similar approach for the HGFR was utilised, with 
immunofluorescence analysis using an antibody to the extracellular N-terminal 
domain of the HGFR.  Stimulation with HGF caused a time-dependent reduction in 
surface HGFR levels (Figure 3.6). However, in contrast to the effect on VEGFR-2, 
siRNA mediated silencing of RCAN1 expression did not affect HGFR 
internalisation, suggesting that the effect of RCAN1 on receptor internalisation was 
not a general effect on RTKs. 
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Figure 3.6: RCAN1 siRNA and HGFR internalisation 
HDMECs were seeded at 7 × 104 cells/well onto gelatin pre-coated glass slides for 24 hour 
using FGM. The following day, cells were transfected with siRNA of RCAN1 and non-
silencing (N.S). Cells were serum starved in 1%FCS media overnight. A scratch was 
introduced to each well using a sterile 200µl Gilson pipette and stimulated with HGF 
50ng/ml for 10, 30 and 60 minutes. The cells were fixed with 2% PFA for 10 minutes. Cells 
were blocked for 1 hour in 5%BSA then incubated for one hour with anti-HGFR (R&D 
system) (1:200) following that secondary for 1 hour. Final staining with Hoechst for nuclei 
using Hoechst for 10 minutes. Images were taken pairwise with same exposure time for HGF 
samples for each assay analyzed at 40x object using Zen software. Scale bar: 20µm. The data 
is representative of three experiments.  
3.3.1 Early endosome co-localization with kinase receptors 	  
The activation of receptor tyrosine kinases by growth factor can lead to 
downregulation of these receptors and internalisation into early endosomal 
compartments before trafficking to recycling endosomal compartments or lysosomal 
degradation of the receptor (Horowitz and Seerapu, 2012). To analyse the trafficking 
of VEGFR-2, an antibody to the early endosomal marker EEA1 was used. 
Immunofluorescence staining identified co-localization of VEGFR2 and EEA1 
(Figure 3.7). In untreated conditions, co-localization of VEGFR2 and EEA1 in basal, 
30 and 60 minutes were clearly visible in peri-nuclear areas.  siRNA-mediated 
silencing of RCAN1 appeared to affect co-localisation between VEGFR-2 and EEA1 
at 10 minute time points, suggesting that VEGFR-2 entry into early endosomes was 
reduced. Pearson’s correlation analysis revealed a medium correlation of around 0.46 
in all conditions except for RCAN1 siRNA silencing at 10 mins when the correlation 
reduces to 0.25. Analysis of HGFR co-localisation with EEA1 in HDMECs revealed 
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that similar to VEGFR-2, the HGFR showed a medium degree of co-localisation as 
evidenced by Pearson’s correlation of approximately 0.4; siRNA silencing of 
RCAN1 did not affect the co-localisation (Figure 3.8). 




Figure 3.7: Co-localisation of VEGFR-2 and EEA1 
 HDMECs were seeded at 7 × 104 cells/wells onto pre-coated gelatin for 24 hour using 
FGM. Cells were serum starved in 1%FCS media overnight. A scratch was introduced to 
each well using a sterile 200µl Gilson pipette tip and stimulated with VEGF-A165 50ng/ml 
for 10, 30 or 60 minutes. The cells were fixed with 2% PFA for 10 minutes and 
permeabilised with Triton X-100 for 10 minutes. Cells were blocked for 1 hour in 5%BSA 
then incubated for one hour with anti-KDR (R&D system) (1:200) and anti-EEA1 (Cell 
signal) (1:200), following that secondary for 1 hour. Final staining with HOECHST for 
nuclei using Hoechst for 10 minutes. Images were taken pairwise with same exposure time 
for VEGF-A samples for each assay analyzed at 40x object using Zen software. Scale bar: 
20µm. Bar chart shows quantitative colocalisation analysis of HDMECs by Pearson’s 
correlation coefficient for VEGFR-2 and EEA1. Data shows mean ± SD (n=3). *P<0.05 
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Figure 3.8: Co-localization of HGFR and EEA1 
HDMECs were seeded at 7 × 104 cells/wells onto pre-coated gelatin for 24 hour using FGM. 
Cells were serum starved in 1%FCS media overnight. A scratch was introduced to each well 
using a sterile 200µl Gilson pipette and cells were stimulated with HGF (50ng/ml) for 10, 30 
or 60minutes. The cells were fixed with 2% PFA for 10 minutes and permeabilised with 
Triton X-100 for 10 minutes. Cells were blocked for 1 hour in 5%BSA then incubated for 
one hour with anti-HGFR (R&D system) (1:200) and anti-EEA1 (Cell signal) (1:200), 
following that secondary for 1 hour. Final staining with Hoechst for nuclei using Hoechst 
for 10 minutes. Images were taken pairwise with same exposure time for untreated samples 
for each assay analyzed at 40x object using Zen software. Scale bar: 20µm. Bar chart shows 
quantitative colocalisation analysis of HDMECs by Pearson’s correlation coefficient for 
HGFR and EEA1. Data shows mean ± SD. The data is representative of three experiments. 
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3.3.2 Time course of VEGFR-2 and RCAN1 co-localization  	  
The ability of RCAN1 silencing to affect VEGFR-2 internalisation suggested that 
there could be a possible co-localisation and interaction between VEGFR-2 and 
RCAN1 in HDMECs following VEGF-A stimulation.  In order to analyse this 
possibility immunofluorescence analysis was performed using antibodies to VEGFR-
1 and RCAN1 (Figure 3.9). Co-localisation was apparent at 0, 1, 2 minutes 
throughout the cell, whereas at later time points of 5, 10 and 60, co-localisation was 
evident in more peri-nuclear areas.  
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Figure 3.9: Co-localisation of VEGFR-2 and RCAN1 
HDMECs were seeded at 7 × 104 cells/wells onto pre-coated glass with gelatin for 24 hour 
using full growth media. Following day cells were serum starved in 1%FCS media 
overnight. Cells were stimulated with VEGF-A 50 ng/ml for 1, 2, 5,10, 30, 60 and 180 
minutes. The cells were fixed with 2% PFA for 10 minutes. Cells were permeabilized with 
Triton X-100 for 10 minutes and blocked with 5% BSA and incubated for one hour for anti- 
RCAN1 (Sigma) (1:200) or anti-KDR (R&D system) (1:200) following that secondary for 1 
hour. Final staining with Hoechst for nuclei using Hoechst for 10 minutes. Images were 
taken pairwise with same exposure time for VEGF-A samples for each assay analyzed at 40x 
object using Zen software. Scale bar: 20µm. The data is representative of three experiments. 
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3.3.3 RCAN1 association with VEGFR-2 	  
The previous immunofluorescence analysis had suggested an association between 
RCAN1 and VEGFR-2. This was investigated further using co-immunoprecipitation. 
Analysis of the interaction between RCAN1 and VEGFR-2 was technically 
challenging in HDMECs due to the low endogenous levels of these proteins. 
HEK293 cells transiently co-transfected with plasmids encoding VEGFR-2 and 
GFP-RCAN1.4 were utilised. Cells were stimulated with VEGF for 0, 10 and 60 
minutes and lysates prepared in Triton X-100 lysis buffer. Cells were also transfected 
with empty control plasmids encoding GFP. GFP pull down using anti-GFP agarose 
beads appeared to show an association on basal between RCAN1.4 and VEGFR-2, 
which was reduced on VEGF stimulation (Figure 3.10).  
	  
Figure 3.10: RCAN1 and VEGFR2 association by immunoprecipitation 
HEK293a were transfected with pcDNA3.1 vector and GFP vector as control or pcDNA3.1-
VEGFR2 wild type and GFP-RCAN1.4. Following transfection cells were serum starved for 
24 hours then stimulated for 10 and 60 minutes. Cells were lysed with X-100 Triton. Lysates 
incubated with beads anti-GFP or anti-IgG antibody overnight. The samples were boiled in 
2× LDS buffer and subjected to SDS-PAGE gel. The membranes were probed with 
antibodies to VEGFR-2, phospho VEGFR-2, GFP and RCAN1. The data is representative of 
three experiments. 
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The profound effect of RCAN depletion on delaying internalization of ligand-
activated VEGFR-2 suggested that RCAN may interact directly with VEGFR-2. The 
immunoprecipitation experiment was not conclusive in determining an association 
between RCAN1 and VEGFR-2. Therefore a proximity ligation assay (PLA) was 
utilised to analyse any potential spatial and temporal interaction between VEGFR-2 
and RCAN.  This technique generates a fluorescence signal at the precise site of 
interaction of the proximity ligation probes and consequently the primary antibodies 
targeting RCAN1 and VEGFR-2 (Söderberg et al., 2006).  The PLA revealed a rapid 
and transient increased co-localisation between VEGFR-2 and RCAN1 in the 
HDMECs at the leading edge following stimulation with VEGF (Figure 3.11). 
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Figure 3.11: RCAN1 and VEGFR2 association by PLA 
Detection of RCAN1 and VEGFR2 association in HDMECs using a proximity ligation assay 
(PLA). HDMECs were seeded at 7 × 104 cells/wells onto pre-coated glass with gelatin for 24 
hour using full growth media. Following day cells were serum starved in 1%FCS media 
overnight. Cells were stimulated with VEGF-A 50 ng/ml for 1, 2, 5,10, 30 and 60 minutes. 
The cells were fixed with 2% PFA for 10 minutes. Cells were worked using PLA 
commercial protocol. Images were taken pairwise with same exposure time for VEGF-A 
samples for each assay analyzed at 40x object using Zen software. Scale bar: 20µm. This 
experiment has been performed twice. 	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3.4 RCAN1 regulates VEGFR2 mediated cytoskeleton reorganisation and 
cells polarity  
Cell migration is important in many biological functions such as angiogenesis, 
embryonic morphogenesis and tissue repair (Lamalice et al., 2007, Affolter et al., 
2009). The mechanism of cell migration involves many multistep processes started 
by the protrusion of the cell membrane. Cell migration is activated by many growth 
factors acting on RTKs. These ligands can bind receptors on the cell membrane and 
pass the signalling to an intracellular pathway that activates reorganisation of the 
actin cytoskeleton. Filopodia play a role in facilitating directionality of cell migration 
but the entire mechanism is still unclear. Lamellipodia are formed as flat sheets on 
the cell membrane located at the leading edge of migrating cells (Swaney et al., 
2010, Iglesias and Devreotes, 2008). Analysis of the cytoskeletal reorganization at 
the scratch wound edge in HDMECs revealed that VEGF induced a number of 
cellular protrusions reminiscent of filopodia (Figure 3.12). This effect was blocked 
with siRNA mediated silencing of RCAN1 expression, as leading edge cells were 
devoid of any protrusions under both basal and VEGF-stimulated conditions, with an 
apparent cortical ring of polymerised actin at the leading edge. However, HGF was 
able to induce cytoskeletal reorganization even in HDMECS with depleted RCAN1 
levels, revealing that RCAN1 knockdown did not block cytoskeletal reorganisation 
in response to all agonists (Figure 3.12). 
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Figure 3.12: RCAN1 depletion and cytoskeleton reorganization 
HDMECs were seeded at 7 × 104 cells/wells onto gelatin-coated glass coverslips for 24 hour 
using FGM. The following day cells were transfected with siRNA of RCAN1 and non-
silencing (N.S) for 6 hours. Cells were serum starved in 1%FCS media overnight. A scratch 
was introduced to each well using a sterile 200µl Gilson pipette and stimulated with VEGF-
A 50ng/ml or HGF for 3 hour. The cells were fixed with 2% PFA for 10 minutes. Cells were 
permeabilized with Triton X-100 for 10 minutes and blocked for 1 hour in 5%BSA then 
incubated for one hour for anti-RCAN1 (Sigma) following that secondary and phalloidin 
(Invitrogen) for one hour. Final staining with Hoechst for nuclei using Hoechst for 10 
minutes. Images were taken pairwise with same exposure time for VEGF-A or HGF sample 
for each assay analyzed at 40x object using Zen software. Scale bar: 20µm. This data is 
representative of three experiments.  
 
 
3.4.1 Disruption of RCAN1 lead to loss of cells polarity 	  
Directed cell migration in response to agonists requires asymmetric activation of cell 
membrane receptors to induce polarised signals that result in the generation of 
protrusions at front of the cell (leading edge) and retraction at the back of the cell 
(trailing edge) (Iglesias and Devreotes, 2008, Swaney et al., 2010). In light of the 
known roles of RCAN1 in regulating HDMEC cell migration, analysis of the effect 
of RCAN1 depletion on cell polarity was performed. The scratch wound assay 
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allows analysis of cell polarity as directed migration in this assay is accompanied by 
reorganisation of the centrosome and Golgi apparatus, relative to the nucleus, to face 
the direction of cell migration (Uetrecht and Bear, 2009, Chaki et al., 2013). To 
analyse the effect of RCAN1 on HDMEC cell polarity, the orientation of the Golgi 
apparatus was visualised using an antibody to GM130 and the centrosome using an 
antibody to pericentrin (Figure 3.13). Following VEGF stimulation of HDMECs cell 
polarity increased at the leading edge over a period of 6 hours from 28% to 75%. 
This increase in cell polarity was considerably reduced in RCAN1-depleted cells, 




Figure 3.13: Analysis of Golgi and Centrosome polarization in RCAN1 knockdown 
HDMECs treated with control, two duplexes RCAN1 siRNA for 48 hours were scratch 
wounded and then stimulated for 0, 3, 6 and 12 hours as showed. The cells were fixed and 
stained with antibodies to the centriolar marker pericentrin and to the Golgi marker GM130. 
Also DNA was stained with Hoechst. The scale bar is 20 µm. Cell polarization towards the 
wound was assessed by drawing a circle centred over the nucleus with a 120° segment facing 
the wound and counted. Ten images were taken per condition. This data is representative of 
three experiments.  
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Figure 3.14: Analysis of Centrosome and Golgi polarization in RCAN1 Knockdown 
Cell polarisation at 0, 3, 6 and 12 is plotted in the bar graph. Error bars indicate the standard 
error of the mean (n=3). *P<0.05, **<0.01,***<0.001, siRNA versus N.S unpaired student’s 
t-test. The data is representative of three experiments.  
 
3.5 In vitro 3D collagen study optimization  
Angiogenesis requires coordinated cell migration. It has previously been reported 
that RCAN1 regulates efficient tubular morphogenesis in HDMEC cells in a 3D 
collagen gel assay (Holmes et al., 2010). This assay was chosen to allow 
visualisation of cells depleted of RCAN1 and control siRNA treated cells in the same 
sample to allow closer visualisation of the defect in tubular morphogenesis.  Initial 
validation of Cell Tracker dyes was performed in order to optimise dye 
concentrations to minimise effects of cell labelling on tubular morphogenesis in 
HDMECs. Firstly Green CMFDA Dye (Life Technologies) and Red CMTPX Dye 
(Life Technologies) were selected to label HDMECs on collagen gel. Cells were 
plated on a plastic dish pre-coated with 1% gelatin and serum-starved overnight. The 
following day, cells were labelled with 1µM or 5µM of Green or Red Cell Tracker 
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Figure 3.15: CellTracker Dye Red and Green validation 
HDMECs were seeded at 7 × 104 cells/wells onto pre-coated gelatin for 24 hour using FGM. 
Cells were serum starved in 1%FCS media overnight followed by staining for 45 minutes 
with 1 or 5µM Cell Tracker dye Red and Green. Cells were lift in serum free media for one 
hour and seeded onto collagen matrix, and stimulated with VEGF-A165 50ng/ml. for 18 
hours. The cells were fixed with 2% PFA for 10 minutes. Images were taken using a Nikon 
imaging microscope at × 10 objective. Scale bar: 100µm. This experiment has been 
performed once. 
 
Cells were incubated for one hour after staining before detachment with accutase and 
plating onto a collagen layer. After two hours a second layer of collagen was 
introduced on top of the cells. Cells were then stimulated with VEGF-A for 18 hours 
and then cells fixed with 4% PFA and stained with Hoechst.  Cells were visualised in 
bright field using phase contrast microscopy (Figure 3.15) and immunofluorescence 
microscopy (Figure 3.16). With Red Cell Tracker dye at 1 or 5µM it appeared cells 
died on collagen gel in comparison to Green Cell Tracker dye, suggesting that the 
Red dye interfered with tubular morphogenesis via an unknown mechanism. 
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Figure 3.16: CellTracker Dye Red and Green IF 
HDMECs were seeded at 7 × 104 cells/wells onto pre-coated gelatin for 24 hour using FGM. 
Cells were serum starved in 1%FCS media overnight followed by staining for 45 minutes 
with 1 or 5µM Cell Tracker dye Red and Green. Cells were left in serum free media for one 
hour and seeded onto collagen matrix, and stimulated with VEGF-A165 50ng/ml. for 18 
hours. The cells were fixed with 2% PFA for 10 minutes. Final staining with Hoechst for 
nuclei using Hoechst for 10 minutes. Images were taken for each assay analyzed at 20x 
object using Zen software. Scale bar: 50µm. This experiment has been performed once. 
Further optimisations of Cell Tracker dyes used Blue CMAC Dye (Life 
Technologies) or Orange CMTMR Dye (Life Technologies). Serial dilutions of the 
dyes used 1, 5, 10 and 20 µM for Blue dye (Figure 3.17 and Figure 3.18). Dilution of 
Blue dye below 10 µM gave a weak staining of HDMECs (data not shown). 
Concentrations of 10 and 20 µM gave cell staining although toxicity was evident.  In 
contrast, cells labelled with Orange dye retained the ability to undergo efficient 
tubular morphogenesis (Figure 3.17 and Figure 3.18). In conclusion Green and 
Orange dye was chosen for further study in this project.  
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Figure 3.17: CellTracker Dye Blue and Orange validation 
HDMECs were seeded at 7 × 104 cells/wells onto pre-coated gelatin for 24 hour using FGM. 
Cells were serum starved in 1%FCS media overnight followed by staining for 45 minutes 
with 1, 5, 10 or 20µM Cell Tracker dye Blue and Orange. Cells were left in serum free media 
for one hour and seeded onto collagen matrix, and stimulated with VEGF-A 50ng/ml. for 18 
hours. The cells were fixed with 2% PFA for 10 minutes. Images were taken using a Nikon 




Chapter 3                                                                   RCAN1 and VEGFR-2 activation  
	  97	  
	  
Figure 3.18: CellTracker Dye Blue and Orange validation 
HDMECs were seeded at 7 × 104 cells/wells onto pre-coated gelatin for 24 hour using FGM. 
Cells were serum starved in 1%FCS media overnight followed by staining for 45 minutes 
with 1, 5, 20, 30 or 100µM Cell Tracker dye Blue and Orange. Cells were lift in serum free 
media for one hour and seeded onto collagen matrix, and stimulated with VEGF-A165 
50ng/ml. for 18 hours. The cells were fixed with 2% PFA for 10 minutes. Staining with 
Hoechst for nuclei using Hoechst for 10 minutes. Images were taken for each assay analyzed 
at 20x object using Zen software. Scale bar: 50µm. This experiment has been performed 
once. 
 
3.5.1 In vitro 3D collagen study 	  
 To study HDMECs in a 3D model the cells needed to be labelled prior to plating 
onto a collagen matrix. A Cell Tracker dye was validated for this study. Cells were 
plated on plastic dishes pre-coated with 1% gelatin and siRNA transfection method 
was used to knockdown RCAN1. Cells were serum-starved overnight and the 
following day cells were labelled with 5µM of Green Cell Tracker dye for the non-
silencing siRNA and 5µM of Orange Cell Tracker for RCAN1 siRNA for 45 minutes 
and washed with serum free media. Labelled HMDEC populations were detached by 
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accutase and mixed equally before performing the 3D collagen gel assay. Cells were 
fixed and washed with PBS to be ready for imaging with a Zeiss microscope. Tube 
formation was quantified by measuring the connecting cells distance using a ruler in 
Zen software (µm). 
HDMECs incubated in the absence of growth factor did not undergo any tube 
formation visualised by phase contrast and immunofluorescence (Figure 3.19). In 
contrast, stimulation with VEGF-A induced tubular morphogenesis of HDMECs, by 
formation of capillary structures that consists of many aligned endothelial cells. 
Furthermore, stimulation of HDMECs with HGF induced capillary sprouting in some 
HDMECs but these capillary sprouts did not efficiently form tubules compared to 
VEGF-A stimulation. It was evident from the immunofluorescence images, which 
allowed discrimination between cells with RCAN1 silencing (Red colour) and 
control non-silencing siRNA (Green colour), that cells with depleted RCAN1 levels 
were not able to align properly and form continuous tubes (Figure 3.19). This was 
confirmed by quantification, showing that VEGF-A stimulated of HDMECs with 
depleted RCAN1 levels failed to align.  
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Figure 3.19: The role of RCAN1 in tubular morphogenesis 
HDMECs were seeded at 7 × 104 cells/wells onto pre-coated gelatin for 24 hour using FGM. 
Following day cells were transfected with siRNA of RCAN1 and non-silencing (N.S). Cells 
were serum starved in 1%FCS media overnight followed by staining for 45 minutes with 
5µM Cell Tracker dyes Green and Orange. Cells were left in serum free media for one hour 
and mixed then seeded onto collagen matrix, and stimulated with VEGF-A 50ng/ml. for 18 
hours. The cells were fixed with 2% PFA for 10 minutes. Staining with Hoechst for nuclei 
using Hoechst for 10 minutes. Images were taken for each assay analyzed at 20x object using 
Zen software. Scale bar: 50µm. This figure illustrated the total length of tube quantified from 
15 fields (x20 objective) per conditions per experiments using Zen software as described in 
method chapter. Data shows ± SD,(N=3), (**P<0.01,***P<0.001, siRNA versus N.S). The 
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3.5.2 In vivo 3D spheroid on collagen study 	  
Sprouting angiogenesis requires endothelial tip cells to become polarised and extend 
filopodia with the coordinated regulation of stalk cells allowing the formation and 
stabilisation of the sprout and ultimately a lumen containing vessel (De Smet et al., 
2009). It has previously been shown that RCAN1 is required for efficient tubular 
morphogenesis using a collagen gel assay (Holmes et al., 2010) pointing to a role for 
RCAN1 in allowing efficient tubular morphogenesis. Cells were plated on plastic 
dishes pre-coated with 1% gelatin and the siRNA transfection method was used to 
knockdown RCAN1. Cells were serum-starved over night and the following day 
cells were labelled for 45 mins with 5µM of Green Cell Tracker dye for the non-
silencing condition and 5µM of Orange Cell Tracker for RCAN1 siRNA silencing. 
Labelled HMDEC populations were detached by accutase and mixed equally 1:1. 
The mixtures were plated in 96 non-adherent well plates with methylcellulose and 
grown overnight. The following day, 3D spheroids were embedded onto a collagen 
gel then growth factors were added for 18 hours to examine sprouting tubular 
morphogenesis in HDMECs with Cell Tracker dyes. Cells were fixed and washed 
with PBS ready for imaging with a Zeiss microscope. Tube formation quantification 
was carried out by measuring the length of cells from edge of the spheroids to end of 
sprouting using a ruler in Zen software and the measurement unit was µm. 
RCAN1 depleted HDMECs showed a reduced ability to achieve a tip position 
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Figure 3.20: The role of RCAN1 in VEGF-A-mediated sprouting angiogenesis 
HDMECs were seeded at 7 × 104 cells/wells onto pre-coated gelatin for 24 hour using FGM. 
Following day cells were transfected with RCAN1 siRNA and non-silencing siRNA  (N.S). 
Cells were serum starved in 1%FCS media overnight followed by staining for 45 minutes 
with 5µM Cell Tracker dye Green and Orange. Cells were mixed with 
carboxymethylcellulose in non-adherent bottom 96-well plates for 18 hours before spheroids 
were embedded and seeded onto collagen matrix, and stimulated with VEGF-A FGF and 
HGF 50 ng/ml for 18 hours. The cells were fixed with 2% PFA for 10 minutes. Images were 
taken for each assay analyzed at 20x object using Zen software. Scale bar: 50µm. This figure 
illustrated the total sprouting length of tube was quantified from 10 fields (x20 objective) per 
condition per experiment using Zen software as described in method chapter. Data shows ± 
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It has previously been reported that in addition to its established role in inhibiting 
calcineurin function and subsequently VEGF-stimulated gene expression, RCAN1 is 
able to regulate VEGF-mediated tubular morphogenesis in endothelial cells (Holmes 
et al., 2010).  The aim of this chapter was to determine the mechanism through which 
RCAN1 is able to regulate VEGFR-2 signalling and affect endothelial cell function.  
 
Work in the group has previously shown that RCAN1.4 expression is stimulated by 
VEGF in HDMECs, unlike other growth factors such as FGF-2 and HGF (Holmes et 
al., 2010). The siRNA duplexes used in this study did not discriminate between the 
two RCAN1 isoforms and it was confirmed that both isoforms were silenced in 
HDMECs with these duplexes (3.1). The initial experiments confirmed that VEGF 
was able to induce expression of the RCAN1.4 isoform but not RCAN1.1 isoform as 
measured by mRNA and western blotting.  
 
The ligand induced activation of RTKs and their subsequent internalisation and 
trafficking allows signalling from the plasma membrane and endosomal 
compartments as well as cessation of signalling via lysosomal degradation of 
receptors (Horowitz and Seerapu, 2012). The initial data defined a role for RCAN1 
in regulating ligand activated VEGFR-2 internalisation (Figure 3.3) but not HGFR 
(Figure 3.4), suggesting a specific role for RCAN1 in VEGF signalling. Previous 
work has shown that VEGF is unique, compared with other growth factors such as 
FGF and HGF, in stimulating RCAN1.4 expression in HDMECs via a pathway 
requiring calcineurin and PKC-delta (Holmes et al., 2010). However, the effect on 
VEGFR-2 internalisation occurred prior to an increase in RCAN1.4 levels showing 
that basal RCAN1 levels were able to regulate VEGFR-2 internalisation.  
Furthermore, VEGF-mediated internalisation of VEGFR-2 was not sensitive to the 
calcineurin inhibitor cyclosporin A (CsA)  (data not shown), which is known to 
prevent VEGF-mediated induction of RCAN1 mRNA and protein (Holmes et al., 
2010). This data suggests a novel role for RCAN1, distinct from its previous 
assigned role in inhibiting calcineurin and playing a negative regulatory role in 
VEGF signalling (Hesser et al., 2004). 
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RTK internalisation follows the canonical clathrin-dependent endocytic route 
involving the small GTP binding protein Rab5 (Goh and Sorkin, 2013). 
Immunoprecipitation experiments to identify co-localisation of VEGFR-2 and 
RCAN1 were inconclusive, although the data suggested a transient association.  
However, use of a proximity ligation assay (PLA) showed a close association 
between VEGFR-2 and RCAN1 in response to VEGF, which was rapid and 
transient.  The PLA assay has proved successful in identifying weak transient 
interactions between proteins in endothelial cells (Figure 3.11) (Mellberg et al., 
2009). It was not possible to explore this interaction between RCAN1 and VEGFR-2 
further during the course of these studies and this is something which would be 
interesting to explore further through the use of VEGFR-2 mutants lacking specific 
tyrosine residues and C-terminal truncations. 
 
 
Analysis of the amino acid sequence of RCAN1 reveals no classical SH2 or SH3 
domains required for association with RTKs suggesting that RCAN1 may interact 
with VEGFR-2 by a novel mechanism. The ability of RCAN1 silencing to affect 
VEGFR-2 internalisation relative to HGFR suggests that RCAN1 may either interact 
directly with the VEGFR-2 or ancilliary proteins specifically required for VEGFR-2 
internalisation, such as neuropilin 1 (Nrp-1) (Soker et al., 1998), synectin (Lanahan 
et al., 2010) and recently ephrin–B2 (Sawamiphak et al., 2010).   
 
It is also possible that RCAN1 can influence VEGFR-2 phosphorylation as RCAN1 
depletion resulted in decreased VEGFR-2 degradation and increased transient 
phosphorylation on Y1175 (Figure 3.3). Dephosphorylation of VEGFR-2 is 
regulated by a number of recently identified phosphatases such as VE-PTP (Mellberg 
et al., 2009) and DEP1, which causes delayed VEGFR-2 internalisation 
(Lampugnani et al., 2003). Previous data has shown that VEGFR-2 internalisation is 
required for phosphorylation of Y1175 in VEGFR-2 in mouse endothelial cells 
(Sawamiphak et al., 2010).  However, the data in HDMECs suggests that reducing 
RCAN1 expression delays VEGFR-2 internalisation and transiently increases Y1175 
phosphorylation. 
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Studies on guided cell migration in Drosophila have revealed the physiological role 
of RTK endocytosis is to ensure localized intracellular response to guidance cues by 
stimulating spatial restriction of signalling allowing organised cell migration (Jékely 
et al., 2005).  siRNA mediated silencing of RCAN1 had a profound effect on 
VEGFR-2 mediated cytoskeletal reorganisation in HDMECs (Figure 3.12). The lack 
of actin remodelling and filopodia was restricted to VEGF, as addition of HGF 
allowed agonist-dependent remodelling of the cytoskeleton.  This important finding 
suggests that RCAN1 did not regulate cytoskeletal remodelling at the level of the 
small molecular weight GTP binding proteins such as Rho, important for actin stress 
fibre formation (Ridley et al., 1992) Rac, important for lamellipodia formation 
(Ridley et al., 1992) and Cdc42 important for filopodia (Nobes and Hall, 1995) as a 
block at the level of these GTP binding proteins would be expected to affect all 
agonist stimulated cytoskeletal reorganisation.    
 
Migrating cells are known to undergo polarisation where the nucleus, the Golgi 
apparatus and microtubules act in concert with cytoskeletal reorganisation to 
facilitate migration (Omelchenko et al., 2002). siRNA mediated silencing of RCAN1 
resulted in a profound reduction in HDMEC cell polarisation in response to VEGF, 
suggesting that cells were not able to efficiently generate polarity for directed 
migration. Cdc 42 plays a key role in establishing cell polarity (Etienne-Manneville, 
2004). However, it is unlikely that RCAN1 transduces its effects through Cdc42 as 
HGFR signalling was not affected by RCAN1 silencing as discussed above.  Effects 
on Cdc42 would be expected to affect all growth factor signalling and prevent cell 
polarity and cell migration. 
 
Efficient migration of endothelial cells establishes a vascular sprout through 
establishment of tip cells and stalk cells (De Smet et al., 2009). siRNA mediated 
silencing of RCAN1 resulted in defective tubular morphogenesis (Figure 3.19) and in 
defective sprout formation (Figure 3.20). HDMECs in which RCAN1 gene 
expression was reduced were unable to efficiently compete to be tip cells.  Research 
over the last decade has shown that tip cells induce the Notch receptors Dll4 which 
binds to the Notch receptor on adjacent stalk cells leading to intracellular cleavage of 
Notch generating the Notch intracellular domain (NICD) that acts as a transcriptional 
regulator to downregulate VEGFR-2 and upregulate VEGFR-1 which results in 
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dampened VEGF-A signalling in these stalk cells (Gerhardt et al., 2003). Our data 
would suggest that RCAN1 is also working to allow efficient directed migration of 
tip cells in response to VEGF-A.	  
 
In conclusion, the results in this chapter describe a novel role for the RCAN1 protein 
in endothelial cell function, distinct from its previously established role in acting as a 
negative regulator of VEGF-mediated gene expression. RCAN1 regulates VEGF-
mediated acute effects with respect to VEGFR-2 internalisation and cell polarity and 
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The role of RCAN1.4 in regulating VEGF-mediated 
endothelial cell migration 
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4.1 RCAN1 regulates VEGF-mediated migration in endothelial cells 
 
Cell migration is a fundamental process for multicellular organisms. It is a vital part 
of wound healing, embryonic development, tissue engineering, and immunity.  
Understanding the mechanisms behind cell migration may lead to the development 
of new therapeutic targets for aberrant cell migration during pathologies such as 
tumour metastasis. Cells respond to extracellular stimuli including chemical or 
physical signalling, to migrate (Girard and Springer, 1995, Lamalice et al., 2007, 
Takahashi and Shibuya, 2005).  
 
Endothelial cells play a critical function in the angiogenic process. They form a thin 
lining between the capillary blood flow and the surrounding tissue. During  
angiogenesis, these endothelial cells must migrate in response to stimuli to form new 
vessels, which involves finely regulated migration and interactions with the 
surrounding extracellular matrix. This angiogenic process can even involve the 
careful coordination of other cell types such as smooth muscle and pericytes 
(Lamalice et al., 2007).  
 
VEGF induces endothelial cell migration both in vivo and in vitro (Zachary, 2003). 
Utilising in vitro assays, cell migration can be studied to try to understand 
angiogenesis mechanisms, using extracellular stimuli that can be managed. Many 
factors could play a critical role in cell migration such as serum, cell number and 
extracellular matrix proteins. A classical assay used to study cell migration is the 
scratch wound assay in which a confluent lawn of cells is wounded leaving a gap 
across which cells can migrate (Liang et al., 2007). This method is a well-established 
tool to study cell migration, cell polarity and cell directionality. There are many 
advantages of the scratch wound assay as it mimics cell migration in vivo and is 
relatively easy to perform. 
 
The role of RCAN1 in regulating growth factor-stimulated endothelial cell migration 
was assessed by an in vitro scratch wound assay. This protocol was used to mimic 
endothelial cell migration in vivo and allows for easy quantification of migration as 
well as fluorescent staining and further image analysis. Migration experiments in this 
Chapter 4                                       RCAN1.4 and VEGF-mediated migration 
	  109	  
study measure the relative degree of endothelial cell migration induced by a range of 
growth factors including VEGF-A165, VEGF-A121, EGF, FGF-2, and HGF.  
	  
Figure 4.1: Cell migration at different cell densities and in the presence of different 
sera 
In all conditions, the cells were seeded onto gelatine pre-coated 12-well plates for 24 hours 
in FGM. Cells were serum starved in media supplemented with either 1% PromoCell FCS or 
1% Gibco FCS for 24 hours. A scratch was introduced using a sterile 200-µl Gilson pipette 
tip and stimulated with VEGF-A165 (50 ng/ml) for 18 hours. Cells were then washed with 
PBS, fixed with 2% PFA for 15 minutes and stained with Crystal Violet. Images were taken 
using a Nikon imaging microscope at ×10 objective. The lower phase contrast image 
represents the wound at time point zero and the upper Crystal Violet stained image 
represents the wound after 18 hours of migration. The migration distance was calculated 
from this (µm). A. HUVECs were seeded at 2.5 × 103 cells per well B. HUVECs were 
seeded at 3.5 × 103 cells per well C. HDMECs were plated at 3.5 × 103 cells per well and D. 
HDMECs were plated at 7 × 104 cells per well. Data shows mean ± SD. The data is 
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4.1.1 Optimisation and Validation of the Scratch Wound Assay 
 
HUVECs or HDMECs were plated for 48 hours prior to serum starvation with 1% 
FCS for 16 hours before the introduction of a scratch wound in the monolayer. Cells 
were then stimulated with a range of agonists. Two sera from commercially available 
sources (PromoCell and Gibco) were compared. Previous work in the group has 
suggested that variation in the serum utilised for starvation can have a profound 
effect on endothelial cell migration (data not shown). HUVECs were seeded at either 
2.5 × 103 cells per well (Figure 4.1A) or 3.5 × 103 cells per well (Figure 4.1B) in a 
12-well plate and the migration response to VEGF-A165 in the presence of either 1% 
PromoCell FCS or 1% Gibco FCS was compared. VEGF-A165 consistently 
stimulated an increase in migration; however there appeared to be no significant 
difference between the sera or cell seeding densities. Similarly HDMECs were 
seeded at either 3.5 × 104 (Figure 4.1C) or 7 × 104 (Figure 4.1D) cells per well in 12 
well plates and again migration was studied in response to VEGF-A165 in the 
presence of either 1% PromoCell FCS or 1% Gibco FCS. Again, VEGF-A165 
consistently stimulated an increase in migration without any significant difference 
observed between the sera or seeding densities.  
 
Therefore, all experiments were conducted using PromoCell serum as this was the 
same supplier that the cells were originally sourced from and the main full growth 
media was purchased through, thus providing consistency between the media in 
which the cells were grown and the media in which experiments were conducted. 
4.1.2 RCAN1 Regulates VEGF-Mediated Endothelial Cell Migration  
 
Previous work within the group has identified a role for RCAN1 in the regulation of 
VEGF-mediated migration of endothelial cells using a scratch wound assay (Holmes 
et al., 2010). It has further been shown that RCAN1 has a significant role in the 
regulation of endothelial cell migration both in vitro as well as in vivo (Iizuka et al., 
2004). Work presented in the previous chapter has defined a role for RCAN1 in 
regulating VEGFR-2 and establishing cell polarity and cytoskeletal reorganisation in 
response to VEGF. This data was based on siRNA-mediated gene silencing. The aim 
of this chapter was to focus on the effect of RCAN1 on cell migration using both 
siRNA- and adenoviral-mediated overexpression of the RCAN1.4 isoform. 
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To investigate this the role of RCAN1 in the migration response of HDMEC cells 
was examined after stimulation with VEGF-A165, and other known pro-angiogenic 
growth factors including VEGF-A121, FGF-2 and HGF.  
Once again a scratch wound assay was used to analyse cell migration, but only after 
the use of selective siRNA gene silencing targeted against human RCAN1.1 and 
RCAN1.4, to specifically knock down RCAN1 expression, or a scrambled non-
silencing control. Two duplexes of RCAN1 siRNA were selected to ensure efficient 
knockdown and used as a pool. HDMECs were seeded for 24 hours before 
transfection with siRNA using 10v nM of each RCAN1 silencing duplex to give a 
final concentration of 20 nM RCAN1 siRNA pool, or 20 nM non-silencing siRNA 
(N.S). This transfection mix was incubated with the cells for 6 hours before returning 
them to full growth media. The following day cells were serum starved with media 
supplemented with 1% PromoCell FCS and incubated for a further 24 hours before 
introducing a scratch in the HDMEC monolayer. Cells were then stimulated with 
VEGF-A165, VEGF-A121, FGF-2 or HGF (50 ng/ml) for 18 hours and cells allowed to 
migrate. 
 
This experiment was conducted after seeding the cells at either 3.7 × 104 cells per 
well in a 12-well plate (Figure 4.2) or 7 × 104 cells per well (Figure 4.3). When the 
cells were seeded at 3.7 × 104 cells per well, all basal samples of HDMECs, 
including untreated, non-silencing and RCAN1 siRNA showed no significant 
migration; whereas upon stimulation with growth factors in untreated and non-
silencing samples, there was a greater than twofold increase in HDMEC migration. 
Upon siRNA knockdown of RCAN1, this migration response was notably 
diminished in VEGF-A165, VEGF-A121 and FGF-2 conditions but did not reduce 
HGF-induced migration (Figure 4.2). 
 
By comparison, with an increased number of cells seeded per well of 7 × 104 cells 
(Figure 4.3) it was found that there was a more consistent increase in cell migration 
between the different growth factors in the untreated and N.S siRNA conditions, with 
an approximate doubling in migration over basal conditions. This suggests that the 
more confluent monolayer is a more consistent model; so perhaps at the lower 
seeding density there was more variation in the surface area of cells exposed to the 
growth factor or there is more variation in the spacing between the cells, all of which 
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might alter migration responses. At this cell density, knockdown of RCAN1 was 
discovered to prevent 80% of VEGF-A165- and VEGF-A121-induced migration 
whereas it had a much smaller effect on FGF-2 and HGF.  
 
To conclude, RCAN1 silencing specifically inhibited migration in response to 
VEGF-A165 and VEGF-A121 but not in response to FGF-2 or HGF. Unlike VEGF-
A165, VEGF-A121 does not bind the VEGFR-2 co-receptor Nrp1. As RCAN1 
knockdown reduced the migration stimulated by both isoforms of VEGF-A, it 
suggests that Nrp1 is potentially not required for RCAN1 to regulate VEGFR-2 
mediated endothelial cell migration. 
	  
Figure 4.2: Effect of RCAN1 knockdown on HDMEC migration in response to 
different growth factors 
HDMECs were seeded at 3.7 × 104 cells per well in a gelatine pre-coated 12-well plate for 
24 hours in FGM before being transfected with siRNA targeting RCAN1.1 and 1.4 or a non-
silencing sequence (N.S) for 48 hours. Cells were serum starved with media supplemented 
with 1% PromoCell FCS for 24 hours prior to introduction of a scratch in each well using a 
sterile 200-µl Gilson pipette tip and cells stimulated with VEGF-A165, VEGF-A121, FGF-2 or 
HGF (50 ng/ml) for 18 hours. Cells were washed with PBS, fixed with 2% PFA for 15 
minutes and stained with Crystal Violet. Images were taken using a Nikon imaging 
microscope at ×10 objective. The lower phase contrast image represents the wound at time 
point zero and the upper Crystal Violet stained image represents the wound after 18 hours of 
migration. The migration distance was calculated from this (µm). Data shows ± SD, (N = 3), 
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Figure 4.3: Effect of RCAN1 knockdown on HDMEC migration in response to 
different growth factors 
HDMECs were seeded at 7 × 104 cells per well in a gelatine pre-coated 12-well plate for 24 
hours in FGM before being transfected with siRNA targeting RCAN1.1 and 1.4 or a non-
silencing scramble sequence (N.S) for 48 hours. Cells were serum starved with media 
supplemented with 1% PromoCell FCS for 24 hours prior to introduction of a scratch in each 
well using a sterile 200-µl Gilson pipette tip and cells stimulated with VEGF-A165, VEGF-
A121, FGF-8 or HGF (50 ng/ml) for 18 hours. Cells were washed with PBS, fixed with 2% 
PFA for 15 minutes and stained with Crystal Violet. Images were taken using a Nikon 
imaging microscope at ×10 objective. The lower phase contrast image represents the wound 
at time point zero and the upper Crystal Violet stained image represents the wound after 18 
hours of migration. The migration distance was calculated using this (µm) unit. Data shows 
± SD, (N = 3), (**P < 0.01, ***P < 0.001, siRNA versus N.S. Student’s t-test). The data is 
representative of three experiments. 
 
4.1.3 RCAN1 is Required for Cell Directionality  
 
The directionality of a cell is vital to co-ordinated and efficient cell migration. After 
demonstrating that RCAN1 depletion causes a defect in cell migration and the 
establishment of cell polarity, we wanted to examine if RCAN1 played a role in the 
directionality of migration. In order to do this, time-lapse DIC imaging of HDMECs 
was utilised during the scratch wound assay in response to agonist stimulation with 
VEGF-A or HGF. HDMECs were once again seeded at 7 × 104 cells per well in a 
gelatine pre-coated 12-well plate, before transfecting with siRNA targeted against 
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were serum starved in 1% PromoCell FCS for 24 hours before a wound was 
introduced using a 200-µl Gilson pipette tip, and agonists were added. Live cell 
imaging was then started and images taken every three minutes for 24 hours (Figure 
4.4).  
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Figure 4.4: Frames  from live cell imaging of RCAN1 knockdown experiment. 
HDMECs were seeded at 7 × 104 cells per well in a gelatine pre-coated 12-well plate for 24 
hours in FGM before being transfected with siRNA targeting RCAN1.1 and 1.4 or a non-
silencing scramble sequence (N.S) for 48 hours. Cells were serum starved with media 
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supplemented with 1% PromoCell FCS for 24 hours prior to introduction of a scratch in each 
well using a sterile 200-µl Gilson pipette tip and cells stimulated with VEGF-A, or HGF (50 
ng/ml) for 24 hours. Scale bar: 50µm. Extended time course for this figure is shown in 
appendix 1, pages 154-155.  
 
Migration trajectories were tracked for 20 individual cells over 24 hours using free 
software (Ibidi®) for visualisation to quantitate cell migration. This analysis is able 
to track movement of single cells toward the leading edge of wound healing over a 
period of 24 hours. It is clear that cells stimulated with VEGF-A165 or HGF 
demonstrate strong directionality compared to basal media alone. However, 
depletion of RCAN1 resulted in a reduced migration directionality compared to the 
control non-silencing siRNA in the VEGF-A165 treated condition specifically (Figure 
4.5A and B).  
 
This is quantified in Figure 4.5C, showing that RCAN1 depletion resulted in a 
slower and more convoluted migration in response to VEGF-A165 compared to 
untransfected and non-silencing conditions. In contrast, RCAN1 depletion did not 
affect HGF-stimulated cells, which showed normal migration distance and trajectory 
indicating that RCAN1 did not influence HGF-induced migration. A number of 
different parameters were measured: velocity (total path length [µm]/time [min]), 
straightness (displacement [µm]/total path length [µm]), and forward migration index 
which represents the efficiency of forward migration. All three parameters were 
reduced following RCAN1 depletion and stimulated with VEGF-A165, compared 
with untreated and non-silencing VEGF-A165 stimulated cells, suggesting that both 
cell directionality and overall migration speed are dependent on RCAN1 and upon 
VEGF-A-induced migration. 
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Figure 4.5: RCAN1 is required for cell directionality 
HDMECs were seeded at 7 × 104 cells per well in a gelatine pre-coated 12-well plate for 24 
hours in FGM before being transfected with siRNA targeting RCAN1.1 and 1.4 or a non-
silencing scramble sequence (N.S) for 48 hours. Cells were serum starved with media 
supplemented with 1% PromoCell FCS for 24 hours prior to introduction of a scratch in each 
well using a sterile 200-µl Gilson pipette tip and cells stimulated with VEGF-A, or HGF (50 
ng/ml) for 24 hours. A. Migration trajectories of representative cells (n = 20) from non-
silencing siRNA control and RCAN1 siRNA knockdown. Each track presented from the 
start. B. Rose diagram illustrating the distribution of the trajectories and migration angles. C. 
Graphs representing the (total path length [µm]/time [min]), (displacement [µm]/total path 
length [µm]), and forward migration index (FMI). Data shows ± SD, (N = 3), (*P < 0.05, 
***P < 0.001, siRNA versus N.S. Student’s t-test). This data is representative of three 
repeats from single experiments. 
 
To investigate the defect in cell polarity and migration further in RCAN1 depleted 
cells the migration of HDMEC cells treated with non-silencing siRNA and RCAN1 
siRNA were simultaneously analysed using specific Cell Tracker dyes. Two 
populations of HDMEC were treated with either non-silencing siRNA or RCAN1 
specific siRNA before each population was labelled with either Cell Tracker Green 
or Cell Tracker Orange fluorescent dye, mixed together and seeded as usual for the 
scratch wound assay. Cells were then stimulated with VEGF-A for 0, 3, 6, and 12 
hours and the average number of cells from each population that was at the leading 
edge was quantified. It was therefore possible to analyse the effect of RCAN1 
knockdown on cell migration in this mixed cell population (Figure	  4.6). 
 
Cells with depleted RCAN1 were defective in orientating themselves at the leading 
edge of the wound following stimulation with VEGF-A165, as fewer RCAN1 
knockdown cells reached the leading edge of the wound. As a further control, the 
labelling dye for each condition was switched and the same result was observed.  
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Figure 4.6: Tracking the effect of RCAN1 knockdown in a mixed cell population 
After siRNA knockdown HDMECs were grown on a pre-coated gelatine dish for 24 hours in 
FGM. Cells were serum starved in 1% PromoCell FCS media overnight followed by staining 
for 45 minutes with either 5 µM Cell Tracker dye red or green. Cells were then left in serum-
free media for 1 hour and seeded onto glass cover slips pre-coated with gelatine for 24 hours 
in FGM. Cells were serum starved with 1% PromoCell FCS media for 24 hours. A scratch 
was introduced to each well using a sterile 200-µl Gilson pipette tip and cells were 
stimulated with VEGF-A165 (50 ng/ml) for 3, 6 and 12 hours. Scale bar: 20 µm. Average 
number of cells at leading edge was collected and plotted in scatter chart. Data shows ± SD, 
(N = 3), (**P < 0.01, ***P < 0.001, siRNA or N.S versus basal. Student’s t-test). 
 
4.1.4 RCAN1.4 Requires VEGFR2 Activation to Drive Migration 
 
To confirm that the RCAN1.4 isoform was able to regulate VEGFR2 mediated 
migration in HDMECs adenovirus-mediated gene transduction has already been used 
to specifically overexpress the RCAN1.4 isoform in HDMECs. Infection with this 
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agonist stimulation and therefore, it was important to determine if this effect was 
independent of VEGFR2. To do this, three selective inhibitors were utilised. Firstly, 
the cell permeable small molecule receptor tyrosine kinase inhibitor ZM323881 
(Toullec et al., 1991) which specifically blocks VEGFR2. Secondly, SGX-523, 
which is an ATP-competitive inhibitor with a high affinity for the HGFR (Buchanan 
et al., 2009). And finally, cyclosporin A, which is a potent inhibitor of the 
calcineurin pathway (Fruman et al., 1992) that blocks VEGFR2-mediated RCAN1.4 
induction (Holmes et al., 2010).  
 
In order to confirm the specific effects of these inhibitors. western blot analysis was 
performed, and the specificity of these inhibitors against their intended target was 
confirmed (Figure	  4.7A), with ZM323881 specifically inhibiting activated VEGFR-
2 and SGX-523 specifically inhibiting activated HGFR. Then using the classical 
scratch wound assay their effects on migration were assessed (Figure	  4.7B and C). 
VEGF-A165 and HGF showed a strong induction of migration in untreated and 
DMSO vehicle control conditions (Figure	   4.7). However, blocking VEGFR2 with 
ZM323881 was found to prevent VEGF-induced migration and not HGF induced 
migration. Conversely, the addition of SGX-523 which blocks the HGFR receptor 
was found to prevent HGF-induced migration and not VEGF-A induced migration. 
Interestingly, treatment with cyclosporin A was also found to specifically inhibit 
VEGF-induced migration but not HGF. This agent is known to block VEGF-induced 
RCAN1.4 induction (Holmes et al., 2010), confirming the importance of RCAN1.4 
in regulating VEGF-A165 induced migration.  
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Figure 4.7: The Effects of Specific Inhibitors on Migration  
A. Western blotting analysis of HDMECs seeded at 5 × 104 cells per well in a gelatine pre-
coated 12-well plate for 24 hours in FGM. Cells were then serum starved with 1% 
PromoCell FCS media for 24 hours before being treated with DMSO vehicle control, 3 µM 
ZM323881, 3 µM SGX-523 and 3 nM Cyclosporin A for 30 minutes prior to stimulation 
with VEGF-A165 or HGF (50 ng/ml) for 10 minutes. Cells were washed with PBS and lysed 
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phospho-VEGFR2, total HGFR, phospho-HGFR, phospho-AKT, phospho-Erk1/2, and 
RCAN1. GAPDH was used as a loading control. B. HDMECs were seeded at 7 × 104 cells 
per well in a gelatine pre-coated 12-well plate for 24 hours in FGM. Cells were serum 
starved with 1% PromoCell FCS media for 24 hours. A scratch was introduced to each well 
using a sterile 200-µl Gilson pipette tip. Cells were then treated with vehicle control, 3 µM 
ZM323881, 3 µM SGX-523 and 3 nM Cyclosporin A and stimulated with VEGF-A165 or 
HGF (50 ng/ml) for 18 hours. Cells were washed with PBS, fixed with 2% PFA for 15 
minutes and stained with Crystal Violet. Images taken using a Nikon imaging microscope at 
×10 objective. C. Quantification of migration (µm) after stimulation with VEGF-A165 or 
HGF and inhibitors. Data shows mean ±SD, (N = 3), (*P < 0.05, **P < 0.01, VEGF-A, HGF 
versus untreated). 
 
The siRNA complex used to knockdown RCAN1 in Figure 3.1B was not specific for 
RCAN1.4 but knocked down both RCAN1.1 and RCAN1.4 isoforms. Therefore, to 
confirm the specific role of RCAN1.4 in regulating VEGFR-2 mediated cell 
migration, an adenovirus that specifically expressed RCAN1.4 was used. In this 
overexpression study HDMECs were transduced either with this adenovirus or a 
control adenovirus encoding GFP and 24 hours later were plated out for use in the 
same scratch wound assay method (Figure	   4.8). It was found that untreated, n.s. 
siRNA and adenovirus-control HDMECs underwent minimal migration in the basal 
condition, but on stimulation, VEGF-A165 and HGF induced strong migration. 
However, once again siRNA knockdown of RCAN1 was found to prevent VEGF-
A165 induced migration but had no effect on HGF induced migration. Interestingly, 
overexpression of RCAN1.4 using adenoviral mediated gene delivery resulted in an 
increased migration of HDMECs, to the same degree as agonist stimulation with 
VEGF. This RCAN1.4 specific increase in migration suggests that the RCAN1.4 
isoform plays an important role in VEGF-mediated cell migration.  
 
Examining the cell morphology, it appears that lamellipodia and filopodia formation 
could be one possible mechanism for this RCAN1 regulation, as cell protrusions only 
appear in the VEGF-A165 and HGF stimulated conditions whereas they appear to be 
absent in the RCAN1-depleted conditions. These protrusions were also increased on 
RCAN1.4 overexpression, further suggesting a role for RCAN1.4 in cell migration. 
 




Figure 4.8: RCAN1.4 regulates VEGF-mediated migration of HDMECs 
HDMEC were transfected with siRNA or adenovirus as indicated. 48 hours post-transfection 
cells were serum starved with media supplemented with 1% PromoCell FCS for 24 hours 
prior to introduction of a scratch in each well using a sterile 200-µl Gilson pipette tip and 
cells stimulated with VEGF-A165, VEGF-A121, FGF-2 or HGF (50 ng/ml) for 18 hours. Cells 
were washed with PBS, fixed with 2% PFA for 15 minutes and stained with Crystal Violet. 
Images were taken using a Nikon imaging microscope at ×10 objective. The graph shows 
quantification of the distance migrated (µm). Data shows mean ±SD, (N = 3), ***P < 0.001, 
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To study the requirement of VEGFR2 in RCAN1.4 mediated migration, RCAN1.4 
was over-expressed in HDMECs using adenoviral-mediated gene transduction. The 
increased levels of RCAN1.4 were then subsequently verified by SDS-PAGE and 
western blot analysis (Figure	  4.9A), where a clear increase in RCAN1.4 (29kDa) can 
be seen in the adenovirus RCAN1.4 transfected cells compared to those transfected 
with control adenoviruses. Furthermore, this analysis confirmed overexpression of 
RCAN1.4 did not cause any defect in the expression of VEGFR2 or HGFR.  
 
Using the scratch wound assay, the effects of this overexpression, in combination 
with the selective inhibitors validated above, was then examined (Figure	   4.9B). 
Cells transfected with the adenovirus encoding RCAN1.4 showed an increase in 
migration even in basal or DMSO conditions, unlike the adenovirus control. This 
migration was approximately double that of the cells treated with the VEGFR2 
selective inhibitor, ZM323881. Although previous studies within the lab have 
demonstrated that RCAN1.4 plays a role in cell migration, this is the first time it has 
been shown that RCAN1.4 overexpression increases migration via a pathway 
requiring VEGFR-2 kinase activity. 
 
Interestingly, samples treated with the HGFR inhibitor SGX-523 or cyclosporin A 
did not show this same inhibitory effect, with the RCAN1.4 overexpression still 
resulting in increased migration. This important result suggests RCAN1.4 
overexpression is able to act independently of the CsA target calcineurin, defining a 
novel role for this protein in endothelial cell function. 
 
To conclude this result, analysis of cell migration revealed that RCAN1.4-mediated 
cell migration was inhibited by the VEGFR2 kinase inhibitor ZM323881 but not the 
HGFR kinase inhibitor SGX-523 or the calcineurin pathway inhibitor cyclosporin A. 
Taken together, this data shows RCAN1.4 can drive cell migration in HDMECs via a 
mechanism requiring VEGFR2 kinase activity but is independent of calcineurin 
activity, the known target for RCAN1.4.  
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Figure 4.9: Adenoviral mediated overexpression of RCAN1.4 
A. Western blotting analysis confirmed the overexpression of RCAN1.4 in HDMECs 
compared with adeno-control. HDMECs were seeded at 7 × 104 cells per well on gelatine 
pre-coated 12-well plates for 24 hours in FGM. Cells were serum starved with 1% 
PromoCell FCS media for 24 hours. They were then treated with vehicle control, 3 µM 
ZM323881, 3 µM SGX-523 and 3nM Cyclosporin A for 30 minutes before being washed 
with PBS and lysed with 1xLDS and subjected to western blotting analysis probing for Total 
VEGFR2, Total HGFR and RCAN1. GAPDH was used as a loading control. B. Scratch 
wound assay in which the HDMECs were seeded at 7 × 104 cells per well on gelatine pre-
coated 12-well plates for 24 hours in FGM. Cells were transfected with adenovirus 
RCAN1.4 or adeno-control for 24 hours followed by serum starving with 1% PromoCell 
FCS media for 24 hours. A scratch was introduced to each well using a sterile 200-µl Gilson 
pipette tip. Cells were treated with vehicle control, 3 µM ZM323881, 3 µM SGX-523 and 3 
nM Cyclosporin A. After 18 hours migration, cells were washed with PBS, fixed with 2% 
PFA for 15 minutes and stained with Crystal Violet. Images taken using a Nikon imaging 
microscope at ×10 objective. C. A graph quantifying migration distance (µm) after inhibitor 
treatment. Data shows mean ±SD, (N = 3), ***P < 0.001, Adeno-RCAN1.4 versus Adeno-
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4.2 Discussion  
The migration of endothelial cells is a critical component of angiogenesis as 
endothelial cells migrate towards a VEGF gradient and form a vascular sprout, which 
eventually differentiates into a lumen-containing vessel. This process is critical for 
normal physiological angiogenesis and pathological tumour angiogenesis.  
Previous results in the group have revealed a role for RCAN1.1 in regulating 
VEGFR-2 mediated migration of HDMECs (Holmes et al., 2010).  However, whilst 
this previous data showed that RCAN1.4 regulation was specifically induced by 
VEGF/VEGFR-2 it did not determine if RCAN1 regulation of endothelial cell 
migration was specific to VEGF. Analysis of VEGF-A, FGF and HGF-stimulated 
migration revealed that RCAN1 specifically regulated VEGF-A migration (Figure 
4.2 and 4.3). This important result suggests that RCAN1 does not regulate cell 
migration at the level of small GTP binding proteins such as Rac and Cdc42, which 
are critical for cell migration in response to agonists (Ridley, 2012). Instead the data 
suggests that the regulation of migration in response to VEGF-A is specific to the 
VEGFR-2.  It is possible that RCAN1 binds directly to VEGFR-2, although attempts 
to co-immunoprecipitate VEGFR-2 and RCAN1 presented in the previous chapter 
were not conclusive.  A transient association was suggested by the proximity ligation 
assay (PLA) data presented in the previous chapter.  The amino acid structure of 
RCAN1 does not reveal any obvious motifs known to bind to RTKs such as SH2 
domain. However, a proline-rich domain is present in RCAN1 (Fuentes et al., 1995), 
which could potentially allow binding to SH3 domain containing proteins, which are 
then able to bind to VEGFR-2, meaning that RCAN1 indirectly links to VEGFR-2. 
It is possible that RCAN1 links to VEGFR-2 via ancilliary molecules such as 
neuropilin, which is known to act as a co-receptor for VEGFR-2 (Soker et al., 1998). 
However, the ability of RCAN1 to regulate migration in response to both VEGF-A165 
and the VEGF-A121 isoform would suggest that the co-receptor neuropilin is not 
involved in providing specificity to the VEGFR-2 response as in contrast to VEGF-
A165, VEGF-A121 does not bind to neuropilin-1 (Holmes et al., 2007).    
 
  
Using time-lapse imaging it was possible to obtain more detail about the defect in 
migration following RCAN1 silencing. Analysis of the movie (supplementarty 
material and figure 4.4) showed that RCAN1 depleted cells were not able to send out 
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protrusions to sense the leading edge. Quantification of cell movement using 
available software (Ibidi®) revealed that cells treated with non-silencing siRNA or 
untreated cells migrated faster, over longer distances and straighter than cells that 
had been depleted of RCAN1 (Figure	   4.5).  This data agrees with data from the 
previous chapter describing a role for RCAN1 in achieving cell polarity and 
cytoskeletal reorganisation. Indeed, analysis of cell alignment using a mixed 
population of cells with either non-silencing knockdown or RCAN1 knockdown 
confirmed a role for RCAN1 in cell alignment (Figure	   4.6). The cell time-lapse 
imaging also revealed specificity in the VEGF response as HGF-stimulated 
migration did not appear to be affected by RCAN1 silencing. This appears to confirm 
previous findings in that RCAN1 appears to specifically regulate VEGFR-2 effects 
on migration.  
Previous work utilising siRNA-mediated gene silencing has not been able to assign 
specific effects to either the RCAN1.1 or RCAN1.4 isoform as both are silenced by 
the commercial siRNA RCAN1 duplexes used.  Whilst it has been shown in Chapter 
3 that VEGF only induces expression of the RCAN1.4 isoform, suggesting that this 
isoform is more important for regulating VEGF effects, proof of the role of 
RCAN1.4 came from over-expression of this specific isoform in the endothelial 
cells. A number of methods were used for overexpression ranging from liposomal 
based methods (Lipofectamine 2000) and nucleofection (Amaxa).  However, 
adenoviral mediated transduction offered the highest transfection efficiency with 
sustained expression in HDMECs.  Using adenovirus encoding human RCAN1.4 it 
was evident that RCAN1.4 overexpression could induce HDMEC migration in the 
absence of ligand (Figure	  4.9). Agonist stimulation did not increase this migration 
suggesting that RCAN1.4 overexpression achieved maximal stimulation. Use of cell 
permeable inhibitors targeting VEGFR-2 and HGFR revealed that RCAN1.4 
overexpression required VEGFR-2 kinase activity to stimulate cell migration, but not 
HGFR kinase activity (Figure	  4.9). Addition of cyclosporine-A, a potent inhibitor of 
calcineurin, revealed that VEGF-A mediated migration was dependent on calcineurin 
activity (Figure 4.7C).  This probably reflects the ability of calcineurin to inhibit 
VEGF-A mediated RCAN1.4 expression (data not shown; Holmes et al., 2010). In 
contrast, addition of cyclosporin-A did not block the ability of adenoviral mediated 
expression of RCAN1.4 to stimulate HDMEC migration (Figure 4.9C) suggesting 
that RCAN1.4, once expressed, acts independently of calcineurin to regulate 
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HDMEC migration. From the data presented, it appears that RCAN1.4 
overexpression is able to effectively substitute for VEGF-A activation of VEGFR-2 
in stimulating cell migration. It would be interesting to also over-express the 
RCAN1.1 isoform to determine if this protein is also able to regulate cell migration.  
It was not possible to confirm RCAN1.4 mediated activation of VEGFR-2 kinase 
activity following overexpression of RCAN1.4 and a more detailed time-course 
experiment followed by western blotting for phospho-VEGFR-2 would be important 
in confirming this.  However, it is possible that RCAN1 requires a basal VEGFR-2 
kinase activity to keep the receptor in a conformation that is amenable to regulation 
and trafficking by RCAN1.4.  It would be interesting to determine the effect of 
RCAN1.4 over-expression on VEGFR-2 trafficking and in this respect a GFP-tagged 
RCAN1.4 would be very useful for analysing intracellular localisation of this 
protein. 
 
In conclusion, results in this chapter have confirmed a role for RCAN1 in regulating 
VEGF-A mediated migration and shown that this effect appears to be restricted to 
VEGFR-2 relative to other RTKs.  Importantly, it has been possible to show that the 
RCAN1.4 isoform is able to stimulate migration in HDMECs via a pathway 
independent of calcineurin but requiring VEGFR-2 kinase activity suggesting a novel 
role for RCAN1.4 in directly regulating VEGFR-2 function.	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Role of PLD regulation in endothelial cells 
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5.1 Introduction  
The role of phospholipase D in tumour angiogenesis and cancer has been 
demonstrated over the last ten years. Phospholipase D is a regulator of several 
cellular processes, including vesicle transport, endocytosis, exocytosis, cell migration 
and mitosis (Foster and Xu, 2003). Dysregulation of these processes occurs in 
carcinogenesis, and abnormalities in PLD expression have been implicated in the 
progression of several types of cancer (Exton, 2002, Peng and Frohman, 2012). 
Furthermore, a mutation conferring elevated PLD2 activity has been observed in 
several malignant breast cancers (Peng and Frohman, 2012).  Elevated PLD 
expression has also been correlated with tumour size in colorectal carcinoma, gastric 
carcinoma and renal cancer (Saito et al., 2007). However, the molecular pathways 
through which PLD drives cancer progression remain unclear. One potential 
hypothesis identifies a critical role for phospholipase D in the activation of mTOR, a 
suppressor of cancer cell apoptosis (Rodrik et al., 2005). The ability of PLD to 
suppress apoptosis in cells with elevated tyrosine kinase activity makes it a candidate 
oncogene in cancers where such expression is typical (Rodrik et al., 2005, Saito et 
al., 2007). In addition, VEGF is known to activate PLD activity in endothelial cells 
(Seymour et al., 1996). VEGF is known to activate VEGFR2 in endothelial cells 
resulting in migration, tube formation, differentiation and proliferation (Holmes et 
al., 2007). In contrast to other phospholipases such as phospholipase C and 
phospholipase A2, the role of PLD in endothelial cell function has not been studied 
in detail.  
PLD has been reported to become highly active in response to VEGF in HUVECs 
via a mechanism requiring PKC (Seymour et al., 1996, Cho et al., 2004). In this 
chapter, the physiological role of PLD activation will be addressed using a number of 
approaches, ranging from small molecule inhibitors of PLD1 and PLD2, siRNA-
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5.1.1 Cellular expression of PLD isoforms 	  
PLD is known to be a ubiquitously expressed enzyme (Kam and Exton, 2001). PCR 
primers were designed for human PLD1 and PLD2 mRNA, and their expression was 
analysed in a range of human cell types and organ tissues. Expression of PLD1 was 
the most abundant and highest in the foetal heart and in HDMECs compared to 
PLD2 which was most highly expressed in HDMECs (Figure	  5.1).  
 
	   	  
Figure 5.1: qRT-PCR analysis of PLD1or PLD2 mRNA splicing in various tissues and 
primary cells. 
RNA and cDNA were extracted from cells and tissues and prepared. Data were analysed by 
the ΔΔCt value method and expression was normalized to β-actin expression and illustrated 
as fold change. HDMEC= human dermal microvascular endothelial cells, HCMEC= human 
cardiac microvascular endothelial cells, HCM= human cardiac myocytes and NHDF= 
normal human dermal fibroblasts. Data shows mean ± SD. The data is representative of three 
experiments. 
5.1.2 Knockdown of PLD1 and PLD2 expression: siRNA validation and 
optimisation  
Selective commercial siRNA duplexes targeting the human PLD1 or PLD2 gene 
used for this study (see Table	  2.7) were purchased from Dharmacon. Furthermore, 
for controls in all experiments in this study, cells were transfected with non-silencing 
siRNA as a negative control (NS). Transfection was performed using the transfection 
reagent Lipofectamine RNAi MAX. The transfection efficiency for PLD1 was 
determined at the protein level and mRNA level by qRT-PCR, whereas PLD2 was 
only validated by qRT-PCR due to lack of a suitable antibody. To confirm that the 
PLD-specific siRNA duplexes were able to knock down PLD1&2 expression in 
HDMECs, cells, were lysed 48 hours after transfection and analysed using western 
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knockdown of PLD1 at the protein level (Figure	   5.2A) and mRNA level (Figure	  5.2B).  From this data, the PLD1 duplexes 1 and 2 were chosen for further study. For 
PLD2 validation, the lack of a good commercial antibody meant that it was not 
possible to perform western blotting.  Validation of siRNA mediated gene silencing 
was performed by qRT-PCR, and PLD duplexes 2 and 6 were chosen for further 




Figure 5.2: Analysis of PLD1&2 silencing in HDMECs. 
A. and B. HDMECs were seeded at 7 × 104 cells/wells on to pre-coated gelatine for 24 hours 
using F.G.M. Many separate siRNA duplexes targeting PLD were used. HDMECs were 
transfected with siRNA to PLD1, PLD2 and NS siRNA as indicated. Actin was used as a 
loading control. C. qRT-PCR analysis for PLD1&2 mRNA level: RNA and cDNA were 
extracted from HDMECs and prepared. Data were analysed by the ΔΔCt value method and 
expression was normalized to β-actin expression and illustrated as fold increase. Data shows 
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5.1.3 Analysis of PLD expression in HDMECs 
The expression of both PLD1 and PLD2 was induced in cells in response to growth 
factors and cytokines (Kang et al., 2013). To determine the profile of PLD1 
expression in response to stimulation with growth factors, screening was conducted. 
Cells were treated with growth factors (VEGF-A, FGF-2, HGF) and the phorbol ester 
PMA, followed by cell lysis and analysis of RCAN1 and PLD activation using 
western blotting with selective antibodies (see Figure	  5.3). It was found that VEGF 
is a potent activator of RCAN1 in HDMECs, whereas other growth factors did not 
induce RCAN1 up-regulation. However, PLD expression was not induced at the 
protein level with a range of growth factors.  
	  
Figure 5.3: Growth factor screening. 
HDMECs were seeded at 7 × 104 cells/wells onto gelatine-coated 12-well plates for 24 hours 
using growth media, incubated overnight and then serum-starved in 1% FCS media for 18 
hours prior to stimulation. Cells were stimulated with Basal, 50 ng/ml VEGF; 50 ng/ml FGF-
2; 50 ng/ml HGF or 100 nM PMA for 10 minutes each and A431= epidermal carcinoma 
expressed high levels of EGFR. Cell lysates were then separated on 4-12 Nu Page gel and 
probed with antibodies against PLD1, RCAN1 and actin as loading controls asindicated 
above in the figure. This experiment has been performed once. 
 
5.1.4 Effect of PLD knockdown on VEGFR-2 signalling in HDMECs 	  
In order to investigate the effect of PLD activity on VEGFR-2 signalling, the 
validated siRNA duplexes were utilised to silence both PLD1 and PLD2 in HDMECs 
and the activation of key downstream signalling molecules such as PLC-gamma and 
AKT were analysed. Cells were stimulated with VEGF for 10 minutes and 60 
minutes to allow analysis of signalling pathways at two separate time points. siRNA-
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mediated silencing of PLD1 and PLD2 appeared to have a slight effect on activation 
of Akt at 10 mins, although there was variation between both duplexes. Analysis at 
the 1-hour stimulation time point revealed no significant effect of silencing PLD1 
and PLD2 on VEGFR-2 mediated intracellular signalling (Figure	  5.4). 
 
	  
Figure 5.4: The role of PLD in VEGFR-2 signalling 
HDMECs were seeded at 7 × 104 cells/wells onto pre-coated gelatine for 24 hours using 
F.G.M. Two separate siRNA duplexes were used targeting PLD1&2. HDMECs were 
transfected with siRNA to PLD1, PLD2 and NS siRNA control as indicated. HDMECs were 
stimulated with VEGF as illustrated in the diagram for 10 minutes and 1 hour. Actin was 
used as a loading control. The data is representative of three experiments. 
5.1.5 Optimisation of PLD on collagen and gelatine  	  
In response to stimulation with certain growth factors, endothelial cells undergo 
tubular morphogenesis and form capillary-like structures in 3D models (Holmes et 
al., 2010). To determine if PLD plays a role in angiogenesis, HDMECs were plated 
in parallel within a collagen gel and also onto gelatin-coated dishes. After growth 
factor stimulation overnight, cells were lysed to facilitate extraction of RNA and 
protein. According to the mRNA and protein levels from both collagen and gelatine, 
RCAN1 was highly up-regulated following stimulation with VEGF-A. In HDMECs, 
PLD1&2 did not show any induction in mRNA or protein level in response to 
VEGF-A (see Figure	  5.5A,B,C,D).  
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Figure 5.5: Analysis of PLD expression on collagen & gelatin  
A. C. D. qRT-PCR analysis for RCAN and PLD1&2 mRNA level: RNA and cDNA were 
extracted from HDMECs and prepared. Data were analysed by the ΔΔCt value method, and 
expression was normalized to β-actin expression and illustrated as fold increase. Data shows 
mean ± SD. The data is representative of three experiments. B. HDMECs were seeded at 7 × 
104 cells/wells on to pre-coated gelatine or for 24 hours using F.G.M. Used two separate 
siRNA duplexes targeting PLD1&2. HDMECs were transfected with siRNA to PLD1, PLD2 
and NS siRNA control as indicated. HDMECs were stimulated with VEGF as illustrated in 
the diagram for 18 hours. Actin was used as a loading control.  
 
5.2 PLD and the regulation of cellular migration 	  
Cell migration is a critical component of the angiogenic cascade as endothelial cells 
migrate at the leading edge to form a capillary sprout. The scratch wound healing 
assay allows the study of the effects of growth factors upon cell migration in 
endothelial cells. To examine VEGF-A, EGF and HGF, HDMECs were plated on 
12-well gelatine-coated dishes for 24 hours. The following day, cells were 
transfected with siRNA duplexes and the next day serum-starved with 1% FCS 
media. Cells were scratched with 200-µl yellow micropipette tips and washed with 
PBS to remove debris. Cells were stimulated with growth factors for 18 hours. 
Images were taken for time zero and additional images were taken after 18 hours. 
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1% FCS media. From the five images, the width of each wound was assessed and 
averages of these measurements were plotted in a bar chart.  
In this diagram (Figure	  5.6.A), images were taken for HDMECs at time zero where 
images were stained with Crystal Violet taken after 18 hours of the experiment. It is 
clear that the edge of the monolayer in basal conditions did not migrate, whereas in 
the present VEGF-A and HGF in untreated and siRNA controls, the edge moved 
forward to close the wound. VEGF-A and HGF enhanced endothelial migration 
toward the leading edge. In contrast with PLD1&2 depletion, the figure illustrates a 
clear defect in cell migration as a result of VEGF-A, whereas in contrast HGF 
migration was not affected by PLD silencing. 
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Figure 5.6: Effect of PLD on HDMEC migration. 
Migration assay shows siRNA of PLD and non-silencing (NS) for 6 hours. Cells were 
serum-starved with (1% FCS PromoCells) media for 24 hours. A scratch was introduced to 
each well using a sterile 200-µl Gibson pipette tip and stimulated with VEGF-A165 and HGF 
50ng/ml for 18 hours. Cells were washed with PBS, fixed with 2% PFA for 15 minutes and 
stained with Crystal Violet. Images were taken using a Nikon imaging microscope with a × 
10 objective. This figure explains scratch distance (µm) after siRNA transfection followed 
by VEGF-A and HGF stimulation using 1% FCS Promo for 18 hours. Data shows mean ± 
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5.3 PLD and tubular morphogenesis 
VEGF-A stimulates endothelial cells to form tube-like structures in 3D collagen gels. 
However, PLD activation and regulation on a collagen gel had not been reported. To 
examine the formation of PLD1&2 in in vitro vascular structures, tube formation 
analysis was undertaken to confirm physiological function. HDMECs were plated 
out onto a pre-coated dish with gelatin for 24 hours. HDMECs were transfected with 
siRNA for both PLD and PLD2 isoforms. Cells were serum-starved overnight and, 
on the following day, cells were detached by accutase and plated onto 3D collagen 
gel with VEGF-A for 18 hours. Subsequently, cell sprouts were imaged and the 
number of junctions or mesh areas were counted using ImageJ software.   
Endothelial cell sprouting was seen after stimulation with VEGF-A for 18 hours on 
to HDMECs on collagen gel in untreated or siRNA control samples. Clearly, this 
figure illustrates strong sprouting in response to VEGF-A with respect to cellular 
junction formation (Figure	   5.7A). SiRNA-mediated silencing of either PLD1 or 
PLD2 resulted in severely reduced tubular morphogenesis (Figure	  5.7).  
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Figure 5.7: Phospholipase D1&2 are required for tubular morphogenesis in HDMECs 
Cells were transfected with two individual siRNAs to PLD1, PLD2 and NS. Cells were 
plated on collagen matrix and stimulated with VEGF-A (50ng/ml). 3D collagen gels were 
fixed at 18 hours to determine visualization of tubules. Bar = 100µm. The figure illustrates 
quantification of tubular morphogenesis using ImageJ software plugins to quantify the 
number of cellular junctions and total meshes in an area. Data shows ± SD (N=4), 
(p***<0.001, siRNA versus NS. Students t-test). The data is representative of three 
experiments. B=Basal, V=VEGF-A. 
 
 
5.4 Effects of PLD on the proliferation of HDMECs 
PLD could play a role in cell physiology and could act as a proliferative factor in 
mammalian cells. The aim of these experiments was to examine the role of PLD in 
cell proliferation in response to VEGF-A, FGF-2 and HGF in human endothelial 
cells. HDMEC cells were plated at 7 × 104 cells per well in growth media for 24 
hours, and siRNA was introduced on the following day. Cells were grown for 48 
hours in low serum before stimulation with growth factors for 48 hours.  
VEGF precipitated a twofold increase in cell viability as measured by ATP levels. 
siRNA-mediated silencing of PLD1 or PLD2 resulted in the inhibition of VEGF-
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Figure 5.8: Phospholipase D1&2 are required for proliferation of HDMECs. 
Cells were transfected with two individual siRNAs to phospholipase D1 and D2 or non-
silencing (NS) and stimulated with VEGF-A and HGF (50ng/ml) for 72 hours. Cell 
proliferation was determined by measuring viable cells using Cell Titer Glow or Crystal 
Violet staining. Data shows mean ± SD. The data is representative of three experiments. 
5.5 Characterization of PLD function by overexpression  	  
HDMECs utilized in the following experiments were transfected with PLD1-GFP 
and PLD2-GFP in order to study the role of PLD1&2 in endothelial cells and to 
determine transfection efficiency so as to identify the most effective strategies for 
transfection. Three different methods of transfection were assessed for this study. 
The first transfection attempt was performed using the transfection reagent called 
Tans Pass NEB, but it did not work (data not shown).  Then, another method to 
transfect these plasmids to HDMECs was tried using Lipofectamine 2000, but the 
transfection efficiency was too low. The most effective transfection of PLD-GFP was 
achieved with the Amaxa Nucleofector Technology kit (Lonza). HDMECs were 
electroporated using Amaxa solution at 4 × 105 cells per condition and plated on to 
dishes. Transfection efficiency was assessed by western blot and fluorescence 
microscopy.  
Optimisation of transfection efficiency was run on western blots by plating 
HDMECs cells and transfected with PLD1&2 plasmids or pcDNA3.1 vector to 
determine if the overexpression of PLD1&2 was able to increase cell migration, 
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plasmids were transfected into HDMECs and compared with PLD1&2 plasmids 
(Figure	   5.9). Transfection with untreated and empty vector did not show any 
significant expression with PLD1 and GFP antibody. In contrast, transfection with 
PLD1-GFP was highly successful due to availability of specific antibody and, in 
addition, transfection efficiency was very high.  
 
	  
Figure 5.9: HDMECs transfected with PLD-GFP or pcDNA expression plasmid 
HDMECs were seeded at 7 × 104 cells/wells on to pre-coated gelatine for 24 hours using 
F.G.M. Cells were transfected with plasmids using Amaxa according to the standard 
protocols included in the Amaxa Nucleofector Technology kit (Lonza). After transfection, 
the cells were plated into appropriate plates.  After 24 hours, the cells were lysed with 1x 
LDS. PLD1 and GFP levels were determined by western blot. This experiment has been 
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5.5.1 Validation of PLD-GFP 	  
HDMECS cells were transfected with the PLD1&2 plasmid to evaluate the effect 
when stimulated with growth factor. The first investigation was undertaken to assess 
the expression of PLD1-GFP with specific commercial antibody and PLD2-GFP. 
HDMECs were grown on plastic dishes and transfected with PLD1-GFP and PLD2-
GFP using the Amaxa kit. The cells were then fixed and stained according to the 
immunofluorescence protocol. Figure	  5.10 clearly shows the transfection of PLD1-
GFP in immunofluorescence (bottom-left figure). In addition, PLD1 expression in 
comparison to PLD2 (bottom-right figure) only reveals PLD2-GFP due to lack of 
specific antibody for PLD2. 
	  
Figure 5.10: HDMECs transfected with PLD-GFP or pcDNA 
HDMECs were seeded at 7 × 104 cells/wells on to pre-coated gelatine for 24 hours using 
F.G.M. Cells were transfected with plasmids using the standard protocols included in the 
Amaxa Nucleofector Technology kit (Lonza). After transfection, the cells were plated on to 
appropriate plates. After 24 hours, the cells were fixed in 2% formaldehyde followed by 
immuno-staining with PLD1 or PLD2 antibody. This experiment has been performed once.  




Chapter 5                                                                                                PLD regulation 
	  144	  
5.6 Discussion 
PLD1 and PLD2 mRNA was found to be highly expressed in endothelial cells 
compared to other types of cells and tissues. The physiological role of phospholipase 
D is thought to be endocytosis and membrane trafficking (Jones et al., 1999). The 
role of PLD in endothelial cells has not received widespread attention.  Early work 
utilising porcine aortic endothelial (PAE) cells defined a novel role for PLD in LPA-
mediated stress fibre formation (Cross et al., 1996).  Further work with PAE cells 
showed that FGF-mediated PLD activation was downstream of FGFR-1 mediated 
autophosphorylation of Y766 and subsequent activation of PLC-gamma (Cross et al., 
2000). VEGFR-2 mediated activation of PLD was first reported by Seymour 
(Seymour et al., 1996) but this has not been followed up with subsequent studies to 
define the physiological role for this enzyme in endothelial cell biology. 
 
The data presented in this chapter shows that both PLD1 and PLD2 are required for 
VEGF-mediated migration, tubular morphogenesis and proliferation in endothelial 
cells.  Despite these profound effects on cell physiology, an effect on acute VEGF 
intracellular signalling in endothelial cells was not observed following siRNA 
mediated silencing of both PLD1 and PLD2.  This would suggest that PLD plays a 
novel role in VEGFR-2 mediated effects.  Data from the previous chapter would 
potentially highlight an effect on VEGFR-2 internalisation, which is known to affect 
migration and tubular morphogenesis and could be investigated further. An effect on 
VEGFR-2 receptor internalisation may explain why HGFR (c-Met) effects were not 
blocked by si-RNA mediated silencing of PLD1 and PLD2 
 
The work presented in this chapter was hampered by the lack of a reliable and 
specific antibody to PLD2. Whilst the mRNA analysis suggested efficient gene 
silencing it would have been good to confirm this by western blotting.  Also, it was 
not possible to determine the contribution of each PLD isoform to the overall 
enzymatic generation of phosphatidic acid (PA) in response to VEGF and other 
agonists to determine the flux through each PLD isoform. 3H myristate labelled 
endothelial cells would need to be utilised to allow radioactive incorporation into the 
phosphatdiylcholine pool. The transphosphatidylation reaction in the presence of 
butan-1-ol would then be utilised to generate 3H phosphatidylbutanol, which can be 
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isolated by thin layer chromatography (TLC). SiRNA mediated silencing of PLD1 or 
PLD2 would have allowed analysis of PLD activity using this method.  Recently, 
this radioactive method has been superceded by lipidomics as each PA species 
analysed by mass spec (Wakelam et al., 2007). This has allowed analysis of the 
individual fatty acid species of the PA molecule, determining if it was originally 
generated by PLD or by interconversion of DAG generated by PLC mediated 
hydrolysis of phosphatidylinositol (4,5)bisphosphate by the enzyme DAG kinase  
(Hodgkin et al., 1998).  
 
In summary, this study suggests a role for phospholipase D (PLD) in VEGFR-2 
signalling in endothelial cells with the subsequent regulation of cell proliferation, 
migration and tubular morphogenesis.  
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6 Chapter 6 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
General Discussion  	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6.1 RCAN1 and the regulation of VEGFR-2 signalling 
The regulators of calcineurin family (RCAN1; formerly known as DSCR) are known 
to regulate cellular function through inhibition of calcineurin (Serrano-Candelas et 
al., 2014). The original discovery of RCAN1.4 as a VEGF-regulated gene outlined 
its role as an endogenous inhibitor of VEGFR-2 mediated gene transcription (Hesser 
et al., 2004). In this context, RCAN1.4 induction via transcription and translation is 
expected to act as a negative feedback to effectively reduce flux through the 
calcineurin/NFAT pathway leading to transcription of genes such as Cox-2 and E-
selectin, which are implicated in inflammatory responses.  Hence it was originally 
thought that RCAN1.4 operates to regulate inflammatory responses in the 
vasculature, similar to its role in other cell types.   Previous work in the group has 
discovered a novel pathway regulating the expression of RCAN1.4 that involves the 
classical calcineurin/NFAT pathways and a calcineurin independent pathway 
requiring protein kinase C-delta (Holmes et al., 2010).  Both pathways converge to 
allow maximal induction of RCAN1.4, which plays a role in regulating endothelial 
cell migration and tubular morphogenesis (Holmes et al., 2010). The work presented 
in this thesis builds on the previous data in the group to define a novel role for 
RCAN1.4 in regulating VEGFR-2 function at the level of receptor internalisation in 
addition to its previously assigned function in regulating VEGFR-2 mediated gene 
expression via inhibition of calcineurin.  
 
6.2 RCAN1 and regulation of VEGFR-2 internalisation and endothelial 
migration. 
The data presented in chapter 3 outlined a role for RCAN1 in regulating VEGFR-2 
internalisation. The use of siRNA targeting both RCAN1.1 and RCAN1.4 meant it 
was not possible to definitively define a role for each RCAN1 isoform in regulating 
this acute response.  Furthermore, the effect on internalisation was evident on 10 
minutes, which is a time point before induction of the RCAN1.4 isoform is seen in 
response to VEGF. Previous work in the group also showed that VEGFR-2 
internalisation was not sensitive to the calcineurin inhibitor cyclosporin A (K. 
Holmes, unpublished results), suggesting that basal rather than induced RCAN1 
levels were responsible for acute VEGFR-2 effects.  It is therefore possible that the 
basal level of both isoforms is able to regulate VEGFR-2 internalisation.  The major 
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question regarding this effect is how RCAN1 actually physically regulates VEGFR-2 
internalisation.  The lack of effect on the HGFR internalisation suggests that this 
effect could be specific to VEGFR-2, suggesting that the canonical clathrin-
dependent endocytic pathway for RTKs, which include the small GTP binding 
protein Rab5 (Horowitz and Seerapu, 2012, Goh and Sorkin, 2013) is not the route 
through which RCAN1 regulates VEGFR-2 internalisation. It is possible that 
RCAN1 interacts with proteins specifically implicated in VEGFR-2 internalisation 
such as neuropilin 1 (Soker et al., 1998), ephrin-B2 (Sawamiphak et al., 2010) and 
synectin (Lanahan et al., 2010). However, the lack of a differential effect between 
VEGF-A165 and VEGF-A121 also suggests that neuropilin is not required for the 
RCAN1 mediated effect on internalisation. The proximity ligation (PLA) data 
suggested a rapid transient interaction between RCAN1 and VEGFR-2 at the leading 
edge of cells.  This would suggest a potential mechanism whereby RCAN1 is able to 
sense VEGFR-2 activation at the leading edge and allow internalisation of VEGFR-2 
at this site allowing the establishment of cell polarity and cytoskeletal reorganisation 
aimed at facilitating efficient directed migration of the endothelial cell. In 
Drosophila, studies on cell migration directionality have revealed the role of receptor 
tyrosine kinase endocytosis in stimulating spatial restriction of signalling allowing 
organised cell migration (Jékely et al., 2005). The results presented show that 
RCAN1 facilitates the coupling of VEGFR-2 internalisation to the establishment of 
cell polarity at the leading edge and ultimately angiogenic sprout formation.  
 
The mechanism of RCAN1 interaction with VEGFR-2 remains obscure and could be 
investigated further using immunoprecipitation experiments with cells over-
expressing VEGFR-2 and receptor mutants in which parts of the receptor have been 
mutated or truncated. It is technically possible to IP RCAN1 and to western blot for 
VEGFR-2 which would allow one to determine if there is a physical interaction 
between RCAN1 and VEGFR-2. Similarly, it would also be feasible to utilise 
RCAN1.1 and RCAN1.4 receptor mutants to define the region of RCAN1 that 
potentially interacts with the VEGFR-2. 
In defining a role for RCAN1 in regulating cellular migration, overexpression of 
RCAN1.4 confirmed that this isoform was capable of regulating VEGFR-2 mediated 
migration. This backed up the siRNA mediated silencing of RCAN1, which showed 
that RCAN1 was required for endothelial cells to polarise, undergo cytoskeletal 
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reorganisation and orientate themselves at the leading edge to undergo directed 
migration. Importantly, the RCAN1.4 overexpression showed that this effect on 
migration was independent of calcineurin activity, as the effect was not blocked by 
cyclosporin A. However, VEGF-stimulated migration of HDMECs was blocked by 
cyclosporin A, which is known to block induction of RCAN1.4 (Holmes et al., 
2010).  This would suggest that sustained induced RCAN1.4 expression is required 
for VEGF-stimulated migration but not VEGFR-2 internalisation and that once 
expression has been induced, RCAN1.4 acts independently of calcineurin to regulate 
cellular migration.  The ability of the VEGFR-2 kinase inhibitor ZM323881 to block 
RCAN1.4-mediated HDMEC migration suggests that an association between 
phosphorylated VEGFR-2 and RCAN1.4 is required for sustained cell migration. 
This allows us to generate an overall hypothesis based on the data presented in 
chapter 3 and 4 to explain the role of RCAN1 in regulating VEGFR-2 mediated 
effects (Figure	   6.1). VEGF stimulation induces VEGFR-2 activation on the cell 
surface and internalisation in an RCAN1.1 and RCAN1.4 driven process over time 
periods of 10-30 mins.  Following stimulation for 60-180mins, VEGFR-2 induces 
expression of RCAN1.4 via a classical pathway requiring the Ca2+/calcineurin/NFAT 
signalling axis and also PKC-delta (Holmes et al., 2010). This sustained level of 
RCAN1.4 facilitates cytoskeletal reorganisation and cell polarisation, ultimately 
allowing cell migration to occur over 3-12 hours. The RCAN1.4 protein is subject to 
proteosomal degradation with a half-life of approximately 15 mins (Beverley 
Rothermel, personal communication). This would suggest that constant VEGF 
stimulation is required to maintain sustained RCAN1.4 levels and ultimately 
stimulate cell migration. Phosphorylation of RCAN1 is another posttranslational 
modification that has been shown to affect protein half-life (Genescà et al., 2003). 
Recent data has shown the protein kinase CK2 can phosphorylate RCAN1 on serine 
residues in the CIC motif resulting in increased affinity for calcineurin and inhibition 
of NFAT function (Martínez-Høyer et al., 2013). It is a distinct possibility that 
activation of VEGFR-2 leads to phosphorylation of RCAN1.1 and RCAN1.4, which 
could be investigated by analysing retardation of phosphorylated species in a Phos-
Tag acrylamide gel (Kinoshita et al., 2006).	  Quantitative phospho-proteomic analysis 
could also be performed using mass spectrometry to identify actual phosphorylation 
sites in the RCAN1 proteins. 
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6.3 The physiological role of RCAN1 
The data presented in this thesis suggests that RCAN1 plays a profound role in 
endothelial cell function.  The role of RCAN1 in vivo has been studied in RCAN-/- 
mice where gene ablation of RCAN1.1 and RCAN1.4 resulted in mice with no 
anatomical differences (Hoeffer et al., 2007). The fact that a more profound 
phenotype was not observed in the knockout mice may be due to a potentially 
different role of RCAN1 in mice and the fact that RCAN1 represents a gene family 
with RCAN1, RCAN2 and RCAN 3 (Serrano-Candelas et al., 2014) offering the 
potential for redundancy. Whilst members of this gene family can inhibit calcineurin, 
so far only RCAN1.4 has been shown to be induced by VEGF. A more recent study 
with RCAN-/- mice focussing on tumour angiogenesis reported hyperactivation of the 
calcineurin/NFAT pathway resulting in endothelial cell apoptosis. This led to 
decreased tumour angiogenesis in a human tumour xenograft study (Ryeom et al., 
2008).  The data presented in this thesis would suggest decreased levels of RCAN1 
will also lead an inhibition of endothelial cell migration, which would be interesting 
to examine in endothelial cells from the DSCR-1-/- mice. Analysis of RCAN1 
ortholog knockdown in zebrafish (Danio rerio) using morpholino anti-sense 
methodology would be interesting in determining the role of RCAN1.1 and 
RCAN1.4 in vascular function using Fli-GFP transgenic zebrafish embryos. 
 
People with Down Syndrome possess an extra copy of chromosome 21 leading to 
elevated levels of a number of genes including DYRK1A and RCAN1. These 
patients exhibit abnormal brain function and often cardiovascular defects (Wiseman 
et al., 2009). Over-expression of RCAN1 in mice causes Down syndrome-like 
hippocampal deficits that alter learning and memory (Martin et al., 2012). The data 
presented in this thesis would suggest that elevated levels of RCAN1 could 
potentially lead to increased endothelial migration and potentially aberrant 
angiogenesis in patients.   
 
Therapeutically, inhibiting RCAN1 function could prevent endothelial cell migration 
and inhibit angiogenesis.  However, other researchers have shown that silencing of 
RCAN1 in cancer cells leads to increased cell migration (Wiseman et al., 2009), 
suggesting that this strategy, if possible, may have a number of pleiotropic effects. 
The long-term therapeutic use of the immunosuppressive drug cyclosporin A has 
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been associated with a number of adverse effects that include nephrotoxicity, renal 
vascular damage and hypertension (Morris et al., 2000). The data presented in this 
thesis would suggest that cyclosporin can prevent VEGF-induced RCAN1.4 
expression and VEGF-mediated endothelial cell migration, which may contribute to 
some of the adverse effects seen in patients taking cyclosporin A.  
 
In order to take the research on RCAN1 forward it will be interesting to determine 
the expression level of both RCAN1.1 and RCAN1.4 in endothelial cells from 
different vascular beds in humans under both normal and disease conditions known 
to affect vascular function/angiogenesis such as cancer and diabetes. Aberrant 
expression of RCAN1 may affect vascular homeostasis and offer a potential 






Chapter 6                                                                                               Discussion 
	  152	  
	  
Figure 6.1: RCAN1 regulates VEGFR-2 function via a novel mechanism in endothelial 
cells 
VEGFR-2 activation leads to PLC-γ activation and increase in intracellular Ca2+ that causes 
activation of calcineurin and dephosphorylation of NFAT. This allows the nuclear 
translocation of NFAT and the transcriptional regulation of RCAN1.4 via NFAT binding 
sites in the promoter region. Basal levels of RCAN1.1 and RCAN1.4 can regulate VEGFR-2 
internalisation via a transient association with the VEGFR-2 at the leading edge of migrating 
cells. Following transcription and translational increases in the level of RCAN1.4 protein, 
this newly synthesised protein acts as both an endogenous inhibitor of calcineurin and as a 
regulator of cytoskeletal reorganisation in response to VEGF. Hence RCAN1 acts to regulate 
spatiotemporal VEGFR-2 activation and downstream effects leading to cell migration.	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6.4 PLD1&2 are involved in regulating endothelial cell physiology 
The role of PLD in cell physiology is only recently being addressed as tools such as 
antibodies, small molecule inhibitors and siRNA duplexes become available to 
researchers. Mice lacking Pld1 have a defect in thrombus formation (Elvers et al., 
2010) whilst mice lacking Pld2 appear normal (Norton et al., 2011). The role of 
PLD1 and PLD2 in endothelial cell function has not been addressed. The data 
presented in this thesis shows that endothelial cells express relatively high levels of 
PLD1 and PLD2 mRNA. siRNA mediated silencing of each PLD isoform showed 
that both PLD1 and PLD2 were required for VEGF mediated endothelial cell 
proliferation, migration and tubular morphogenesis suggesting that these enzymes 
play a critical function in VEGF-mediated signalling. Recent experiments have 
defined a role for Pld1 in inter-segmental blood vessel development in zebrafish 
(Zeng et al., 2009), suggesting that this isoform is critical for vascular development. 
The lack of effect of PLD silencing on HGF-stimulated migration and proliferation 
would suggest a degree of specificity in regulating the VEGF response.  It is possible 
that PLD is activated downstream of PLC, as is the case for FGF-stimulated PLD 
activity in porcine aortic endothelial cells (Cross et al., 2000), as VEGF but not HGF 
is known to activate PLC-gamma in HDMECs (Holmes et al., 2010). It was not 
possible to measure PLD activity directly to determine the amount of phosphatidic 
acid (PA) generation attributable to each isoform of PLD on VEGF stimulation in 
HDMECs. One possibility is to utilise lipidomics based on mass spectrometry to 
measure the actual molecular species of PA and DAG as this allows discrimination 
of PA derived directly from PLD mediated hydrolysis of PtdCho and that derived 
from phosphorylation of DAG derived from PLC mediated hydrolysis of 
PtdIns(4,5)P2 (Hodgkin et al., 1998, Wakelam et al., 2007). The precise mechanism 
through which PLD has a profound effect on VEGF-mediated endothelial cell 
physiology remains obscure. It is possible that PLD derived PA is required for MAP 
Kinase activation as one of the early functions assigned to PLD was regulation of 
Raf-1 (Rizzo et al., 1999). PLD is also known to play a critical role in cytoskeletal 
reorganisation (Cross et al., 1996). Recent data has shown a role for PLD2 in 
regulating endothelial cell permeability via cytoskeletal reorganisation (Zeiller et al., 
2009), thus it is possible that PLD-regulated cytoskeletal reorganisation is a critical 
component for a number of physiological responses in endothelial cells. 
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Appendix 1  
 
Extended time course for figure 4.4 (page 115). RCAN1. siRNA knockdown control 
experiment. For conditions refer to figure 4.4. 
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Extended time course for figure 4.4 (page 115). RCAN1 siRNA knockdown experiment. 
For conditions refer to figure 4.4. 
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